UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 10-Q

(Mark One)


☒			QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended June 30, ~~2022~~2023


☐			TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from to

Commission file number 001-39729

SOTERA HEALTH COMPANY

(Exact name of registrant as specified in its charter)

Delaware

47-3531161

(State or other jurisdiction of incorporation or organization)

(I.R.S. Employer Identification No.)

9100 South Hills Blvd, Suite 300

Broadview Heights, Ohio

44147

(Address of principal executive offices)

(Zip Code)

Registrant’s telephone number, including area code

(440)

262-1410

Securities registered pursuant to Section 12(b) of the Act:


Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common Stock, $0.01 par value per share	SHC	The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. ☒ Yes ☐ No

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). ☒ Yes ☐ No

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.


Large accelerated filer	☒	Accelerated filer	☐
Non-accelerated filer	☐	Smaller reporting company	☐
		Emerging growth company	☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). ☐ Yes ☒ No

As of July 27, ~~2022,~~2023, there were ~~282,902,367~~282,615,723 shares of the registrant’s common stock, $0.01 par value per share, outstanding.

Table of Contents

SOTERA HEALTH COMPANY

- TABLE OF CONTENTS -

Table of Contents

CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS

This Quarterly Report on Form 10-Q includes “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. ~~Forward looking~~Forward-looking statements are often characterized by the use of ~~the~~ words such as “believes,” “estimates,” “expects,” “projects,” “may,” “intends,” “plans” or “anticipates,” or by discussions of strategy, plans or intentions. Such forward-looking statements involve known and unknown risks, uncertainties and other important factors that could cause our actual results, performance, or achievements, or industry results, to differ materially from historical results or any future results, performance or achievements expressed, suggested or implied by such forward-looking statements. Such risks and uncertainties include, but are not limited to:

•any disruption in the availability or supply of, or increases in the price of, ethylene oxide (“EO”), Cobalt-60 (“Co-60”) or our other direct materials, services and supplies, including as a result of ~~current~~ geopolitical instability and sanctions arising from ~~U.S.,~~United States, Canadian, ~~and~~United Kingdom or European Union relations with ~~Russia and related sanctions;~~Russia;

•~~adverse~~foreign currency exchange rates and changes in ~~industry trends;~~those rates;

•changes in environmental, health and safety regulations or ~~preferences;~~preferences, and general economic, social and business conditions;

•health and safety risks associated with the use, storage, transportation and disposal of potentially hazardous materials such as EO and Co-60;

•~~liability claims relating to health risks associated with~~ the ~~use~~impact and outcome of ~~EO;~~

•current and future legal ~~proceedings;~~

•~~competition we face;~~

•~~market changes,~~proceedings and liability claims, including ~~inflationary trends,~~litigation related to purported exposure to emissions of EO from our facilities in Illinois, Georgia and New Mexico and the possibility that ~~impact our long-term supply contracts with variable price clauses and increase our cost of revenues;~~other claims will be made in the future relating to these or other facilities;

•allegations of our failure to properly perform services and potential product liability claims, recalls, penalties and reputational harm;

•compliance with the extensive regulatory requirements to which we are subject, the related costs, and any failures to receive or maintain, or delays in receiving, required clearance or approvals;

•adverse changes in industry trends;

•competition we face;

•market changes, including inflationary trends, that impact our long-term supply contracts with variable price clauses and increase our cost of revenues;

•business continuity hazards, including supply chain disruptions and other risks associated with our operations;

•~~the ongoing impact of the COVID-19 pandemic;~~

•~~our ability to increase capacity at existing facilities, build new facilities in a timely and cost-effective manner and renew leases for our facilities;~~

•~~our ability to attract and retain qualified employees;~~

•the risks of doing business internationally, including global and regional economic and political instability and compliance with numerous laws and regulations in multiple jurisdictions;

•our ability to increase capacity at existing facilities, build new facilities in a timely and cost-effective manner and renew leases for our leased facilities;

•our ability to attract and retain qualified employees;

•severe health events, such as the COVID-19 pandemic, or environmental events;

•cyber security breaches, unauthorized data disclosures, and our dependence on information technology systems;

•any inability to pursue strategic transactions ~~including our ability to~~or find suitable acquisition targets, or our failure to integrate strategic acquisitions successfully into our business;

•our ability to maintain effective internal controls over financial reporting;

•our reliance on intellectual property to maintain our competitive position and the risk of claims from third parties that we infringe or misappropriate their intellectual property rights;

•our ability to comply with rapidly evolving data privacy and security laws and regulations and any ineffective compliance efforts with such laws and regulations;

•~~the effects of unionization efforts and labor regulations in certain countries in which we operate;~~

•our ability to maintain profitability in the future;

•impairment charges on our goodwill and other intangible assets with indefinite lives, as well as other long-lived assets and intangible assets with definite lives;

•the effects of unionization efforts and labor regulations in certain countries in which we operate;

•adverse changes to our tax positions in U.S. or non-U.S. jurisdictions, the interpretation and application of recent U.S. tax legislation or other changes in U.S. or non-U.S. taxation of our operations; and

•our significant leverage and how this significant leverage could adversely affect our ability to raise additional capital, limit our ability to react to changes in the economy or our industry, limit our flexibility in operating our business through restrictions contained in our debt agreements ~~and~~and/or prevent us from meeting our obligations under our existing and future ~~indebtedness; and~~indebtedness.

•~~uncertainty around discontinuation~~Table of ~~LIBOR and transition to certain other interest “benchmarks.”~~Contents

These statements are based on current plans, estimates and projections, and therefore you should not place undue reliance on them. Forward-looking statements speak only as of the date they are made, and we undertake no obligation to update them publicly in light of new information or future events, except as required by law. The inclusion of this forward-looking information should not be regarded as a representation by us or any other person that the future plans, estimates or expectations contemplated by us will be achieved.

~~Table of Contents~~

You should carefully consider the above factors, as well as the factors discussed elsewhere in this Quarterly Report on Form 10-Q, including under Part II, Item 1A, “Risk Factors,” as well as Part I, Item 1A, “Risk Factors” of our Annual Report on Form 10-K for the year ended December 31, ~~2021~~2022 (the ~~“2021~~“2022 Form 10-K”). If any of these trends, risks or uncertainties actually ~~occurs~~occur or ~~continues,~~continue, our business, financial condition or operating results could be materially adversely affected, the trading prices of our securities could decline and you could lose all or part of your investment. All forward-looking statements attributable to us or persons acting on our behalf are expressly qualified in their entirety by this cautionary statement.

Unless expressly indicated or the context requires otherwise, the terms “Sotera Health,” “Company,” “we,” “us,” and “our” in this document refer to Sotera Health Company, a Delaware corporation, and, where appropriate, its subsidiaries on a consolidated basis.

Table of Contents

Part I—FINANCIAL INFORMATION

Item 1. Financial Statements

Sotera Health Company

Consolidated Balance Sheets

(in ~~thousands)~~thousands, except per share amounts)


		As of					As of
		June 30, 2022		December 31, 2021			June 30, 2023		December 31, 2022
Assets	Assets	(Unaudited)				Assets	(Unaudited)
Current assets:	Current assets:					Current assets:
Cash and cash equivalents	Cash and cash equivalents	$	139,564	$	106,917	Cash and cash equivalents	$	262,700	$	395,214
Restricted cash short-term	Restricted cash short-term	1,054		7		Restricted cash short-term	7,790		1,080
Accounts receivable, net of allowance for uncollectible accounts of $1,816 and $1,287, respectively		119,852		108,183
Accounts receivable, net of allowance for uncollectible accounts of $1,965 and $1,871, respectively						Accounts receivable, net of allowance for uncollectible accounts of $1,965 and $1,871, respectively	117,307		118,482
Inventories, net	Inventories, net	39,652		54,288		Inventories, net	42,102		37,145
Prepaid expenses and other current assets	Prepaid expenses and other current assets	81,173		71,923		Prepaid expenses and other current assets	90,910		80,995
Income taxes receivable	Income taxes receivable	17,386		4,643		Income taxes receivable	25,883		12,094
Total current assets	Total current assets	398,681		345,961		Total current assets	546,692		645,010
Property, plant, and equipment, net	Property, plant, and equipment, net	699,571		650,797		Property, plant, and equipment, net	859,138		774,527
Operating lease assets	Operating lease assets	29,853		39,946		Operating lease assets	25,179		26,481
Deferred income taxes	Deferred income taxes	5,425		5,885		Deferred income taxes	4,157		4,101
Investment in unconsolidated affiliate		—		9,405
Post-retirement assets	Post-retirement assets	8,788		5,478		Post-retirement assets	39,004		35,570
Other assets	Other assets	38,308		12,866		Other assets	34,082		38,983
Other intangible assets, net	Other intangible assets, net	543,057		598,844		Other intangible assets, net	456,120		491,265
Goodwill	Goodwill	1,116,002		1,120,320		Goodwill	1,110,498		1,101,768
Total assets	Total assets	$	2,839,685	$	2,789,502	Total assets	$	3,074,870	$	3,117,705
Liabilities and equity	Liabilities and equity					Liabilities and equity
Current liabilities:	Current liabilities:					Current liabilities:
Accounts payable	Accounts payable	$	65,271	$	72,868	Accounts payable	$	55,580	$	74,139
Accrued liabilities	Accrued liabilities	52,658		61,861		Accrued liabilities	103,450		490,130
Deferred revenues	Deferred revenues	6,863		8,669		Deferred revenues	13,840		12,140

Current portion of long-term debt						Current portion of long-term debt	5,225		197,119
Current portion of finance lease obligations	Current portion of finance lease obligations	1,615		1,160		Current portion of finance lease obligations	8,605		1,722
Current portion of operating lease obligations	Current portion of operating lease obligations	8,132		9,289		Current portion of operating lease obligations	7,111		7,554
Current portion of asset retirement obligations	Current portion of asset retirement obligations	606		619		Current portion of asset retirement obligations	793		2,896
Income taxes payable	Income taxes payable	6,876		6,695		Income taxes payable	5,726		5,867
Total current liabilities	Total current liabilities	142,021		161,161		Total current liabilities	200,330		791,567
Long-term debt	Long-term debt	1,745,548		1,743,534		Long-term debt	2,221,987		1,747,115
Finance lease obligations, less current portion	Finance lease obligations, less current portion	57,140		40,877		Finance lease obligations, less current portion	61,283		56,955
Operating lease obligations, less current portion	Operating lease obligations, less current portion	24,546		33,017		Operating lease obligations, less current portion	20,538		21,577
Noncurrent asset retirement obligations	Noncurrent asset retirement obligations	42,688		41,833		Noncurrent asset retirement obligations	44,492		42,586
Deferred lease income	Deferred lease income	20,146		20,745		Deferred lease income	19,045		18,902
Post-retirement obligations	Post-retirement obligations	11,198		11,464		Post-retirement obligations	8,008		7,910
Noncurrent liabilities	Noncurrent liabilities	15,668		16,274		Noncurrent liabilities	12,626		12,831
Deferred income taxes	Deferred income taxes	144,730		134,501		Deferred income taxes	68,194		68,024
Total liabilities	Total liabilities	2,203,685		2,203,406		Total liabilities	2,656,503		2,767,467
See Commitments and contingencies note	See Commitments and contingencies note	0		0		See Commitments and contingencies note
Equity:	Equity:					Equity:
Common stock, with $0.01 par value, 1,200,000 shares authorized; 286,037 shares issued at June 30, 2022 and December 31, 2021, respectively.		2,860		2,860
Preferred stock, with $0.01 par value, 120,000 authorized; no shares issued at June 30, 2022 and December 31, 2021, respectively		—		—
Treasury stock, at cost (3,135 and 3,052 shares at June 30, 2022 and December 31, 2021, respectively)		(32,654)		(33,545)
Common stock, with $0.01 par value, 1,200,000 shares authorized; 286,037 shares issued at June 30, 2023 and December 31, 2022						Common stock, with $0.01 par value, 1,200,000 shares authorized; 286,037 shares issued at June 30, 2023 and December 31, 2022	2,860		2,860
Preferred stock, with $0.01 par value, 120,000 authorized; no shares issued at June 30, 2023 and December 31, 2022						Preferred stock, with $0.01 par value, 120,000 authorized; no shares issued at June 30, 2023 and December 31, 2022	—		—
Treasury stock, at cost (3,493 and 3,616 shares at June 30, 2023 and December 31, 2022, respectively)						Treasury stock, at cost (3,493 and 3,616 shares at June 30, 2023 and December 31, 2022, respectively)	(28,700)		(29,775)
Additional paid-in capital	Additional paid-in capital	1,181,995		1,172,593		Additional paid-in capital	1,202,972		1,189,622
Retained deficit	Retained deficit	(411,187)		(472,246)		Retained deficit	(679,461)		(705,816)
Accumulated other comprehensive loss	Accumulated other comprehensive loss	(105,014)		(83,566)		Accumulated other comprehensive loss	(79,304)		(106,653)
Total equity attributable to Sotera Health Company		636,000		586,096
Noncontrolling interests		—		—
Total equity	Total equity	636,000		586,096		Total equity	418,367		350,238
Total liabilities and equity	Total liabilities and equity	$	2,839,685	$	2,789,502	Total liabilities and equity	$	3,074,870	$	3,117,705

See notes to consolidated financial statements.

Table of Contents

Sotera Health Company

Consolidated Statements of Operations and Comprehensive Income (Loss)

(in thousands, except per share amounts)

(Unaudited)


		Three Months Ended June 30,				Six Months Ended June 30,					Three Months Ended June 30,				Six Months Ended June 30,
		2022		2021		2022		2021			2023		2022		2023		2022

Revenues:	Revenues:									Revenues:
Service	Service	$	221,529	$	208,710	$	427,747	$	397,408	Service	$	226,050	$	221,529	$	440,560	$	427,747
Product	Product	45,110		43,207		75,646		66,657		Product	29,232		45,110		35,312		75,646
Total net revenues	Total net revenues	266,639		251,917		503,393		464,065		Total net revenues	255,282		266,639		475,872		503,393
Cost of revenues:	Cost of revenues:									Cost of revenues:
Service	Service	98,407		91,391		192,983		176,427		Service	103,900		98,407		208,110		192,983
Product	Product	17,836		16,765		31,139		28,505		Product	11,794		17,836		16,671		31,139
Total cost of revenues	Total cost of revenues	116,243		108,156		224,122		204,932		Total cost of revenues	115,694		116,243		224,781		224,122
Gross profit	Gross profit	150,396		143,761		279,271		259,133		Gross profit	139,588		150,396		251,091		279,271
Operating expenses:	Operating expenses:									Operating expenses:
Selling, general and administrative expenses	Selling, general and administrative expenses	63,132		49,828		122,674		102,293		Selling, general and administrative expenses	60,287		63,132		122,197		122,674
Amortization of intangible assets	Amortization of intangible assets	15,769		15,661		31,610		32,204		Amortization of intangible assets	16,097		15,769		32,324		31,610

Total operating expenses	Total operating expenses	78,901		65,489		154,284		134,497		Total operating expenses	76,384		78,901		154,521		154,284
Operating income	Operating income	71,495		78,272		124,987		124,636		Operating income	63,204		71,495		96,570		124,987
Interest expense, net	Interest expense, net	14,044		19,163		24,448		40,445		Interest expense, net	30,728		14,044		59,598		24,448
Impairment of investment in unconsolidated affiliate	Impairment of investment in unconsolidated affiliate	9,613		—		9,613		—		Impairment of investment in unconsolidated affiliate	—		9,613		—		9,613
Loss on extinguishment of debt		—		—		—		14,312
Foreign exchange (gain) loss		(755)		76		33		654
Other expense (income), net		485		(2,764)		(2,482)		(6,654)
Foreign exchange loss (gain)										Foreign exchange loss (gain)	465		(755)		812		33
Other (income) expense, net										Other (income) expense, net	(2,474)		485		(3,727)		(2,482)
Income before income taxes	Income before income taxes	48,108		61,797		93,375		75,879		Income before income taxes	34,485		48,108		39,887		93,375
Provision for income taxes	Provision for income taxes	17,690		19,182		32,316		22,199		Provision for income taxes	10,972		17,690		13,532		32,316
Net income	Net income	30,418		42,615		61,059		53,680		Net income	23,513		30,418		26,355		61,059
Less: Net income attributable to noncontrolling interests		—		16		—		239
Net income attributable to Sotera Health Company		30,418		42,599		61,059		53,441
Other comprehensive income (loss) net of tax:	Other comprehensive income (loss) net of tax:									Other comprehensive income (loss) net of tax:
Pension and post-retirement benefits (net of taxes of $179, $(142), $87, and $(226), respectively)		532		(421)		258		(670)
Interest rate derivatives (net of taxes of $1,241, $0, $3,350 and $0, respectively)		3,178		—		9,357		—
Pension and post-retirement benefits (net of taxes of $6, $179, $(11), and $87, respectively)										Pension and post-retirement benefits (net of taxes of $6, $179, $(11), and $87, respectively)	18		532		(33)		258
Interest rate derivatives (net of taxes of $1,036, $1,241, $(2,360) and $3,350, respectively)										Interest rate derivatives (net of taxes of $1,036, $1,241, $(2,360) and $3,350, respectively)	4,002		3,178		(5,249)		9,357
Foreign currency translation	Foreign currency translation	(46,038)		20,425		(31,063)		17,339		Foreign currency translation	21,374		(46,038)		32,631		(31,063)
Comprehensive income (loss)	Comprehensive income (loss)	(11,910)		62,619		39,611		70,349		Comprehensive income (loss)	$	48,907	$	(11,910)	$	53,704	$	39,611
Less: comprehensive income attributable to noncontrolling interests		—		326		—		534
Comprehensive income (loss) attributable to Sotera Health Company		$	(11,910)	$	62,293	$	39,611	$	69,815
Earnings per share:	Earnings per share:									Earnings per share:
Basic	Basic	$	0.11	$	0.15	$	0.22	$	0.19	Basic	$	0.08	$	0.11	$	0.09	$	0.22
Diluted	Diluted	0.11		0.15		0.22		0.19		Diluted	0.08		0.11		0.09		0.22
Weighted average number of shares outstanding:	Weighted average number of shares outstanding:									Weighted average number of shares outstanding:
Basic	Basic	279,990		279,078		279,910		278,953		Basic	280,893		279,990		280,793		279,910
Diluted	Diluted	280,171		279,214		280,038		279,078		Diluted	283,147		280,171		283,040		280,038

See notes to consolidated financial statements.

Table of Contents

Sotera Health Company

Consolidated Statements of Cash Flows

(in thousands)

(Unaudited)


		Six Months Ended June 30,					Six Months Ended June 30,
		2022		2021			2023		2022
Operating activities:	Operating activities:					Operating activities:
Net income	Net income	$	61,059	$	53,680	Net income	$	26,355	$	61,059
Adjustments to reconcile net income to net cash provided by operating activities:
Adjustments to reconcile net income to net cash provided by (used in) operating activities:						Adjustments to reconcile net income to net cash provided by (used in) operating activities:
Depreciation	Depreciation	31,611		31,062		Depreciation	37,920		31,611
Amortization of intangible assets	Amortization of intangible assets	41,378		44,060		Amortization of intangible assets	41,108		41,378
Impairment of investment in unconsolidated affiliate	Impairment of investment in unconsolidated affiliate	9,613		—		Impairment of investment in unconsolidated affiliate	—		9,613
Loss on extinguishment of debt		—		14,312
Deferred income taxes	Deferred income taxes	10,416		3,504		Deferred income taxes	315		10,416
Share-based compensation expense	Share-based compensation expense	10,339		6,942		Share-based compensation expense	15,661		10,339
Accretion of asset retirement obligations	Accretion of asset retirement obligations	1,118		1,153		Accretion of asset retirement obligations	1,127		1,118
Unrealized foreign exchange losses	Unrealized foreign exchange losses	1,274		1,097		Unrealized foreign exchange losses	4,601		1,274
Unrealized gains on derivatives not designated as hedging instruments	Unrealized gains on derivatives not designated as hedging instruments	(8,029)		(1,614)		Unrealized gains on derivatives not designated as hedging instruments	(747)		(8,029)
Amortization of debt issuance costs	Amortization of debt issuance costs	2,836		3,245		Amortization of debt issuance costs	4,112		2,836
Other	Other	(4,043)		(4,241)		Other	(2,623)		(4,043)
Changes in operating assets and liabilities:	Changes in operating assets and liabilities:					Changes in operating assets and liabilities:
Accounts receivable	Accounts receivable	(13,921)		(25,754)		Accounts receivable	2,549		(13,921)
Inventories	Inventories	14,012		(770)		Inventories	(3,877)		14,012
Other current assets	Other current assets	(6,683)		983		Other current assets	(9,220)		(6,683)
Accounts payable	Accounts payable	(9,993)		15,080		Accounts payable	(20,325)		(9,993)
Accrued liabilities	Accrued liabilities	(11,869)		(4,375)		Accrued liabilities	22,273		(11,869)
Income taxes payable / receivable		(15,968)		(3,998)
Illinois EO litigation settlement						Illinois EO litigation settlement	(407,712)		—
Income taxes payable / receivable, net						Income taxes payable / receivable, net	(14,067)		(15,968)
Other liabilities	Other liabilities	(468)		(95)		Other liabilities	(512)		(468)
Other long-term assets	Other long-term assets	(4,426)		(15)		Other long-term assets	358		(4,426)
Net cash provided by operating activities		108,256		134,256
Net cash provided by (used in) operating activities						Net cash provided by (used in) operating activities	(302,704)		108,256
Investing activities:	Investing activities:					Investing activities:
Purchases of property, plant and equipment	Purchases of property, plant and equipment	(71,642)		(44,789)		Purchases of property, plant and equipment	(98,134)		(71,642)
Purchase of mandatorily redeemable noncontrolling interest in Nelson Laboratories Fairfield, Inc.		—		(12,425)
Purchase of BioScience Laboratories, LLC, net of cash acquired		—		(13,760)
Adjustment to purchase of Regulatory Compliance Associates Inc.	Adjustment to purchase of Regulatory Compliance Associates Inc.	450		—		Adjustment to purchase of Regulatory Compliance Associates Inc.	—		450
Other investing activities						Other investing activities	32		—
Net cash used in investing activities	Net cash used in investing activities	(71,192)		(70,974)		Net cash used in investing activities	(98,102)		(71,192)
Financing activities:	Financing activities:					Financing activities:
Purchase of noncontrolling interests in China subsidiaries		—		(7,720)
Payments of debt issuance costs		(27)		(3,661)
Proceeds from long-term borrowings						Proceeds from long-term borrowings	500,000		—
Payment of revolving credit facility						Payment of revolving credit facility	(200,000)		—
Payments of debt issuance costs and debt discount						Payments of debt issuance costs and debt discount	(24,672)		(27)
Other financing activities	Other financing activities	(1,056)		(709)		Other financing activities	(2,122)		(1,056)
Net cash used in financing activities		(1,083)		(12,090)
Net cash provided by (used in) financing activities						Net cash provided by (used in) financing activities	273,206		(1,083)
Effect of exchange rate changes on cash and cash equivalents	Effect of exchange rate changes on cash and cash equivalents	(2,287)		2,578		Effect of exchange rate changes on cash and cash equivalents	1,796		(2,287)
Net increase in cash and cash equivalents, including restricted cash		33,694		53,770
Net increase (decrease) in cash and cash equivalents, including restricted cash						Net increase (decrease) in cash and cash equivalents, including restricted cash	(125,804)		33,694
Cash and cash equivalents, including restricted cash, at beginning of period	Cash and cash equivalents, including restricted cash, at beginning of period	106,924		102,454		Cash and cash equivalents, including restricted cash, at beginning of period	396,294		106,924
Cash and cash equivalents, including restricted cash, at end of period	Cash and cash equivalents, including restricted cash, at end of period	$	140,618	$	156,224	Cash and cash equivalents, including restricted cash, at end of period	$	270,490	$	140,618
Supplemental disclosures of cash flow information:	Supplemental disclosures of cash flow information:					Supplemental disclosures of cash flow information:
Cash paid during the period for interest	Cash paid during the period for interest	$	42,057	$	36,615	Cash paid during the period for interest	$	78,352	$	42,057
Cash paid during the period for income taxes, net of tax refunds received	Cash paid during the period for income taxes, net of tax refunds received	37,340		22,785		Cash paid during the period for income taxes, net of tax refunds received	27,590		37,340
Purchases of property, plant and equipment included in accounts payable	Purchases of property, plant and equipment included in accounts payable	17,923		9,670		Purchases of property, plant and equipment included in accounts payable	16,986		17,923

See notes to consolidated financial statements.

Table of Contents

Sotera Health Company

Consolidated Statements of Equity

(in thousands)

(Unaudited)


		Three Months Ended June 30, 2022																						Three Months Ended June 30, 2023
		Common Stock					Additional Paid-In Capital				Retained Earnings / (Accumulated Deficit)		Accumulated Other Comprehensive (Loss) Income			Noncontrolling Interests				Total Equity				Common Stock							Additional Paid-In Capital			Retained Earnings / (Accumulated Deficit)			Accumulated Other Comprehensive (Loss) Income			Total Equity
		Shares	Amount		Treasury Stock										Shares								Amount			Treasury Stock
Balance at March 31, 2022		282,930	$	2,860	$	(33,536)			$	1,177,097			$	(441,605)				$	(62,686)			$	—		$	642,130
Balance at March 31, 2023																							Balance at March 31, 2023	282,516			$	2,860	$	(29,420)		$	1,195,357		$	(702,974)		$	(104,698)		$	361,125
Share-based compensation plans	Share-based compensation plans	(28)	—		882		4,898				—		—			—				5,780			Share-based compensation plans	28			—		720		7,615			—			—			8,335
Comprehensive income (loss):	Comprehensive income (loss):																						Comprehensive income (loss):																	—
Pension and post-retirement plan adjustments, net of tax	Pension and post-retirement plan adjustments, net of tax	—	—		—		—				—		532			—				532			Pension and post-retirement plan adjustments, net of tax	—			—		—		—			—			18			18
Foreign currency translation	Foreign currency translation	—	—		—		—				—		(46,038)			—				(46,038)			Foreign currency translation	—			—		—		—			—			21,374			21,374
Interest rate derivatives, net of tax	Interest rate derivatives, net of tax	—	—		—		—				—		3,178			—				3,178			Interest rate derivatives, net of tax	—			—		—		—			—			4,002			4,002
Net income	Net income	—	—		—		—				30,418		—			—				30,418			Net income	—			—		—		—			23,513			—			23,513
Balance at June 30, 2022		282,902	$	2,860	$	(32,654)	$	1,181,995			$	(411,187)	$	(105,014)		$	—			$	636,000
Balance at June 30, 2023																							Balance at June 30, 2023	282,544			$	2,860	$	(28,700)	$	1,202,972		$	(679,461)		$	(79,304)		$	418,367


		Six Months Ended June 30, 2022																				Six Months Ended June 30, 2023
		Common Stock					Additional Paid-In Capital		Retained Earnings / (Accumulated Deficit)		Accumulated Other Comprehensive (Loss) Income			Noncontrolling Interests				Total Equity				Common Stock							Additional Paid-In Capital		Retained Earnings / (Accumulated Deficit)		Accumulated Other Comprehensive (Loss) Income		Total Equity
		Shares	Amount		Treasury Stock								Shares								Amount			Treasury Stock
Balance at December 31, 2021		282,985	$	2,860	$	(33,545)			$	1,172,593	$	(472,246)				$	(83,566)			$	—		$	586,096
Balance at December 31, 2022																					Balance at December 31, 2022	282,421			$	2,860	$	(29,775)	$	1,189,622	$	(705,816)	$	(106,653)	$	350,238
Share-based compensation plans	Share-based compensation plans	(83)	—		891		9,402		—		—			—				10,293			Share-based compensation plans	123			—		1,075		13,350		—		—		14,425
Comprehensive income (loss):	Comprehensive income (loss):																				Comprehensive income (loss):
Pension and post-retirement plan adjustments, net of tax	Pension and post-retirement plan adjustments, net of tax	—	—		—		—		—		258			—				258			Pension and post-retirement plan adjustments, net of tax	—			—		—		—		—		(33)		(33)
Foreign currency translation	Foreign currency translation	—	—		—		—		—		(31,063)			—				(31,063)			Foreign currency translation	—			—		—		—		—		32,631		32,631
Interest rate derivatives, net of tax	Interest rate derivatives, net of tax	—	—		—		—		—		9,357			—				9,357			Interest rate derivatives, net of tax	—			—		—		—		—		(5,249)		(5,249)
Net income	Net income	—	—		—		—		61,059		—			—				61,059			Net income	—			—		—		—		26,355		—		26,355
Balance at June 30, 2022		282,902	$	2,860	$	(32,654)	$	1,181,995	$	(411,187)	$	(105,014)		$	—			$	636,000
Balance at June 30, 2023																					Balance at June 30, 2023	282,544			$	2,860	$	(28,700)	$	1,202,972	$	(679,461)	$	(79,304)	$	418,367

See notes to consolidated financial statements.

Table of Contents

Sotera Health Company

Consolidated Statements of Equity (continued)

(in thousands)

(Unaudited)


		Three Months Ended June 30, 2021																				Three Months Ended June 30, 2022
		Common Stock					Additional Paid-In Capital		Retained Earnings / (Accumulated Deficit)		Accumulated Other Comprehensive (Loss) Income			Noncontrolling Interests				Total Equity				Common Stock							Additional Paid-In Capital		Retained Earnings / (Accumulated Deficit)		Accumulated Other Comprehensive (Loss) Income		Total Equity
		Shares	Amount		Treasury Stock								Shares								Amount			Treasury Stock
Balance at March 31, 2021		282,900	$	2,860	$	(34,000)			$	1,169,852	$	(578,286)				$	(97,162)			$	2,480		$	465,744
Acquisition of noncontrolling interests		—	—		—		(5,772)		—		—			(2,806)				(8,578)
Issuance of shares		47	—		—		1,080		—		—			—				1,080
Balance at March 31, 2022																					Balance at March 31, 2022	282,930			$	2,860	$	(33,536)	$	1,177,097	$	(441,605)	$	(62,686)	$	642,130
Share-based compensation plans	Share-based compensation plans	(30)	—		—		2,406		—		—			—				2,406			Share-based compensation plans	(28)			—		882		4,898		—		—		5,780
Comprehensive income (loss):	Comprehensive income (loss):																				Comprehensive income (loss):
Pension and post-retirement plan adjustments, net of tax	Pension and post-retirement plan adjustments, net of tax	—	—		—		—		—		(421)			—				(421)			Pension and post-retirement plan adjustments, net of tax	—			—		—		—		—		532		532
Foreign currency translation	Foreign currency translation	—	—		—		—		—		20,115			310				20,425			Foreign currency translation	—			—		—		—		—		(46,038)		(46,038)

Interest rate derivatives, net of tax																					Interest rate derivatives, net of tax	—			—		—		—		—		3,178		3,178
Net income	Net income	—	—		—		—		42,599		—			16				42,615			Net income	—			—		—		—		30,418		—		30,418
Balance at June 30, 2021		282,917	$	2,860	$	(34,000)	$	1,167,566	$	(535,687)	$	(77,468)		$	—			$	523,271
Balance at June 30, 2022																					Balance at June 30, 2022	282,902			$	2,860	$	(32,654)	$	1,181,995	$	(411,187)	$	(105,014)	$	636,000


		Six Months Ended June 30, 2021																				Six Months Ended June 30, 2022
		Common Stock					Additional Paid-In Capital		Retained Earnings / (Accumulated Deficit)		Accumulated Other Comprehensive (Loss) Income			Noncontrolling Interests				Total Equity				Common Stock							Additional Paid-In Capital		Retained Earnings / (Accumulated Deficit)		Accumulated Other Comprehensive (Loss) Income		Total Equity
		Shares	Amount		Treasury Stock								Shares								Amount			Treasury Stock
Balance at December 31, 2020		283,248	$	2,860	$	(34,000)			$	1,166,412	$	(589,128)				$	(93,842)			$	2,272		$	454,574
Acquisition of noncontrolling interests		—	—		—		(5,772)		—		—			(2,806)				(8,578)
Issuance of shares		47	—		—		1,080		—		—			—				1,080
Balance at December 31, 2021																					Balance at December 31, 2021	282,985			$	2,860	$	(33,545)	$	1,172,593	$	(472,246)	$	(83,566)	$	586,096
Share-based compensation plans	Share-based compensation plans	(378)	—		—		5,846		—		—			—				5,846			Share-based compensation plans	(83)			—		891		9,402		—		—		10,293
Comprehensive income (loss):	Comprehensive income (loss):																				Comprehensive income (loss):
Pension and post-retirement plan adjustments, net of tax	Pension and post-retirement plan adjustments, net of tax	—	—		—		—		—		(670)			—				(670)			Pension and post-retirement plan adjustments, net of tax	—			—		—		—		—		258		258
Foreign currency translation	Foreign currency translation	—	—		—		—		—		17,044			295				17,339			Foreign currency translation	—			—		—		—		—		(31,063)		(31,063)

Interest rate derivatives, net of tax																					Interest rate derivatives, net of tax	—			—		—		—		—		9,357		9,357
Net income	Net income	—	—		—		—		53,441		—			239				53,680			Net income	—			—		—		—		61,059		—		61,059
Balance at June 30, 2021		282,917	$	2,860	$	(34,000)	$	1,167,566	$	(535,687)	$	(77,468)		$	—			$	523,271
Balance at June 30, 2022																					Balance at June 30, 2022	282,902			$	2,860	$	(32,654)	$	1,181,995	$	(411,187)	$	(105,014)	$	636,000

See notes to consolidated financial statements.

Table of Contents

Sotera Health Company

Notes to Consolidated Financial Statements

1.Basis of Presentation

Principles of Consolidation – Sotera Health Company (also referred to herein as the “Company,” “we,” “our,” “us” or “its”), is a leading global provider of mission-critical end-to-end sterilization solutions, lab testing and advisory services for the healthcare industry with operations primarily in the Americas, Europe and Asia.

We operate and report in 3three segments, Sterigenics, Nordion and Nelson Labs. We describe our reportable segments in Note ~~18,~~17, “Segment Information”. All significant intercompany balances and transactions have been eliminated in consolidation.

Noncontrolling interests represented the noncontrolling stockholders’ proportionate share of the total equity in the Company’s consolidated subsidiaries. In the second quarter of 2021, we purchased the outstanding noncontrolling interests of 15% and 33% of our 2 China subsidiaries. Refer to Note 4, “Acquisitions”for additional details. Prior to our acquisition of the noncontrolling interests in our 2 subsidiaries in China, we consolidated the results of operations of these subsidiaries with our results of operations and reflected the noncontrolling interest on our Consolidated Statements of Operations and Comprehensive Income (Loss) as “Net income attributable to noncontrolling interests.”

On March 11, 2021, we purchased the 15% noncontrolling interest that remained from the August 2018 acquisition of Nelson Laboratories Fairfield, Inc. (“Nelson Labs Fairfield”). As the purchase of this noncontrolling interest was mandatorily redeemable, no earnings were allocated to this noncontrolling interest. See Note 4, “Acquisitions”~~for additional details.~~

In July 2020, we acquired a 60% equity ownership interest in ~~Auralux Enterprises, Ltd. (“Auralux”),~~ a joint venture to construct an E-beam facility in Alberta, Canada in connection with our acquisition of Iotron Industries Canada, Inc. (“Iotron”). WeOur equity ownership interest in the joint venture was determined ~~this~~ to be an investment in a variable interest entity (“VIE”). The investment was not consolidated as the Company concluded that ~~we are~~it was not the primary beneficiary of the VIE. The Company ~~accounts~~accounted for the joint venture using the equity method. ~~The investment is reflected within “Investment in unconsolidated affiliates” on the Consolidated Balance Sheets.~~

During the ~~three months~~year ended ~~June 30,~~December 31, 2022, we identified certain events and circumstances that indicated a decline in value of our investment in ~~Auralux~~this joint venture that was other-than-temporary. Consequently, asin the second quarter of ~~June 30,~~ 2022, we wrote down the investment in ~~Auralux~~the joint venture to its fair value of $0, resulting in an impairment charge of approximately $9.6 million. In February 2023, we entered into a Share Purchase Agreement to transfer our equity ownership interest to the joint venture partner, thereby terminating our equity ownership interest.

Use of Estimates – In preparing our consolidated financial statements in conformity with U.S. Generally Accepted Accounting Principles (“GAAP”), we make estimates and assumptions that affect the amounts reported and the accompanying notes. We regularly evaluate the estimates and assumptions used and revise them as new information becomes available. Actual results may vary from those estimates.

Interim Financial Statements – The accompanying consolidated financial statements include the assets, liabilities, operating results, and cash flows of the Company and its wholly owned subsidiaries. These financial statements are prepared in accordance with ~~U.S.~~ GAAP for interim financial information, the instructions to the Quarterly Report on Form 10-Q and Rule 10-01 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by ~~U.S.~~ GAAP for complete financial statements. In the opinion of management, all adjustments (consisting of normal recurring adjustments) considered necessary for a fair presentation have been included. These unaudited interim financial statements should be read in conjunction with the Company's annual consolidated financial statements and accompanying notes onin our 2022 Form ~~10-K for the year ended December 31, 2021.~~10-K.

2.Recent Accounting Standards

Adoption of Accounting Standard Updates

Effective January 1, ~~2022,~~2023, we adopted~~Accounting Standards Update (“ASU”) 2016-13, Financial Instruments – Credit Losses~~ ~~(“ASU 2016-13”):~~ ~~Measurement of Credit Losses on Financial Instruments,~~ and the subsequently issued additional guidance that modified ASU 2016-13 which was originally issued by the Financial Accounting Standards Board (“FASB”) in June 2016. The standard requires an entity to change its accounting approach in determining impairment of certain financial instruments, including trade receivables, from an “incurred loss” to a “current expected credit loss” model. The adoption of this standard did not have a material impact on our consolidated financial statements and disclosures.

~~Table of Contents~~

~~Sotera Health Company~~

~~Notes to Consolidated Financial Statements~~

~~Effective January 1, 2022, we adopted~~ ~~ASU 2019-12 - Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes~~ which was issued by the FASB in December 2019. The standard simplifies the accounting for income taxes and makes a number of changes meant to add or clarify guidance on accounting for income taxes. The adoption of this standard did not have a material impact on our consolidated financial statements and disclosures.

~~ASUs Issued But Not Yet Adopted~~

~~In October 2021, the FASB issued~~ ASU 2021-08 - Business Combinations (Topic 805): Accounting for Contract Assets and Contract Liabilities from Contracts with Customers (“ASU 2021-08”). The amendments in ASU 2021-08 require that an acquiring entity recognize and measure contract assets and contract liabilities acquired in a business combination in accordance with Accounting Standards Codification (“ASC”) Topic 606, Revenue from ~~Contract~~Contracts with Customers (“ASC Topic 606”). At the acquisition date, an acquirer should account for the related revenue contracts in accordance with ASC Topic 606 as if it had originated the contracts. For public business entities, these amendments are effective for fiscal years beginning after December 15, 2022, including interim periods within those fiscal years. We are currently assessing the effect that ASU 2021-08 willThe adoption of this standard did not have a material impact on our consolidated financial ~~position, results of operations,~~statements and disclosures.

3.Revenue Recognition

The following table shows disaggregated net revenues from contracts with external customers by timing of revenue and by segment for the three and six months ended June 30, ~~2022~~2023 and ~~2021:~~2022:

Table of Contents

Sotera Health Company

Notes to Consolidated Financial Statements


(thousands of U.S. dollars)	Three Months Ended June 30, 2023
	Sterigenics		Nordion		Nelson Labs		Consolidated
Point in time	$	166,590	$	30,653	$	—	$	197,243
Over time	—		1,322		56,717		58,039
Total	$	166,590	$	31,975	$	56,717	$	255,282


(thousands of U.S. dollars)	Three Months Ended June 30, 2022
	Sterigenics		Nordion		Nelson Labs		Consolidated
Point in time	$	157,792	$	46,386	$	—	$	204,178
Over time	—		4,092		58,369		62,461
Total	$	157,792	$	50,478	$	58,369	$	266,639


(thousands of U.S. dollars)	(thousands of U.S. dollars)	Three Months Ended June 30, 2021								(thousands of U.S. dollars)	Six Months Ended June 30, 2023
		Sterigenics		Nordion		Nelson Labs		Consolidated			Sterigenics		Nordion		Nelson Labs		Consolidated
Point in time	Point in time	$	145,182	$	47,753	$	—	$	192,935	Point in time	$	326,587	$	38,241	$	—	$	364,828
Over time	Over time	—		1,372		57,610		58,982		Over time	—		2,285		108,759		111,044
Total	Total	$	145,182	$	49,125	$	57,610	$	251,917	Total	$	326,587	$	40,526	$	108,759	$	475,872


(thousands of U.S. dollars)	Six Months Ended June 30, 2022
	Sterigenics		Nordion		Nelson Labs		Consolidated
Point in time	$	307,254	$	79,671	$	—	$	386,925
Over time	—		4,809		111,659		116,468
Total	$	307,254	$	84,480	$	111,659	$	503,393

(thousands of U.S. dollars) Six Months Ended June 30, 2021
Sterigenics Nordion Nelson Labs Consolidated
Point in time $ 276,333 $ 73,671 $ — $ 350,004
Over time — 1,372 112,689 114,061
Total $ 276,333 $ 75,043 $ 112,689 $ 464,065

Contract Balances

As of June 30, ~~2022,~~2023, and December 31, ~~2021,~~2022, contract assets included in “Prepaid expenses and other current assets” on the Consolidated Balance Sheets totaled approximately ~~$21.7~~$18.8 million and ~~$15.6~~$19.8 million, respectively, resulting from revenue recognized over time in excess of the amount billed to the customer.

~~Table of Contents~~

~~Sotera Health Company~~

~~Notes to Consolidated Financial Statements~~

When we receive consideration from a customer prior to transferring goods or services under the terms of a sales contract, we record deferred revenue, which represents a contract liability. Deferred revenue totaled ~~$6.9~~$13.8 million and ~~$8.7~~$12.1 million at June 30, ~~2022~~2023 and December 31, ~~2021,~~2022, respectively. We recognize deferred revenue after we have transferred control of the

goods or services to the customer and all revenue recognition criteria are met.

4.Acquisitions

Acquisition of Regulatory Compliance Associates Inc.

On November 4, 2021, we acquired Regulatory Compliance Associates Inc. (“RCA”) for approximately $30.6 million, net of $0.6 million of cash acquired. RCA is an industry leader in providing life sciences consulting focused on quality, regulatory, and technical advisory services for the pharmaceutical, medical device and combination device industries. Headquartered in Pleasant Prairie, Wisconsin, RCA ~~will expand~~expands and further ~~strengthen the~~strengthens our technical consulting and expert advisory capabilities ofwithin our Nelson Labs segment.

The purchase price of RCA was allocated to the underlying assets acquired and liabilities assumed based upon management's estimated fair values at the date of acquisition. ~~Changes to the allocation of the purchase price may occur as these measurements are completed.~~ As of June 30, ~~2022,~~2023, approximately ~~$25.2~~$25.3 million of goodwill was recorded related to the RCA acquisition, representing the excess of the purchase price over ~~preliminary~~the estimated fair values of all of the assets acquired and liabilities assumed. ~~Based on our most recent estimates, we~~We also recorded $6.4 million of finite-lived intangible assets, primarily related to customer relationships. ~~The purchase price allocation will be finalized within a measurement period not to exceed one year from closing.~~ We funded this acquisition using available cash. The acquisition price and the results of operations for this acquired entity are not material in relation to our consolidated financial statements.

~~Acquisition of Noncontrolling Interests in China Subsidiaries~~

On May 18, 2021, we acquired the remaining 15% and 33% noncontrolling interests associated with our 2 subsidiaries located in China. As a result, both entities are now 100% owned by the Company. The purchase price of the remaining equity interests was approximately $8.6 million, net of the cancellation of an $0.8 million demand note. We paid 90% of the cash consideration on the acquisition date. The remaining amounts were partially settled in post-closing payments in the third quarter of 2021; $0.2 million of the post-closing payment remain outstanding as of June 30, 2022 subject to the terms of the equity transfer agreements. As a result of the transactions, we continue to consolidate both of these subsidiaries, however, as of May 18, 2021, we no longer record noncontrolling interests in the consolidated financial statements as these subsidiaries are fully owned by the Company. The purchases were accounted for as equity transactions. As a result of these transactions, noncontrolling interests were reduced by $2.8 million reflecting the carrying value of the interest with $5.8 million of the difference charged to additional paid-in capital.

~~Acquisition of Mandatorily Redeemable Noncontrolling Interest - Nelson Labs Fairfield~~

On March 11, 2021, we completed the acquisition of the remaining 15% ownership of Nelson Labs Fairfield for $12.4 million, resulting in a gain of $1.2 million included in “Other expense (income), net” in the Consolidated Statements of Operations and Comprehensive Income (Loss) relative to the $13.6 million previously accrued. Pursuant to the terms of the acquisition, we initially acquired 85% of the equity interests of Nelson Labs Fairfield in August 2018 and were obligated to acquire the remaining 15% noncontrolling interest within three years from the date of the acquisition.

~~Acquisition of BioScience Laboratories, LLC~~

On March 8, 2021, we acquired BioScience Laboratories, LLC (“BioScience Labs”) for approximately $13.5 million, net of $0.2 million of cash acquired plus the contemporaneous repayment of BioScience Lab's outstanding debt of $1.9 million. BioScience Labs is a provider of outsourced topical antimicrobial product testing in the pharmaceutical, medical device, and consumer products industries with one location in Bozeman, Montana. BioScience Labs is included within the Nelson Labs segment.

Table of Contents

Sotera Health Company

Notes to Consolidated Financial Statements

The purchase price of BioScience was allocated to the underlying assets acquired and liabilities assumed based upon management's estimated fair values at the date of acquisition. Approximately $8.4 million of goodwill was recorded related to the BioScience Labs acquisition, representing the excess of the purchase price over preliminary estimated fair values of all the assets acquired and liabilities assumed. We funded this acquisition using available cash. The acquisition price and the results of operations for this acquired entity are not material in relation to our consolidated financial statements.

5.Inventories

Inventories consisted ~~primarily~~ of the following:


(thousands of U.S. dollars)	(thousands of U.S. dollars)					(thousands of U.S. dollars)
		June 30, 2022		December 31, 2021			June 30, 2023		December 31, 2022
Raw materials and supplies	Raw materials and supplies	$	33,329	$	41,514	Raw materials and supplies	$	36,600	$	36,402
Work-in-process	Work-in-process	484		3,919		Work-in-process	881		584
Finished goods	Finished goods	5,961		8,979		Finished goods	4,739		276
		39,774		54,412			42,220		37,262
Reserve for excess and obsolete inventory	Reserve for excess and obsolete inventory	(122)		(124)		Reserve for excess and obsolete inventory	(118)		(117)
Inventories, net	Inventories, net	$	39,652	$	54,288	Inventories, net	$	42,102	$	37,145

6.Prepaid Expenses and Other Current Assets

Prepaid expenses and other current assets consisted ~~primarily~~ of the following:


(thousands of U.S. dollars)	(thousands of U.S. dollars)					(thousands of U.S. dollars)
		June 30, 2022		December 31, 2021			June 30, 2023		December 31, 2022
Prepaid taxes	Prepaid taxes	$	27,972	$	24,937	Prepaid taxes	$	27,814	$	26,598
Prepaid business insurance	Prepaid business insurance	5,070		10,707		Prepaid business insurance	4,904		9,964
Prepaid rent	Prepaid rent	1,153		920		Prepaid rent	1,083		998
Customer contract assets	Customer contract assets	21,746		15,565		Customer contract assets	18,800		19,777
Insurance and indemnification receivables	Insurance and indemnification receivables	4,245		3,144		Insurance and indemnification receivables	2,039		3,724
Current deposits	Current deposits	647		623		Current deposits	422		660
Prepaid maintenance contracts	Prepaid maintenance contracts	388		279		Prepaid maintenance contracts	683		324
Value added tax receivable	Value added tax receivable	1,128		2,512		Value added tax receivable	3,561		1,640
Prepaid software licensing	Prepaid software licensing	2,444		2,055		Prepaid software licensing	2,873		1,832
Stock supplies	Stock supplies	3,420		3,374		Stock supplies	3,640		3,656
Embedded derivatives	Embedded derivatives	1,389		496		Embedded derivatives	1,551		2,721
Interest receivable - interest rate cap settlement						Interest receivable - interest rate cap settlement	7,596		—
Interest receivable - Illinois EO litigation settlement funds(a)						Interest receivable - Illinois EO litigation settlement funds(a)	1,319		—
Other	Other	11,571		7,311		Other	14,625		9,101
Prepaid expenses and other current assets	Prepaid expenses and other current assets	$	81,173	$	71,923	Prepaid expenses and other current assets	$	90,910	$	80,995

(a)Represents interest receivable on funds on deposit in a settlement escrow fund that was used to pay all settlement fees and expenses and cash payments to the Eligible Claimants participating in the Illinois EO litigation settlement. Refer to Note 15, “Commitments and Contingencies”.

7.Goodwill and Other Intangible Assets

Changes to goodwill during the six months ended June 30, ~~2022~~2023 were as follows:

(thousands of U.S. dollars) Sterigenics Nordion Nelson Labs Total
Goodwill at December 31, 2021 $ 660,743 $ 288,905 $ 170,672 $ 1,120,320
RCA acquisition measurement period adjustments — — 4,601 4,601
Changes due to foreign currency exchange rates (1,857) (4,307) (2,755) (8,919)
Goodwill at June 30, 2022 $ 658,886 $ 284,598 $ 172,518 $ 1,116,002


(thousands of U.S. dollars)	Sterigenics		Nordion		Nelson Labs		Total
Goodwill at December 31, 2022	$	657,458	$	270,966	$	173,344	$	1,101,768
Changes due to foreign currency exchange rates	2,156		6,014		560		8,730
Goodwill at June 30, 2023	$	659,614	$	276,980	$	173,904	$	1,110,498

1312

Table of Contents

Sotera Health Company

Notes to Consolidated Financial Statements

Other intangible assets consisted of the following:


(thousands of U.S. dollars)	(thousands of U.S. dollars)	Gross Carrying Amount		Accumulated Amortization		(thousands of U.S. dollars)	Gross Carrying Amount			Accumulated Amortization
As of June 30, 2022
As of June 30, 2023						As of June 30, 2023			Gross Carrying Amount			Accumulated Amortization
Finite-lived intangible assets	Finite-lived intangible assets					Finite-lived intangible assets
Customer relationships	Customer relationships	$	652,538	$	391,452	Customer relationships	$	656,345		$	454,212
Proprietary technology	Proprietary technology	87,177		47,793		Proprietary technology	84,710			53,332
Trade names	Trade names	2,555		452		Trade names	2,568			965
Land-use rights	Land-use rights	9,255		1,620		Land-use rights	8,542			1,705
Sealed source and supply agreements	Sealed source and supply agreements	214,744		91,341		Sealed source and supply agreements	208,958			101,347
Other	Other	5,679		2,673		Other	4,518			2,453
Total finite-lived intangible assets	Total finite-lived intangible assets	971,948		535,331		Total finite-lived intangible assets	965,641			614,014

Indefinite-lived intangible assets	Indefinite-lived intangible assets					Indefinite-lived intangible assets
Regulatory licenses and other(a)	Regulatory licenses and other(a)	80,878		—		Regulatory licenses and other(a)	78,699			—
Trade names / trademarks	Trade names / trademarks	25,562		—		Trade names / trademarks	25,794			—
Total indefinite-lived intangible assets	Total indefinite-lived intangible assets	106,440		—		Total indefinite-lived intangible assets	104,493			—
Total	Total	$	1,078,388	$	535,331	Total	$	1,070,134		$	614,014


As of December 31, 2021		Gross Carrying Amount		Accumulated Amortization
As of December 31, 2022						As of December 31, 2022	Gross Carrying Amount		Accumulated Amortization
Finite-lived intangible assets	Finite-lived intangible assets					Finite-lived intangible assets
Customer relationships	Customer relationships	$	668,628	$	365,935	Customer relationships	$	652,811	$	422,277
Proprietary technology	Proprietary technology	88,826		44,866		Proprietary technology	86,054		50,952
Trade names	Trade names	145		116		Trade names	2,553		701
Land-use rights	Land-use rights	9,744		1,586		Land-use rights	8,986		1,683
Sealed source and supply agreements	Sealed source and supply agreements	241,611		109,838		Sealed source and supply agreements	204,391		93,034
Other	Other	6,454		2,166		Other	4,469		1,979
Total finite-lived intangible assets	Total finite-lived intangible assets	1,015,408		524,507		Total finite-lived intangible assets	959,264		570,626

Indefinite-lived intangible assets	Indefinite-lived intangible assets					Indefinite-lived intangible assets
Regulatory licenses and other(a)	Regulatory licenses and other(a)	82,110		—		Regulatory licenses and other(a)	76,978		—
Trade names / trademarks	Trade names / trademarks	25,833		—		Trade names / trademarks	25,649		—
Total indefinite-lived intangible assets	Total indefinite-lived intangible assets	107,943		—		Total indefinite-lived intangible assets	102,627		—
Total	Total	$	1,123,351	$	524,507	Total	$	1,061,891	$	570,626

(a)Includes certain transportation certifications, a class 1B nuclear license and other intangibles related to obtaining such licensure. These assets are considered indefinite-lived as the decision for renewal by the Canadian Nuclear Safety Commission is highly based on a licensee’s previous assessments, reported incidents, and annual compliance and inspection results. New applications for license can take a significant amount of time and cost; whereas an existing licensee with a historical record of compliance and current operating conditions more than likely ensures renewal for another ~~10 year~~10-year license period as Nordion has demonstrated over its 75 years of history.

Amounts include the impact of foreign currency translation. Fully amortized amounts are written off.

Amortization expense for other intangible assets was ~~$21.2~~$20.5 million ($~~5.4~~4.4 million is included in “Cost of revenues” and ~~$15.8~~$16.1 million in ~~“Selling, general and administrative expenses”~~“Amortization of intangible assets”) and ~~$41.4~~$41.1 million ($~~9.8~~8.8 million is included in “Cost of revenues” and ~~$31.6~~$32.3 million in ~~“Selling, general and administrative expenses”~~“Amortization of intangible assets”) in the Consolidated Statements of Operations and Comprehensive Income (Loss) for the three and six months ended June 30, ~~2022,~~2023, respectively.

1413

Table of Contents

Sotera Health Company

Notes to Consolidated Financial Statements

Amortization expense for other intangible assets was ~~$21.8~~$21.2 million ($~~6.1~~5.4 million is included in “Cost of revenues” and ~~$15.7~~$15.8 million in ~~“Selling, general and administrative expenses”~~“Amortization of intangible assets”) and ~~$44.1~~$41.4 million ($~~11.9~~9.8 million is included in “Cost of revenues” and ~~$32.2~~$31.6 million in ~~“Selling, general and administrative expenses”~~“Amortization of intangible assets”) in the Consolidated Statements of Operations and Comprehensive Income (Loss) for the three and six months ended June 30, ~~2021,~~2022, respectively.

The estimated aggregate amortization expense for finite-lived intangible assets for each of the next five years and thereafter is as follows:


(thousands of U.S. dollars)	(thousands of U.S. dollars)			(thousands of U.S. dollars)
For the remainder of 2022		$	40,551
2023		81,166
For the remainder of 2023				For the remainder of 2023	$	40,372
2024	2024	80,389		2024	80,050
2025	2025	43,028		2025	42,671
2026	2026	22,788		2026	22,492
2027				2027	21,416
Thereafter	Thereafter	168,695		Thereafter	144,626
Total	Total	$	436,617	Total	$	351,627

The weighted-average remaining useful life of the finite-lived intangible assets was approximately ~~8.8~~nine years as of June 30, ~~2022.~~2023.

8.Accrued Liabilities

Accrued liabilities consisted of the following:

(thousands of U.S. dollars)
June 30, 2022 December 31, 2021
Accrued employee compensation $ 27,500 $ 33,334
Legal reserves 3,119 3,259
Accrued interest expense 782 10,755
Embedded derivatives 2,322 —
Professional fees 7,972 4,314
Accrued utilities 1,671 1,797
Insurance accrual 1,781 2,068
Accrued taxes 3,291 2,209
Other 4,220 4,125
Accrued liabilities $ 52,658 $ 61,861

9.~~Long-Term Debt~~

~~Long-term debt consisted of the following:~~

(thousands of U.S. dollars)
June 30, 2022 December 31, 2021
Term loan, due 2026 $ 1,763,100 $ 1,763,100
Other long-term debt 450 450
Total long-term debt 1,763,550 1,763,550
Less unamortized debt issuance costs and debt discounts (18,002) (20,016)
Total long-term debt, less debt issuance costs and debt discounts $ 1,745,548 $ 1,743,534


(thousands of U.S. dollars)
	June 30, 2023		December 31, 2022
Accrued employee compensation	$	32,385	$	32,936
Illinois EO litigation settlement reserve	288		408,000
Legal reserves	2,954		3,776
Accrued interest expense	30,591		23,291
Embedded derivatives	1,613		3,508
Professional fees	23,259		6,436
Accrued utilities	1,998		1,906
Insurance accrual	2,253		2,392
Accrued taxes	3,070		2,567
Other	5,039		5,318
Accrued liabilities	$	103,450	$	490,130

1514

Table of Contents

Sotera Health Company

Notes to Consolidated Financial Statements

9.Long-Term Debt

Long-term debt consisted of the following:


(thousands of U.S. dollars)
As of June 30, 2023	Gross Amount		Unamortized Debt Issuance Costs		Unamortized Debt Discount		Net Amount
Term loan, due 2026	$	1,763,100	$	(1,911)	$	(12,013)	1,749,176
Term loan B, due 2026	500,000		(8,354)		(14,059)		477,587
Other long-term debt	450		(1)		—		449
	2,263,550		(10,266)		(26,072)		2,227,212
Less current portion	5,450		(84)		(141)		5,225
Long-term debt	$	2,258,100	$	(10,182)	$	(25,931)	$	2,221,987


(thousands of U.S. dollars)
As of December 31, 2022	Gross Amount		Unamortized Debt Issuance Costs		Unamortized Debt Discount		Net Amount
Term loan, due 2026	$	1,763,100	$	(2,140)	$	(13,845)	1,747,115
Revolving credit facility	200,000		(3,328)		$	—	196,672
Other long-term debt	450		(3)		$	—	447
	1,963,550		(5,471)		(13,845)		1,944,234
Less current portion	$	200,450	$	(3,331)	$	—	$	197,119
Long-term debt	$	1,763,100	$	(2,140)	$	(13,845)	$	1,747,115

Debt Facilities

Senior Secured Credit Facilities

On December 13, 2019, Sotera Health Holdings, LLC (“SHH”), our wholly owned subsidiary, entered into senior secured first lien credit facilities (the “Senior Secured Credit Facilities”), consisting of both a prepayable senior secured first lien term loan (the “Term Loan”) and a senior secured first lien revolving credit facility (the “Revolving Credit Facility”) pursuant to a first lien credit agreement (the “Credit Agreement”). The Term Loan matures on December 13, 2026. After giving effect to the Revolving Credit Facility ~~and Term Loan mature on June 13, 2026 and December 13, 2026, respectively. The~~Amendment (defined below), the total borrowing capacity under the Revolving Credit Facility is ~~$347.5~~$423.8 million. The Senior Secured Credit Facilities also provide SHH the right at any time and under certain conditions to request incremental term loans or incremental revolving credit commitments based on a formula defined in the Senior Secured Credit Facilities. As of June 30, ~~2022~~2023 and December 31, ~~2021,~~2022, total borrowings under the Term Loan were $1,763.1 ~~million, respectively, and there were no borrowings outstanding on the Revolving Credit Facility.~~million. The weighted average interest rate on borrowings under the Term Loan for the three months ended June 30, ~~2022~~2023 and June 30, ~~2021~~2022 was ~~3.53%~~7.89% and ~~3.25%~~3.53%, respectively, and ~~3.39%~~7.66% and ~~3.64%~~3.39% for the six months ended June 30, ~~2022~~2023 and June 30, ~~2021,~~2022, respectively.

On ~~January 20, 2021,~~February 23, 2023, we ~~closed on~~entered into the First Lien Credit Agreement (the “2023 Credit Agreement”), which provides for, among other things, a new Term Loan B facility (the “2023 Term Loan”) in an ~~amendment repricing our~~aggregate principal amount of $500.0 million and bears interest, at the Company’s option, at a variable rate per annum equal to either (x) the Term ~~Loan. The interest rate spread over the London Interbank Offered~~Secured Overnight Financing Rate (“~~LIBOR”~~Term SOFR”) on the facility was reduced from 450 basis points to 275 basis points, and the facility’s LIBOR floor was reduced from 100 basis points to 50 basis points. The changes resulted in an effective reduction in current interest rates of 225 basis points. In connection with this amendment, we wrote off $11.3 million of unamortized debt issuance and discount costs and incurred an additional $2.9 million of expense related to debt issuance costs attributable to the refinancing. These costs were recorded to “Loss on extinguishment of debt” in our Consolidated Statements of Operations and Comprehensive Income (Loss).

~~On March 26, 2021, we amended the Revolving Credit Facility, to (i) decrease the Applicable Rate~~ (as defined in the 2023 Credit Agreement) ~~related to any Revolving Loans (as defined in the Credit Agreement) from a rate per annum that ranged from~~plus an applicable margin of 3.75% or (y) an alternative base rate (“ABR”) plus ~~2.50%~~an applicable margin of 2.75%. The 2023 Credit Agreement is secured on a first priority basis on substantially all of our assets and is guaranteed by certain of our subsidiaries. It is prepayable without premium or penalty at any time six months after the closing date. The principal balance shall be paid at 1% of the aggregate principal amount ($5.0 million) per year, with the balance due at the end of 2026. The Company used the proceeds of the 2023 Term Loan to ~~ABR plus 3.00% depending~~fund a previously announced $408.0 million EO litigation settlement in Cook County, Illinois and pay down the $200.0 million of existing borrowings under the Revolving Credit Facility concurrent with the funding of the 2023 Term Loan on ~~SHH’s Senior Secured First Lien Net Leverage Ratio~~February 23, 2023. In addition, the Company plans to ~~ABR plus 1.75%;~~use the remaining proceeds to further enhance liquidity and for general

Table of Contents

Sotera Health Company

Notes to Consolidated Financial Statements

corporate purposes. The weighted average interest rate on borrowings under the 2023 Term Loan for the three and six months ended June 30, 2023 was 8.82%.

On March 21, 2023, the Company entered into an Incremental Facility Amendment to the Credit Agreement (“Revolving Credit Facility Amendment”), which provides for an increase in the ~~case~~commitments under the existing Revolving Credit Facility in an aggregate principal amount of ~~Eurodollar~~$76.3 million. In addition, certain of the lenders providing revolving credit commitments provided additional commitments for the issuance of the letters of credit under the Revolving Credit Facility in an aggregate principal amount of $165.1 million. The Revolving Credit Facility Amendment also provides for the replacement of the reference interest rate option for Revolving Loans ~~(as defined in the Credit Agreement)~~ from London Interbank Offered Rate (“LIBOR”) to SOFR plus an applicable credit spread adjustment of 0.10% (subject to a ~~rate per annum which ranged from the Adjusted LIBOR plus 3.50%~~minimum floor of 0.00%). After giving effect to the ~~Adjusted LIBOR plus 4.00% depending on SHH’s Senior Secured First Lien Net Leverage Ratio (as defined in~~Revolving Credit Facility Amendment, the ~~Credit Agreement), to~~aggregate amount of the ~~Adjusted LIBOR (as defined in the Credit Agreement) plus 2.75%, and (ii) extend the~~Lenders’ Revolving Commitments is $423.8 million. The maturity date of the Revolving Credit Facility ~~from December 13, 2024 to~~remains June 13, 2026. The ~~other material terms of the Credit Agreement remain unchanged and the amendment does not change the capacity of our Revolving Credit Facility. No unamortized debt issuance costs associated with~~Company borrowed $200.0 million under the Revolving Credit Facility ~~were written off and direct fees and costs incurred~~during the fourth quarter of 2022, which was repaid in ~~connection with~~ the ~~amendment were immaterial.~~

first quarter of 2023, as noted above. As of June 30, ~~2022 and December 31, 2021, capitalized debt issuance costs totaled $2.4 million and $2.7 million, respectively, and debt discounts totaled $15.6 million and $17.3 million, respectively, related to~~2023, there were no borrowings outstanding under the ~~Senior Secured~~Revolving Credit ~~Facilities. Such costs are recorded as a reduction of debt on our Consolidated Balance Sheets and amortized as a component of interest expense over the term of the debt agreement.~~Facility.

The Senior Secured Credit Facilities and 2023 Credit Agreement contain additional covenants that, among other things, restrict, subject to certain exceptions, our ability and the ability of our restricted subsidiaries to engage in certain activities, such as incur indebtedness or permit to exist any lien on any property or asset now owned or hereafter acquired, as specified in the Senior Secured Credit ~~Facilities.~~Facilities and 2023 Credit Agreement. The Senior Secured Credit Facilities and 2023 Credit Agreement also contain certain customary affirmative covenants and events of default, including upon a change of control. An event of default under the Senior Secured Credit Facilities and 2023 Credit Agreement would occur if the Company or certain of its subsidiaries received one or more enforceable judgment for payment in an aggregate amount in excess of $100.0 million, which judgment or judgments are not stayed or remain undischarged for a period of 60 consecutive days or if, in order to enforce such a judgment, a judgment creditor attached or levied upon assets that are material to the business and operations, taken as a whole,

of the Company and certain of its subsidiaries. As of June 30, ~~2022,~~2023, we were in compliance with all of the Senior Secured Credit Facilities and 2023 Credit Agreement covenants.

All of SHH’s obligations under the Senior Secured Credit Facilities and 2023 Credit Agreement are unconditionally guaranteed by the Company and each existing and subsequently acquired or organized direct or indirect wholly-owned domestic restricted subsidiary of the Company, with customary exceptions including, among other things, where providing such guarantees is not permitted by law, regulation or contract or would result in material adverse tax consequences. All obligations under the Senior Secured Credit Facilities and 2023 Credit Agreement, and the guarantees of such obligations, are secured by substantially all assets of the borrower and guarantors, subject to permitted liens and other exceptions and exclusions, as outlined in the Senior Secured Credit ~~Facilities.~~

~~Table of Contents~~

~~Sotera Health Company~~

~~Notes to Consolidated Financial Statements~~

Facilities and 2023 Credit Agreement.

Outstanding letters of credit are collateralized by encumbrances against the Revolving Credit Facility and the collateral pledged thereunder, or by cash placed on deposit with the issuing bank. As of June 30, ~~2022,~~2023, the Company had ~~$70.1~~$51.7 million of letters of credit issued against the Revolving Credit Facility, resulting in total availability under the Revolving Credit Facility of ~~$277.4~~$372.1 million.

Term Loan Interest Rate Risk Management

The Company utilizes interest rate derivatives to ~~reduce~~eliminate the variability of cash flows in the interest payments associated with ~~the Term Loan~~our variable rate debt due to changes in LIBOR ~~(or its successor).~~(up to June 22, 2023) and Term SOFR. For additional information on the derivative instruments described above, refer to Note ~~17,~~16, “Financial Instruments and Financial Risk”, “~~Derivatives~~Derivative Instruments.”

~~First Lien Notes~~LIBOR Transition

~~On July 31, 2020, SHH issued $100.0 million aggregate principal amount~~Publication of senior secured first lien notes due 2026 (the “First Lien Notes”), which were scheduled to mature on December 13, 2026. On August 27, 2021 SHH redeemed in full the $100.0 million aggregate principal amount of the First Lien Notes. In connection with this redemption, the Company paid a $3.0 million early redemption premium, in accordanceall U.S. LIBOR tenors ceased after June 30, 2023. To align with the ~~terms~~market phaseout of the First Lien Notes Indenture, and wrote off $3.4 million of debt issuance and discount costs. The Company recognized these expenses within “Loss on extinguishment of debt” in our Consolidated Statements of Operations and Comprehensive Income (Loss) for the year ended December 31, 2021.

~~Prior~~LIBOR, SHH entered into an amendment to the ~~redemption,~~Senior Secured Credit Facilities to replace the ~~First Lien Notes bore~~LIBOR-based reference interest atrate option under the Term Loan with a reference interest rate ~~equal to LIBOR~~option based on Term SOFR plus an applicable credit spread adjustment of 0.11448% (for one-month interest periods), 0.26161% (for three-month interest periods) and 0.42826% (for six-month interest periods) (in all cases, subject to a ~~1.00%~~minimum floor ~~plus 6.00% per annum. Interest was payable on a quarterly basis~~of 0.50%).

Table of Contents

Sotera Health Company

Notes to Consolidated Financial Statements

In accordance with ~~no principal due until maturity. The weighted average~~ASC 848 Reference Rate Reform, we have elected to apply certain optional expedients for contract modifications and hedging relationships for derivative instruments impacted by the benchmark interest rate ontransition. The optional expedients remove the ~~First Lien Notes during 2021 up~~requirement to ~~the August 27, 2021 redemption date was 7.00%.~~remeasure contract modifications or dedesignate hedging relationships impacted by reference rate reform.

Aggregate Maturities

Aggregate maturities of the Company’s long-term debt, excluding debt discounts, as of June 30, ~~2022,~~2023, are as follows:


(thousands of U.S. dollars)	(thousands of U.S. dollars)			(thousands of U.S. dollars)
2022		$	—
2023	2023	450		2023	$	2,950
2024	2024	—		2024	5,000
2025	2025	—		2025	5,000
2026	2026	1,763,100		2026	2,250,600
2027				2027	—
Thereafter	Thereafter	—		Thereafter	—
Total	Total	$	1,763,550	Total	$	2,263,550

10.Income Taxes

Income tax expense is provided on an interim basis based upon our estimate of the annual effective income tax rate. In determining the estimated annual effective income tax rate, we analyze various factors, including projections of our annual earnings and the taxing jurisdictions where the earnings will occur, the impact of state and local taxes, our ability to utilize tax credits and net operating loss carryforwards and available tax planning alternatives.

Our effective tax rates were ~~36.8 %~~31.8% and 33.9% for the three and six months ended June 30, 2023, respectively, compared to 36.8% and 34.6% for the three and six months ended June 30, 2022, ~~respectively, compared to 31.0% and 29.3%~~respectively.

Income tax expense for the three ~~and six~~ months ended June 30, ~~2021, respectively.~~

2023 differed from the statutory rate primarily due to the impact of the foreign rate differential, the valuation allowance attributable to the limitation on the deductibility of interest expense, and global intangible low-tax income (“GILTI”). Income tax expense for the three months ended June 30, 2022 differed from the statutory rate primarily due to a net increase in the valuation allowance attributable to the limitation on the deductibility of interest expense, the impact of the foreign rate differential, and ~~global intangible low-tax income (“GILTI”). The increase in~~GILTI.

Income tax expense for the six months ended June 30, 2023 differed from the statutory rate primarily due to the impact of the foreign rate differential, the valuation allowance ~~was~~ attributable to the limitation on the deductibility of interest expense and ~~the impairment of the investment in Auralux. Provision for income tax expense for the three months ended June 30, 2021 was~~GILTI, partially offset by a ~~discrete item, which reversed the valuation allowance on deferred tax assets related to certain asset retirement obligations.~~

~~Table of Contents~~

~~Sotera Health Company~~

~~Notes to Consolidated Financial Statements~~

benefit for state income taxes. Income tax expense for the six months ended June 30, 2022 differed from the statutory rate primarily due to a net increase in the ~~valuation allowance, the impact of the~~ foreign rate differential and GILTI. Provision for income tax expense for the six months ended June 30, 2021 was offset by an additional discrete item in the first quarter of 2021, which reversed the valuation allowance on deferred tax assets related to certain asset retirement obligations.

11.Employee Benefits

The Company sponsors various post-employment benefit plans including, in certain countries outside the U.S., defined benefit and defined contribution pension plans, retirement compensation arrangements, and plans that provide extended health care coverage to retired employees, the majority of which relate to Nordion.

Defined benefit pension plan

The following defined benefit pension plan disclosure relates to Nordion. Certain immaterial foreign defined benefit pension plans have been excluded from the table below. The interest cost, expected return on plan assets and amortization of net actuarial ~~loss~~gain are recorded in “Other expense (income), net” and the service cost component is included in the same financial statement line item as the applicable employee’s wages in the Consolidated Statements of Operations and Comprehensive

Table of Contents

Sotera Health Company

Notes to Consolidated Financial Statements

Income (Loss). The components of net periodic pension ~~cost~~benefit for the defined benefit plan for the three and six months ended June 30, ~~2022~~2023 and ~~2021~~2022 were as follows:


		Three Months Ended June 30,				Six Months Ended June 30,					Three Months Ended June 30,				Six Months Ended June 30,
(thousands of U.S. dollars)	(thousands of U.S. dollars)	2022		2021		2022		2021		(thousands of U.S. dollars)	2023		2022		2023		2022
Service cost	Service cost	$	247	$	307	$	496	$	605	Service cost	$	132	$	247	$	263	$	496
Interest cost	Interest cost	1,889		1,662		3,792		3,275		Interest cost	2,742		1,889		5,466		3,792
Expected return on plan assets	Expected return on plan assets	(3,676)		(3,665)		(7,380)		(7,222)		Expected return on plan assets	(4,046)		(3,676)		(8,065)		(7,380)
Amortization of net actuarial loss		—		275		—		542
Net periodic benefit	Net periodic benefit	$	(1,540)	$	(1,421)	$	(3,092)	$	(2,800)	Net periodic benefit	$	(1,172)	$	(1,540)	$	(2,336)	$	(3,092)

Other benefit plans

Other benefit plans disclosed below relate to Nordion and include a supplemental retirement arrangement, a retirement and termination allowance, and post-retirement benefit plans, which include contributory health and dental care benefits and contributory life insurance coverage. Certain immaterial other foreign benefit plans have been excluded from the table below. All but one non-pension post-employment benefit plans are unfunded. The components of net periodic ~~pension~~benefit cost for the other benefit plans for the three and six months ended June 30, ~~2022~~2023 and ~~2021~~2022 were as follows:


		Three Months Ended June 30,				Six Months Ended June 30,					Three Months Ended June 30,				Six Months Ended June 30,
(thousands of U.S. dollars)	(thousands of U.S. dollars)	2022		2021		2022		2021		(thousands of U.S. dollars)	2023		2022		2023		2022
Service cost	Service cost	$	4	$	7	$	8	$	14	Service cost	$	2	$	4	$	4	$	8
Interest cost	Interest cost	65		61		130		120		Interest cost	90		65		180		130
Amortization of net actuarial (gain) loss		(2)		9		(4)		17
Amortization of net actuarial gain										Amortization of net actuarial gain	(44)		(2)		(88)		(4)
Net periodic benefit cost	Net periodic benefit cost	$	67	$	77	$	134	$	151	Net periodic benefit cost	$	48	$	67	$	96	$	134

We currently expect funding requirements of approximately ~~$3.1~~$0.3 million in each of the next five years to fund the regulatory solvency deficit, as defined by Canadian federal regulation, which ~~require~~requires solvency testing on defined benefit pension plans.

The Company may obtain a qualifying letter of credit for solvency payments, up to 15% of the market value of solvency liabilities as determined on the valuation date, instead of paying cash into the pension fund. As of June 30, ~~2022,~~2023, and December 31, ~~2021,~~2022, we had letters of credit outstanding relating to the defined benefit plans totaling ~~$46.9~~$43.7 million and ~~$46.2~~$44.1 million, respectively. The actual funding requirements over the five-year period will be dependent on subsequent annual actuarial valuations. These amounts are estimates, which may change with actual investment performance, changes in interest rates, any pertinent changes in Canadian government regulations and any voluntary contributions.

~~Table of Contents~~

~~Sotera Health Company~~

~~Notes to Consolidated Financial Statements~~

12.~~Related Parties~~

We do business with a number of companies affiliated with Warburg Pincus and GTCR, which we refer to collectively as the “Sponsors”. All transactions with these companies have been conducted in the ordinary course of our business and are not material to our operations.

~~13.~~Other Comprehensive Income (Loss)

Amounts in accumulated other comprehensive income (loss) are presented net of the related tax. Foreign currency translation is not adjusted for income taxes.

~~Changes in our accumulated other comprehensive income (loss) balances, net of applicable tax, were as follows:~~

(thousands of U.S. dollars)
Defined
Benefit
Plans
Foreign
Currency
Translation
Interest
Rate
Derivatives
Total
Beginning balance – April 1, 2022 $ (17,855) $ (51,414) $ 6,583 $ (62,686)
Other comprehensive income (loss) before
reclassifications
534 (46,038) 3,178 (42,326)
Amounts reclassified from accumulated other
comprehensive income (loss)
(2) (a) — — (2)
Net current-period other comprehensive income (loss) 532 (46,038) 3,178 (42,328)
Ending balance – June 30, 2022 $ (17,323) $ (97,452) $ 9,761 $ (105,014)
Beginning balance – January 1, 2022 $ (17,581) $ (66,389) $ 404 (83,566)
Other comprehensive income (loss) before
reclassifications
262 (31,063) 9,357 (21,444)
Amounts reclassified from accumulated other
comprehensive income (loss)
(4) (a) — — (4)
Net current-period other comprehensive income (loss) 258 (31,063) 9,357 (21,448)
Ending balance – June 30, 2022 $ (17,323) $ (97,452) $ 9,761 $ (105,014)

(thousands of U.S. dollars)
Defined
Benefit
Plans
Foreign
Currency
Translation
Interest
Rate
Derivatives
Total
Beginning balance – April 1, 2021 $ (44,392) $ (52,770) $ — $ (97,162)
Other comprehensive income (loss) before
reclassifications
(705) 20,115 — 19,410
Amounts reclassified from accumulated other
comprehensive income (loss)
284 (a) — — 284
Net current-period other comprehensive income (loss) (421) 20,115 — 19,694
Ending balance – June 30, 2021 $ (44,813) $ (32,655) $ — $ (77,468)
Beginning balance – January 1, 2021 $ (44,143) $ (49,699) $ — $ (93,842)
Other comprehensive income (loss) before
reclassifications
(1,229) 17,044 — 15,815
Amounts reclassified from accumulated other
comprehensive income (loss)
559 (a) — — 559
Net current-period other comprehensive income (loss) (670) 17,044 — 16,374
Ending balance – June 30, 2021 $ (44,813) $ (32,655) $ — $ (77,468)

1918

Table of Contents

Sotera Health Company

Notes to Consolidated Financial Statements

Changes in our accumulated other comprehensive income (loss) balances, net of applicable tax, were as follows:


(thousands of U.S. dollars)	Defined Benefit Plans			Foreign Currency Translation		Interest Rate Derivatives			Total
Beginning balance – April 1, 2023	$	3,158		$	(119,948)	$	12,092		$	(104,698)
Other comprehensive income (loss) before reclassifications	62			21,374		10,950			32,386
Amounts reclassified from accumulated other comprehensive income (loss)	(44)		(a)	—		(6,948)		(b)	(6,992)
Net current-period other comprehensive income (loss)	18			21,374		4,002			25,394
Ending balance – June 30, 2023	$	3,176		$	(98,574)	$	16,094		$	(79,304)

Beginning balance – January 1, 2023	$	3,209		$	(131,205)	$	21,343		(106,653)
Other comprehensive income (loss) before reclassifications	55			32,631		8,555			41,241
Amounts reclassified from accumulated other comprehensive income (loss)	(88)		(a)	—		(13,804)		(b)	(13,892)
Net current-period other comprehensive income (loss)	(33)			32,631		(5,249)			27,349
Ending balance – June 30, 2023	$	3,176		$	(98,574)	$	16,094		$	(79,304)


(thousands of U.S. dollars)	Defined Benefit Plans			Foreign Currency Translation		Interest Rate Derivatives		Total
Beginning balance – April 1, 2022	$	(17,855)		$	(51,414)	$	6,583	$	(62,686)
Other comprehensive income (loss) before reclassifications	534			(46,038)		3,178		(42,326)
Amounts reclassified from accumulated other comprehensive income (loss)	(2)		(a)	—		—		(2)
Net current-period other comprehensive income (loss)	532			(46,038)		3,178		(42,328)
Ending balance – June 30, 2022	$	(17,323)		$	(97,452)	$	9,761	$	(105,014)

Beginning balance – January 1, 2022	$	(17,581)		$	(66,389)	$	404	$	(83,566)
Other comprehensive income (loss) before reclassifications	262			(31,063)		9,357		(21,444)
Amounts reclassified from accumulated other comprehensive income (loss)	(4)		(a)	—		—		(4)
Net current-period other comprehensive income (loss)	258			(31,063)		9,357		(21,448)
Ending balance – June 30, 2022	$	(17,323)		$	(97,452)	$	9,761	$	(105,014)

(a)For defined benefit pension plans, amounts reclassified from accumulated other comprehensive income (loss) are recorded to “Other expense (income), net” within the Consolidated Statements of Operations and Comprehensive Income (Loss).

(b)For interest rate derivatives, amounts reclassified from accumulated other comprehensive income (loss) are recorded to “Interest expense, net” within the Consolidated Statements of Operations and Comprehensive Income (Loss).

Table of Contents

Sotera Health Company

Notes to Consolidated Financial Statements

~~14.~~13.Share-Based Compensation

Pre-IPO Awards

Restricted stock distributed in respect of pre-IPO Class B-1 time vesting units vests on a daily basis pro rata over a five-year vesting period (20% per year) beginning on the original vesting commencement date of the corresponding Class B-1 time vesting units, subject to the grantee’s continued services through each vesting date. Upon the occurrence of a change in control of the Company, all then outstanding unvested shares of our common stock distributed in respect of Class B-1 Units will become vested as of the date of consummation of such change in control, subject to the grantee’s continued services through the consummation of the change in control.

Restricted stock distributed in respect of pre-IPO Class B-2 Units (which were considered performance vesting units) are scheduled to vest only upon satisfaction of certain thresholds. These units generally vest as of the first date on which (i) our Sponsors have received actual cash proceeds in an amount equal to or in excess of at least two and one-half times their invested capital in Sotera Health Topco Parent, L.P. (of which the Company was a direct wholly owned subsidiary prior to the IPO) and (ii) the Sponsors’ internal rate of return exceeds ~~20 percent,~~20%, subject to such grantee’s continued services through such date. In the event of a change in control of the Company, any outstanding shares of our common stock distributed in respect of Class B-2 Units that remain unvested immediately following the consummation of such a change in control of the Company shall be immediately canceled and forfeited without compensation. Stock based compensation expense attributed to the pre-IPO Class B-2 awards was recorded in the fourth quarter of 2020 as the related performance conditions were considered probable of achievement and the implied service conditions were met. As of June 30, ~~2022,~~2023, these awards remain unvested.

We recognized $0.5 million and ~~$0.7~~$0.5 million of share-based compensation expense related to the pre-IPO Class B-1 awards for the three months ended June 30, ~~2022~~2023 and ~~2021,~~2022, respectively, and ~~$1.1~~$1.0 million and ~~$1.3~~$1.1 million for the six months ended June 30, ~~2022~~2023 and ~~2021,~~2022, respectively.

A summary of the activity for the six months ended June 30, ~~2022~~2023 related to the restricted stock awards distributed ~~to the Company service providers~~ in respect of the pre-IPO awards (Class B-1 and B-2 Units) is presented below:


		Restricted Stock - Pre- IPO B-1	Restricted Stock - Pre- IPO B-2		Restricted Stock - Pre- IPO B-1	Restricted Stock - Pre- IPO B-2
Unvested at December 31, 2021		1,206,089	2,023,959
Unvested at December 31, 2022				Unvested at December 31, 2022	716,091	1,098,415

Forfeited	Forfeited	(32,614)	(136,252)	Forfeited	(5,378)	(80,051)
Vested	Vested	(251,639)	—	Vested	(172,654)	—
Unvested at June 30, 2022		921,836	1,887,707
Unvested at June 30, 2023				Unvested at June 30, 2023	538,059	1,018,364

~~2021~~2020 Omnibus Incentive Plan

We maintain a long-term incentive plan (the “2020 Omnibus Incentive Plan” or the “2020 Plan”) that allows for grants of incentive stock options to employees (including employees of any of our subsidiaries), nonstatutory stock options, restricted stock awards (“RSAs”), restricted stock units (“RSUs”) and other cash-based, equity-based or equity-related awards to employees, directors, and consultants, including employees or consultants of our subsidiaries.

We recognized $7.9 million ($3.7 million for stock options and $4.2 million for RSUs) and $5.3 million ($2.2 million for stock options and $3.1 ~~million for RSUs) and $2.8 million ($1.3 million for stock options and $1.5~~ million for RSUs) of share-based compensation expense for these awards for the three months ended June 30, ~~2022~~2023 and ~~2021,~~2022, respectively. We recognized $14.7 million ($6.8 million for stock options and $7.9 million for RSUs) and $9.2 million ($3.7 million for stock options and $5.5 million for RSUs) ~~and $5.6 million ($2.5 million for stock options and $3.1 million for RSUs)~~ for the six months ended June 30, ~~2022~~2023 and ~~2021,~~2022, respectively, in our Consolidated Statements of Operations and Comprehensive Income (Loss), in “Selling, general and administrative expenses.”

Table of Contents

Sotera Health Company

Notes to Consolidated Financial Statements

Stock Options

Stock options generally vest ratably over a period of ~~three~~two orto four years. They have an exercise price equal to the fair market value of a share of common stock on the date of grant, and a contractual term of 10 years. The following table summarizes our stock option activity for the six months ended June 30, ~~2022:~~2023:


		Number of Shares	Weighted-average Exercise Price			Number of Shares	Weighted-average Exercise Price
At December 31, 2021		2,423,256	$	23.02
At December 31, 2022					At December 31, 2022	5,990,470	$	14.84
Granted	Granted	1,416,967	20.03		Granted	1,059,769	17.55
Forfeited	Forfeited	(61,393)	22.78		Forfeited	(61,571)	20.93
Exercised	Exercised	—	—		Exercised	—	—
At June 30, 2022		3,778,830	$	21.90
At June 30, 2023					At June 30, 2023	6,988,668	$	15.20

As of June 30, ~~2022,~~2023, there were ~~0.6~~1.4 million vested and exercisable stock ~~options vested.~~options.

RSUs

RSUs generally vest ratably over a period of one to four years and are valued based on our market price on the date of grant. The following table summarizes our unvested RSUs activity for the six months ended June 30, ~~2022:~~2023:


		Number of Shares	Weighted-average Grant Date Fair Value			Number of Shares	Weighted-average Grant Date Fair Value
Unvested at December 31, 2021		640,122	$	23.19
Unvested at December 31, 2022					Unvested at December 31, 2022	2,482,435	$	13.09
Granted	Granted	923,137	20.70		Granted	821,673	16.97
Forfeited	Forfeited	(37,499)	22.68		Forfeited	(112,634)	12.47
Vested	Vested	(88,459)	24.13		Vested	(280,557)	20.48
Unvested at June 30, 2022		1,437,301	$	21.55
Unvested at June 30, 2023					Unvested at June 30, 2023	2,910,917	$	13.50

~~15.~~14.Earnings Per Share

Basic earnings per share represents the amount of income attributable to each common share outstanding. Diluted earnings per share represents the amount of income attributable to each common share outstanding adjusted for the effects of potentially dilutive common shares. Potentially dilutive common shares include stock options and other stock-based awards. In the periods where the effect would be antidilutive, potentially dilutive common shares are excluded from the calculation of diluted earnings per share.

In periods in which the Company has net income, earnings per share is calculated using the two-class method. This method is required as unvested restricted stock distributed in respect of pre-IPO Class B-1 and B-2 awards have the right to receive non-forfeitable dividends or dividend equivalents if the Company were to declare dividends on its common stock. Pursuant to the two-class method, earnings for each period are allocated on a pro-rata basis to common stockholders and unvested pre-IPO Class B-1 and B-2 restricted stock awards. Diluted earnings per share is computed using the more dilutive of (a) the two-class method, or (b) treasury stock method, as applicable, to the potentially dilutive instruments.

Table of Contents

Sotera Health Company

Notes to Consolidated Financial Statements

Our basic and diluted earnings per common share are calculated as follows:


		Three Months Ended				Six Months Ended					Three Months Ended				Six Months Ended
in thousands of U.S. dollars and share amounts (except per share amounts)	in thousands of U.S. dollars and share amounts (except per share amounts)	June 30, 2022		June 30, 2021		June 30, 2022		June 30, 2021		in thousands of U.S. dollars and share amounts (except per share amounts)	June 30, 2023		June 30, 2022		June 30, 2023		June 30, 2022
Earnings:	Earnings:									Earnings:
Net income	Net income	$	30,418	$	42,615	$	61,059	$	53,680	Net income	$	23,513	$	30,418	$	26,355	$	61,059
Less: Net income attributable to noncontrolling interests		—		16		—		239
Less: Allocation to participating securities	Less: Allocation to participating securities	308		574		645		746		Less: Allocation to participating securities	137		308		159		645
Net income attributable to Sotera Health Company common shareholders	Net income attributable to Sotera Health Company common shareholders	$	30,110	$	42,025	$	60,414	$	52,695	Net income attributable to Sotera Health Company common shareholders	$	23,376	$	30,110	$	26,196	$	60,414
Weighted Average Common Shares:	Weighted Average Common Shares:									Weighted Average Common Shares:
Weighted-average common shares outstanding - basic	Weighted-average common shares outstanding - basic	279,990		279,078		279,910		278,953		Weighted-average common shares outstanding - basic	280,893		279,990		280,793		279,910
Dilutive effect of potential common shares	Dilutive effect of potential common shares	181		136		128		125		Dilutive effect of potential common shares	2,254		181		2,247		128
Weighted-average common shares outstanding - diluted	Weighted-average common shares outstanding - diluted	280,171		279,214		280,038		279,078		Weighted-average common shares outstanding - diluted	283,147		280,171		283,040		280,038
Earnings per Common Share:	Earnings per Common Share:									Earnings per Common Share:
Net income per common share attributable to Sotera Health Company common shareholders - basic	Net income per common share attributable to Sotera Health Company common shareholders - basic	$	0.11	$	0.15	$	0.22	$	0.19	Net income per common share attributable to Sotera Health Company common shareholders - basic	$	0.08	$	0.11	$	0.09	$	0.22
Net income per common share attributable to Sotera Health Company common shareholders - diluted	Net income per common share attributable to Sotera Health Company common shareholders - diluted	0.11		0.15		0.22		0.19		Net income per common share attributable to Sotera Health Company common shareholders - diluted	0.08		0.11		0.09		0.22

Diluted earnings per share does not consider the following potential common shares as the effect would be anti-dilutive:


		Three Months Ended		Six Months Ended			Three Months Ended		Six Months Ended
in thousands of share amounts	in thousands of share amounts	June 30, 2022	June 30, 2021	June 30, 2022	June 30, 2021	in thousands of share amounts	June 30, 2023	June 30, 2022	June 30, 2023	June 30, 2022
Stock options	Stock options	3,780	2,404	3,337	2,404	Stock options	4,283	3,780	3,928	3,337
RSUs	RSUs	11	4	17	4	RSUs	1,308	11	1,138	17
Total anti-dilutive securities	Total anti-dilutive securities	3,791	2,408	3,354	2,408	Total anti-dilutive securities	5,591	3,791	5,066	3,354

~~16.~~15.Commitments and Contingencies

From time to time, we may be subject to various lawsuits and other claims, as well as gain contingencies, in the ordinary course of our business. In addition, from time to time, we receive communications from government or regulatory agencies concerning investigations or allegations of noncompliance with laws or regulations in jurisdictions in which we operate.

We establish reserves for specific liabilities in connection with regulatory and legal actions that we determine to be both probable and reasonably estimable. NoAs of June 30, 2023 no material amounts have been accrued in our consolidated financial statements with respect to any loss contingencies. If a potentially material loss contingency is not probable, but is reasonably possible, or is probable but cannot be estimated, then the nature of the contingent liability, together with an estimate of the range of possible loss if determinable and material, would be disclosed. In certain of the matters described below, we are not able to make a reasonable estimate of any liability because of the uncertainties related to the outcome and/or the amount or range of loss. While it is not possible to determine the ultimate disposition of each of these matters, we do not expect that the ultimate resolution of pending regulatory and legal matters in future periods, including the matters described below, will have a material effect on our financial condition, or results of ~~operations.~~operations or liquidity. Despite the above, the Company may incur material defense and settlement costs, diversion of management resources and other adverse effects on our business, financial condition, or results of operations.

Ethylene Oxide Tort Litigation

Sterigenics U.S., LLC (“Sterigenics”) and other medical supply sterilization companies have been subjected to ~~personal injury and related~~ tort lawsuits alleging various injuries caused by low-level environmental exposure to EO emissions from sterilization facilities. Those lawsuits, as detailed further below, are individual claims, as opposed to class actions.

Table of Contents

Sotera Health Company

Notes to Consolidated Financial Statements

Illinois

~~Approximately 780~~More than 854 plaintiffs ~~have~~ filed lawsuits, and approximately 28 individuals threatened to file lawsuits, against subsidiaries of the Company and other parties, alleging personal injuries ~~including~~(including cancer and other ~~diseases,~~diseases) or wrongful death resulting from purported emissions and releases of EO from ~~Sterigenics U.S., LLC’s~~Sterigenics’ former Willowbrook facility. Additional derivative claims ~~are~~were alleged on behalf of ~~other individuals related to~~relatives of some of these personal injury plaintiffs. ~~Each plaintiff seeks damages in an amount to be determined by the trier of fact.~~ The lawsuits were consolidated for pre-trial purposes by the Circuit Court of Cook County, ~~Circuit Court,~~ Illinois (the “Consolidated Case”). ~~Plaintiffs have not yet made any specific damages claims.~~

~~Fact discovery~~Jury trials were conducted during 2022 in the Consolidated Case concluded on February 1, 2022. On June 28, 2022 the Court granted summary judgment, dismissing plaintiffs’ ultrahazardous activity / strict liability claims and denying the remainder of the motions. Threetwo of the individual cases included in the Consolidated Case, ~~have been~~and 12 individual cases were scheduled for trials in 2023. The first trial began on August 12, 2022, and on September 19, 2022, the jury rendered a verdict in favor of the plaintiff and awarded damages in the amount of $358.7 million, including $36.1 million of compensatory damages, $320.0 million of punitive damages and $2.6 million of prejudgment interest against Sterigenics and Sotera Health LLC (the “Defendant Subsidiaries”). Post-judgment interest accrued on the compensatory and punitive damages awards from September 20, 2022, the date of the judgment order. The Defendant Subsidiaries filed a Motion for Post Trial Relief, which was denied on December 19, 2022. ~~Plaintiffs~~On January 9, 2023 the Defendant Subsidiaries filed a Notice of Appeal to the First District Appellate Court in ~~those three cases have been granted permission~~Illinois, appealing the September 20, 2022 adverse judgment. The deadline for posting an appellate bond for the appeal was extended to ~~seek punitive damage awards~~February 8, 2023. The second individual trial began on October 6, 2022, and on November 18, 2022, the jury returned a defense verdict on all counts. On January 4, 2023, the plaintiff in the second trial filed a motion for post-trial relief seeking an order reversing and/or vacating the verdict, granting a new trial, and/or entering judgment in the plaintiff’s favor notwithstanding the verdict.

On November 1, 2022 certain plaintiffs in the Consolidated Case filed a lawsuit in the Circuit Court of Cook County against ~~subsidiaries of~~ the Company and ~~another party. The first trial is now expected~~certain affiliates, subsidiaries and current and former officers, alleging that certain transfers of assets occurring after December 2016 were intended to ~~begin~~make assets unavailable to satisfy judgments the plaintiffs might win in future trials in their individual personal injury cases included in the Consolidated Case (the “Asset Transfer Case”). On November 10, 2022, the Asset Transfer Case was removed to the United States District Court for the Northern District of Illinois and all defendants filed answers and affirmative defenses.

On January 9, 2023, the Defendant Subsidiaries (the “Settling Defendants”) entered into binding term sheets (the “Term Sheets”) with the “Plaintiffs’ Executive Committee” (the “PEC”) appointed to act on ~~August 12,~~behalf of the more than 20 law firms (“Plaintiffs’ Counsel”) representing the plaintiffs in the Consolidated Case, the Asset Transfer Case, and other clients with personal injury claims that had not yet been filed (each an “Eligible Claimant” and collectively, the “Eligible Claimants”). Upon entering into the Term Sheets, and based on our assessment that it was probable that the conditions to the Term Sheets would be satisfied or waived, we recorded a charge of $408.0 million for the year ended December 31, 2022. The ~~next two individual trials are scheduled~~Term Sheets provided an agreed path to ~~begin~~final settlement of the Eligible Claimants’ claims, subject to the satisfaction or waiver of certain conditions, including but not limited to the negotiation and execution of full settlement agreements in accordance with the Term Sheets.

On January 11, 2023 and January 13, 2023, the Circuit Court of Cook County entered orders staying all proceedings and deadlines and vacating all trial dates in the ~~third~~Consolidated Case, and ~~fourth quarters~~staying all enforcement proceedings relating to the September 20, 2022 adverse judgment. On January 16, 2023 the United States District Court for the Northern District of ~~2022, followed by five individual trials scheduled to occur consecutively, beginning~~Illinois entered an order staying all proceedings in the ~~first quarter~~Asset Transfer Case. On January 23, 2023 the First District Appellate Court in Illinois entered an order staying the Settling Defendants’ appeal of ~~2023. Additional trial dates~~the September 20, 2022 adverse judgment.

On March 28, 2023, the Settling Defendants and the PEC entered into full settlement agreements (the “Settlement Agreements”). The Settlement Agreements provided a pathway to resolve the claims that were or could have been alleged by 882 Eligible Claimants related to or arising from alleged emissions of EO from Sterigenics’ operations in or around Willowbrook and related claims that were or could have been alleged by Eligible Claimants seeking to challenge any transfer of assets to or from the Company, its subsidiaries and certain affiliates to any other entity or person (the “Covered Claims”). The Company and Settling Defendants deny any liability for the Covered Claims and, per their express terms, the Settlement Agreements are ~~expected~~not to be ~~announced~~construed as an admission of liability or that the Company or Settling Defendants engaged in any wrongful, tortious, or unlawful activity or that use and/or emissions of EO from Sterigenics’ operations in or around Willowbrook posed any safety hazard to the surrounding communities.

Table of Contents

Sotera Health Company

Notes to Consolidated Financial Statements

The Settlement Agreements provided that final settlement was conditioned, among other things, on ~~September 7, 2022.~~successful completion of a claims administration process and satisfaction (or waiver by the Settling Defendants) of specific participation requirements, the dismissal with prejudice of the Covered Claims of all Eligible Claimants participating in the settlement, and court approval of the settlement as a good faith settlement under the Illinois Joint Contribution Among Tortfeasors Act.

On May 1, 2023, Sterigenics contributed $408.0 million to settlement escrow funds (the “Settlement Funds”) to be used, if the conditions of the Settlement Agreements were satisfied or waived, to pay all settlement fees and expenses and cash payments to the Eligible Claimants participating in the settlement.

The claims administration process concluded with 879 of 882 Eligible Claimants providing opt-in consent to participate in the settlement (the “Settling Claimants”). Pursuant to the Settlement Agreements, the three Eligible Claimants who did not opt in (each a “Non-Settling Claimant,” and collectively the “Non-Settling Claimants”) created an option for the Settling Defendants to exercise walkaway rights. On June 22, 2023, after evaluating the available information about the claims of the Non-Settling Claimants, the Settling Defendants waived their walkaway rights and chose to proceed to final settlement with the Settling Claimants (the “Willowbrook Settlement”).

On June 23, 2023 the Circuit Court of Cook County entered an order confirming that the Willowbrook Settlement was a good-faith settlement under the Illinois Contribution Among Joint Tortfeasors Act. On June 30, 2023, the Settlement Funds were released from escrow to the PEC’s Qualified Settlement Funds. The amounts allocated by the PEC to the Non-Settling Claimants represent an immaterial fraction of the Settlement Funds and will remain in escrow until December 31, 2023, at which point, absent an opt-in election by a Non-Settling Claimant, the funds allocated to that Non-Settling Claimant will revert to Sterigenics. On July 6, 2023, the claims of the Settling Claimants against the Settling Defendants were dismissed with prejudice, with the Circuit Court of Cook County retaining jurisdiction to adjudicate disputes over liens on the settlement proceeds to be paid to the Settling Claimants and to oversee the administration of the settlements of the wrongful death cases.

The three Non-Settling Claimants’ cases will proceed in the Circuit Court of Cook County, Illinois. In June 2023, six new personal injury lawsuits relating to the Willowbrook facility were filed in the Circuit Court of Cook County against Sterigenics, Sotera Health Services, LLC and other parties (the “Post-Settlement Cases”). One Post-Settlement Case has been removed to the United States District Court for the Northern District of Illinois, and a motion to remand is pending. The remaining Post-Settlement Cases will proceed in the Circuit Court of Cook County.

Georgia

~~Since August 17, 2020, approximately 300 plaintiffs have filed lawsuits against subsidiaries~~Subsidiaries of the Company and other parties are defendants in lawsuits in the State Court of Cobb County, Georgia and the State Court of Gwinnett County, Georgia alleging that they suffered personal injuries resulting from emissions and releases of EO from Sterigenics’ Atlanta facility. Additional derivative claims are alleged on behalf of other individuals related to some of these personal injury plaintiffs. Our subsidiaries are also defendants in ~~two lawsuits alleging that the Atlanta facility has devalued and harmed plaintiffs’ use of real properties they own in Smyrna, Georgia and caused other damages. These~~which plaintiffs allege personal injury and property devaluation ~~plaintiffs~~resulting from emissions or releases of EO from or at Sterigenics’ Atlanta facility, and seek ~~various~~damages and other forms of ~~relief including damages. All but two of the~~relief.

One personal injury lawsuit pending in Gwinnett County is scheduled for trial in October 2023. Approximately 300 personal injury lawsuits pending in Cobb County have been consolidated for pretrial ~~purposes.~~purposes (the “Consolidated Personal Injury Cases”). The ~~Court has entered~~Consolidated Personal Injury Cases are proceeding under a ~~phased~~ case management ~~schedule for~~order pursuant to which a “pool” of ten ~~of the consolidated~~personal injury cases ~~by which threshold~~will proceed to determination of general causation issues ~~will be decided~~ in Phase 1 ~~followed by~~and, specific causation issues in Phase ~~2 as to any of~~2; the ~~pooled cases that survive Phase 1. The Court has stayed the remainder of the consolidated~~remaining Consolidated Personal Injury Cases are stayed. One personal injury ~~cases~~lawsuit pending in Cobb County has not been consolidated and ~~an immediate appeal of a discrete procedural issue~~ is ~~being pursued by the defendants. One~~proceeding independently. Nine lawsuits pending in Cobb County include both personal injury ~~case~~and property claims (the “Dual Injury Cases”). By agreement of the parties, the Dual Injury Cases will be included in the Consolidated Personal Injury Cases and stayed.

Our subsidiaries are also defendants in approximately 366 property devaluation lawsuits. One property lawsuit is pending in Gwinnett County and ~~is scheduled for trial in June 2023. The remaining two personal injury cases and two property devaluation cases are in various stages of pleadings and motions practice and fact discovery.~~

~~Georgia Facility Operations Litigation~~

~~In October 2019, while Sterigenics had voluntarily suspended~~ the facility’s operations to install emissions reduction enhancements at its Atlanta facility, Cobb County, Georgia officials asserted that the facility had an incorrect “certificate of occupancy” and could not resume operations without obtaining a new certificate of occupancy after a third-party code compliance review. On March 30, 2020 Sterigenics filed suit against Cobb County, Georgia and certain of its officials for wrongfully interfering with operations of the facility. On April 1, 2020 Sterigenics won a Temporary Restraining Order prohibiting Cobb County officials from interfering with the facility’s normal operations, which relief has been extended until entry of a final judgment in the case. The parties are conducting ~~expert~~discovery. The remaining property lawsuits are pending in Cobb County and have been consolidated for pretrial purposes (the “Consolidated Property Cases”). The Consolidated Property Cases are proceeding under a case management order pursuant to which ten cases will proceed with dispositive motions and discovery, ~~which is scheduled~~and the remaining cases are stayed.

Table of Contents

Sotera Health Company

Notes to ~~end in September 2022. A Modified Scheduling Order was entered on July 14, 2022, including that trial will take place no later than March 2023.~~Consolidated Financial Statements

New Mexico ~~Attorney General Litigation~~

On December 22, 2020, the New Mexico Attorney General filed a lawsuit in the Third Judicial District Court, Doña Ana County, New Mexico against the Company and certain subsidiaries alleging that emissions and releases of EO from Sterigenics’ ~~sterilization~~ facility in Santa Teresa, New Mexico have deteriorated the air quality in Santa Teresa and surrounding communities and materially contributed to increased health risks suffered by residents of those communities. The Complaint asserts claims for public nuisance, negligence, strict liability, violations of New Mexico’s Public Nuisance Statute and Unfair Practices Act and seeks various forms of relief including a temporary restraining order, ~~and~~ preliminary injunctive relief and damages. On June 29, 2021, the Court entered an Order Granting Preliminary Injunction (the “Order”)~~. The Order does not require closure of the facility, but prohibits~~ prohibiting Sterigenics from allowing any uncontrolled emission or release of EO from the facility. On December 20,

~~Table of Contents~~

~~Sotera Health Company~~

~~Notes to Consolidated Financial Statements~~

2021 the Court entered an order ~~identifying~~establishing a protocol to monitor Sterigenics’ compliance with the Order. Operations at the facility continue to be in compliance with the June 2021 and December 2021 orders. A motion challenging the Court’s jurisdiction over Sotera Health Company and another defendant, and a motion for summary judgment by Sterigenics and Sotera Health LLC are pending. A Scheduling Order was entered on September 13, 2022, including a June 3, 2024 trial date. The Company expects the Court to issue rulings on the pending motions and address the schedule for the remainder of the case in August 2023.

On April 24, 2023, a lawsuit was filed in the Third Judicial District Court, Doña Ana County, New Mexico against the Company, Sterigenics and certain other ~~defendants has been held~~subsidiaries alleging wrongful death caused by exposure to emissions and releases of EO from Sterigenics’ facility in ~~abeyance until~~Santa Teresa, New Mexico while the ~~completion~~decedent was working at a different company’s facility approximately one mile away. Sterigenics removed the case to the United States District Court for the District of ~~jurisdictional discovery,~~New Mexico on April 27, 2023, and ~~all other motions~~filed a partial motion to dismiss ~~have been denied. The parties are conducting fact discovery.~~on June 2, 2023.

* * *

Additional EO tort lawsuits may be filed in the future against the Company and/or its subsidiaries relating to Sterigenics’ Willowbrook, Atlanta, Santa Teresa or other EO facilities. The Company denies allegations that its EO operations could or have caused the harms alleged in such lawsuits, and does not believe that the facts and law justify the September 20, 2022 adverse judgment in the first trial in Illinois or that the verdict and damage awards in that case or the Willowbrook Settlement are predictive of potential future verdicts in other EO tort cases in Illinois or other jurisdictions. The Company intends to defend itself vigorously in all such litigation, which will be presided over by different judges, tried by different counsel presenting different evidence and fact and expert witness testimony at trial, and decided by different juries. Each plaintiff’s claim involves unique facts and evidence, including but not limited to, the circumstances of the plaintiff’s alleged exposure, the type and severity of the plaintiff’s disease and the plaintiff’s medical history and course of treatment. As a result, we believe that losses in such subsequent cases are not probable and that it is not possible to estimate the range of loss. Due to the uncertainties associated with the amount of any such liability and/or the nature of any other remedy which may be imposed in such litigation, any potential liability determined to be attributable to the Company or any of its subsidiaries arising out of such litigation may have a material adverse effect on the Company’s results of operations, liquidity or financial condition. An estimate of the potential impact on the Company’s results of operations, liquidity or financial condition cannot be made to a reasonable or meaningful degree of certainty due to the aforementioned uncertainties.

Insurance Coverage for Environmental Liabilities

Our insurance for litigation related to alleged environmental liabilities, like the litigation pending in Illinois, Georgia and New Mexico described above, has limits of $10.0 million per occurrence and $20.0 million in the aggregate. The per occurrence limit related to the Willowbrook, Illinois litigation was fully utilized by June 30, 2020. The remaining $10.0 million ~~limit is currently being~~was fully utilized by March 31, 2023 for occurrences related to the EO litigation in Georgia and New Mexico described above. ~~As of June 30, 2022, we have utilized approximately $6.0 million of the remaining $10.0 million limit.~~ Our insurance for future alleged environmental liabilities excludes coverage for EO claims.

In addition, we are pursuing other insurance coverage for ~~EO tort litigation.~~our legal expenses related to litigation like the Illinois, Georgia and New Mexico matters described above. In 2021, Sterigenics ~~U.S., LLC~~ filed an insurance coverage lawsuit in the U.S. District Court for the Northern District of Illinois relating to two commercial general liability policies issued in the ~~1980s. On August 3, 2022, the Court~~1980s (the “No. Dist. of IL Coverage Lawsuit”). The court has issued ~~a Memorandum Opinion and Order concluding~~orders declaring that the defendant insurer owes Sterigenics ~~U.S., LLC~~ and another insured party a duty to defend the EO tort litigation relating to the Willowbrook ~~Illinois litigation, which may allow us to recover~~facility and owes Sterigenics approximately $75.5 million in defense costs ~~related~~through September 30, 2022. Sterigenics is also a party in insurance coverage lawsuits, pending

Table of Contents

Sotera Health Company

Notes to Consolidated Financial Statements

in the Delaware Superior Court and the Circuit Court of Cook County, seeking insurance coverage from various historical commercial general liability policies for certain EO litigation settlement amounts and defense costs the insurer in the No. Dist. of IL Coverage Lawsuit may fail to fund. It is unknown how much, if any, of the insurance proceeds sought will be recovered.

Sotera Health Company Securities Litigation & Related Matters

On January 24, 2023, a putative stockholder class action was filed in the U.S. District Court for the Northern District of Ohio against the Company, its directors, certain senior executives, the Company’s private equity stockholders and the underwriters of the Company’s initial public offering (“IPO”) in November 2020 and the Company’s secondary public offering (“SPO”) in March 2021 (the “Michigan Funds Litigation”). On April 17, 2023 the court appointed the Oakland County Employees’ Retirement System, Oakland County Voluntary Employees’ Beneficiary Association, and Wayne County Employees’ Retirement System (the “Michigan Funds”) to serve as lead plaintiff to prosecute claims on behalf of a proposed class of stockholders who acquired shares of the Company in connection with our IPO or SPO or between November 20, 2020 and September 19, 2022 (the “Proposed Class”). The Michigan Funds allege that ~~litigation.~~statements made regarding the safety of the Company’s use of EO and/or the litigation and other risks of its EO operations violated Sections 11, 12(a)(2) and 15 of the Securities Act of 1933 (when made in the registration statements for the IPO and SPO) and violated Sections 10(b), Section 20(a) and Rule 10b-5 of the Securities Exchange Act of 1934 (when made in subsequent securities filings and other contexts). On June 1, 2023 the Michigan Funds filed an Amended Complaint seeking damages and other relief on behalf of the Proposed Class. Defendants’ motion to dismiss the Amended Complaint was filed on August 2, 2023. In addition, on May 15, 2023 and July 25, 2023 the Company received demands pursuant to 8 Del. C. §220 for inspection of its books and records from individual shareholders purporting to be investigating the Company’s internal operations, disclosure practices and other matters alleged and at issue in the Michigan Funds Litigation (the “220 Demands”). The Company believes that the allegations and claims by the Michigan Funds and in the 220 Demands are without merit, and plans to vigorously defend the Michigan Funds Litigation.

~~17.~~16.Financial Instruments and Financial Risk

Derivative Instruments

We do not use derivatives for trading or speculative purposes and are not a party to leveraged derivatives.

Derivatives Designated in Hedge Relationships

From time to time, the Company utilizes interest rate derivatives designated in hedge relationships to manage interest rate risk associated with our variable rate borrowings. These instruments are measured at fair value with changes in fair value recorded as a component of “Accumulated other comprehensive income (loss)” on our Consolidated Balance Sheets.

In March 2023, we entered into an interest rate swap agreement with a notional amount of $400.0 million. The interest rate swap has a forward start date of August 23, 2023 and expires on August 23, 2025. We have designated the interest rate swap as a cash flow hedge designed to hedge the variability of cash flows attributable to changes in the SOFR benchmark interest rate of our 2023 Term Loan. We receive interest at the one-month Term SOFR rate and pay a fixed interest rate under the terms of the swap agreement.

In May 2022, we entered into 2two interest rate cap agreements with a combined notional amount of $1,000.0 million for a total option premium of $4.1 million. The interest rate caps have a forward start date of July 31, 2023 and expire on July 31, 2024. We have designated these interest rate caps as cash flow hedges designed to hedge the variability of cash flows attributable to changes in the benchmark interest rate of our Term Loan. Under the current terms of the loan agreement, the benchmark interest rate index ~~is expected to transition~~transitioned from LIBOR to ~~the term Secured Overnight Financing Rate (“SOFR”) at the earlier of~~Term SOFR on June 30, ~~2023 or the Company’s election to “early opt-in” to SOFR.~~2023. Accordingly, the interest rate cap agreements hedge the variability of cash flows attributable to changes in SOFR by limiting our cash flow exposure related to ~~the term~~Term SOFR under a portion of our variable rate borrowings to 3.5%.

In October 2021, we entered into 2two interest rate cap agreements with a combined notional amount of $1,000.0 million for a total option premium of $1.8 million. Both interest rate caps ~~have a forward start date of~~were effective on December 31, 2022 and expire on July 31, 2023. These interest rate caps are designated as cash flow hedges and are designed to hedge the variability of cash flows attributable

Table of Contents

Sotera Health Company

Notes to Consolidated Financial Statements

to changes in LIBOR (or its successor), the benchmark interest rate being hedged, by limiting our cash flow exposure related to the LIBOR base rate under a portion of our variable rate borrowings to 1.0%.

Derivatives Not Designated in Hedge Relationships

Additionally, from time to time, the Company enters into interest rate derivatives to manage economic risks associated with our variable rate borrowings that are not designated in hedge relationships. These instruments are recorded at fair value on the Consolidated Balance Sheets, with any changes in the value recorded in “Interest expense, net” in the Consolidated Statements of Operations and Comprehensive Income (Loss).

~~Table of Contents~~

~~Sotera Health Company~~

~~Notes to Consolidated Financial Statements~~

In June 2020, SHH entered into 2 interest rate cap agreements with notional amounts of $1,000.0 million and $500.0 million, respectively, for a total option premium of $0.3 million. These instruments were initially scheduled to terminate on August 31, 2021 and February 28, 2022, respectively. The interest rate caps limit our cash flow exposure related to the LIBOR base rate under a portion of our variable rate borrowings to 1%. In February 2021, we amended the 2 interest rate cap agreements referenced above to reduce the strike rate from 1% to 0.5%. Premiums paid to amend the interest rate caps were immaterial.

We also entered into 2 additional interest rate cap agreements in February 2021 with a combined notional amount of $1,000.0 million, for a total option premium of $0.4 million. These instruments were effective September 30, 2021, and will terminate on December 31, 2022. The amended and new interest rate caps limit our cash flow exposure related to LIBOR under a portion of our variable rate borrowings to 0.5%.

The Company also ~~entered~~routinely enters into foreign currency forward contracts to manage foreign currency exchange rate risk of our intercompany loans in certain of our international subsidiaries. The foreign currency forward contracts expire on a monthly basis. ~~The fair value of the outstanding foreign currency forward contracts was zero as of June 30, 2022 and December 31, 2021, respectively.~~

Embedded Derivatives

We have embedded derivatives in certain of our customer and supply contracts as a result of the currency of the contract being different from the functional currency of the parties involved. Changes in the fair value of the embedded derivatives are recognized in “Other expense (income), net” in the Consolidated Statements of Operations and Comprehensive Income (Loss).

The following table provides a summary of the notional and fair values of our derivative instruments:


		June 30, 2022							December 31, 2021							June 30, 2023							December 31, 2022
(in U.S. Dollars; notional in millions, fair value in thousands)	(in U.S. Dollars; notional in millions, fair value in thousands)				Fair Value						Fair Value				(in U.S. Dollars; notional in millions, fair value in thousands)				Fair Value						Fair Value
		Notional Amount			Derivative Assets		Derivative Liabilities		Notional Amount		Derivative Assets		Derivative Liabilities			Notional Amount			Derivative Assets		Derivative Liabilities		Notional Amount		Derivative Assets		Derivative Liabilities
Derivatives designated as hedging instruments:
Derivatives designated as hedging instruments															Derivatives designated as hedging instruments
Interest rate caps	Interest rate caps	$	2,000.0	(a)	$	19,144	$	—	$	1,000.0	$	2,322	$	—	Interest rate caps	$	2,000.0	(a)	$	20,939	$	—	$	2,000.0	$	34,764	$	—
Derivatives not designated as hedging instruments:
Interest rate caps		$	1,000.0		$	11,100	$	—	$	1,500.0	$	1,654	$	—
Interest rate swaps															Interest rate swaps	400.0		(b)	4,777		—		—		—		—
Derivatives not designated as hedging instruments															Derivatives not designated as hedging instruments
Foreign currency forward contracts															Foreign currency forward contracts	$	157.3		$	24	$	14	$	151.5	$	—	$	272
Embedded derivatives	Embedded derivatives	190.7		(b)	1,389		2,322		144.4		496		—		Embedded derivatives	167.9		(c)	1,551		1,613		179.9		2,721		3,508
Total	Total	$	3,190.7		$	31,633	$	2,322	$	2,644.4	$	4,472	$	—	Total	$	2,325.6		$	27,291	$	1,627	$	2,331.4	$	37,485	$	3,780

(a)$1,000.0 ~~million and $1,000.0~~ million notional amount of interest rate caps designated as hedging instruments have a forward start ~~dates~~date beginning on ~~December 31, 2022 and~~ July 31, ~~2023, respectively.~~2023.

(b)The notional amount of interest rates swaps designated as hedging instruments reflected in the table above has a forward start date beginning on August 23, 2023.

(c)Represents the total notional amounts for certain of the Company’s supply and sales contracts accounted for as embedded derivatives.

Embedded ~~derivative assets~~derivatives and ~~interest rate caps~~foreign currency forward contracts are included in “Prepaid expenses and other current assets” and “Accrued liabilities” on our Consolidated Balance Sheets depending upon their position at period end. Interest rate swaps and interest rate caps are included in “Other assets,” ~~respectively,~~and “Noncurrent liabilities” on the Consolidated Balance Sheets depending upon their ~~respective maturity dates. Embedded derivative liabilities are included in “Accrued liabilities” on the Consolidated Balance Sheets.~~position at period end.

2527

Table of Contents

Sotera Health Company

Notes to Consolidated Financial Statements

The following tables summarize the activities of our derivative instruments for the periods presented, and the line item they are recorded in the Consolidated Statements of Operations and Comprehensive Income (Loss):

(thousands of U.S. dollars) Three Months Ended June 30, Six Months Ended June 30,
2022 2021 2022 2021
Unrealized (gain) loss on interest rate caps recorded in interest expense, net $ (3,100) $ 293 $ (9,446) $ 383
Realized gain on interest rate caps recorded in interest expense, net (1,279) — (1,279) —
Unrealized loss (gain) on embedded derivatives recorded in other expense (income), net 2,435 (761) 1,417 (1,614)
Realized loss (gain) on foreign currency forward contracts recorded in foreign exchange (gain) loss 1,035 231 (495) (2,143)

~~The following table summarizes~~


(thousands of U.S. dollars)	Three Months Ended June 30,				Six Months Ended June 30,
	2023		2022		2023		2022
Unrealized gain on interest rate derivatives recorded in interest expense, net	$	—	$	(3,100)	$	—	$	(9,446)
Realized gain on interest rate derivatives recorded in interest expense, net(a)	(9,400)		(1,279)		(18,571)		(1,279)
Unrealized loss (gain) on embedded derivatives recorded in other expense (income), net	(973)		2,435		(747)		1,417
Realized loss (gain) on foreign currency forward contracts recorded in foreign exchange (gain) loss	(2,393)		1,035		(1,944)		(495)
Unrealized loss (gain) on foreign currency forward contracts recorded in foreign exchange (gain) loss	—		—		(282)		—

(a) For the ~~net gains on our cash flow hedges recognized in “Other comprehensive income (loss)” during the period:~~

(thousands of U.S. dollars) Three Months Ended June 30, Six Months Ended June 30,
2022 2021 2022 2021
Unrealized gain on interest rate derivatives recorded in other comprehensive income (loss), net of tax $ 3,178 $ — $ 9,357 $ —
three and six months ended June 30, 2023, amounts primarily represent quarterly settlement of interest rate caps.

We expect to reclassify approximately ~~$12.5~~$19.3 million of ~~after-tax~~ net gains on derivative instruments from accumulated other comprehensive income (loss) to income during the next 12 months associated with our cash flow hedges. Refer to Note 12,“Other Comprehensive Income (Loss)” for unrealized gains on interest rate derivatives recorded in other comprehensive income (loss) and amounts reclassified from accumulated other comprehensive income to interest expense during the three and six months ended June 30, 2023.

Credit Risk

Certain of our financial assets, including cash and cash equivalents, are exposed to credit risk.

We are also exposed, in our normal course of business, to credit risk from our customers. As of June 30, ~~2022~~2023 and December 31, ~~2021,~~2022, accounts receivable was net of an allowance for uncollectible accounts of ~~$1.8~~$2.0 million and ~~$1.3~~$1.9 million, respectively.

Credit risk on financial instruments arises from the potential for counterparties to default on their contractual obligations to us. We are exposed to credit risk in the event of non-performance, but do not anticipate non-performance by any of the counterparties to our financial instruments. We limit our credit risk by dealing with counterparties that are considered to be of high credit quality. In the event of non-performance by counterparties, the carrying value of our financial instruments represents the maximum amount of loss that would be incurred.

Our credit team evaluates and regularly monitors changes in the credit risk of our customers. We routinely assess the collectability of accounts receivable and maintain an adequate allowance for uncollectible accounts to address potential credit losses. The process includes a review of customer financial information and credit ratings, current market conditions as well as the expected future economic conditions that may impact the collection of trade receivables. We regularly review our ~~customers'~~customers’ past due amounts through an analysis of aged accounts receivables, specific customer past due aging amounts, and the history of trade receivables written off. Upon concluding that a receivable balance is not collectible, the balance is written off against the allowance for uncollectible accounts.

Fair Value Hierarchy

The fair value of our financial instruments is the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. The valuation techniques we would use to determine such fair values are described as follows: Level 1—fair values determined by inputs utilizing quoted prices in active markets for identical assets or liabilities; Level 2—fair values based on observable inputs other than quoted prices included in Level 1, such as quoted prices for similar assets and liabilities in active markets, quoted prices for identical or similar assets and liabilities in

~~Table of Contents~~

~~Sotera Health Company~~

~~Notes to Consolidated Financial Statements~~

markets that are not active, or other inputs that are observable; Level 3—fair values determined by unobservable inputs reflecting our own assumptions, consistent with reasonably available assumptions made by other market participants.

Table of Contents

Sotera Health Company

Notes to Consolidated Financial Statements

The following table discloses the fair value of our financial assets and liabilities:


As of June 30, 2022				Fair Value
As of June 30, 2023										As of June 30, 2023			Fair Value
(thousands of U.S. dollars)	(thousands of U.S. dollars)	Carrying Amount		Level 1		Level 2		Level 3		(thousands of U.S. dollars)	Carrying Amount		Level 1		Level 2		Level 3
Derivatives designated as hedging instruments(a)	Derivatives designated as hedging instruments(a)									Derivatives designated as hedging instruments(a)
Derivative assets - interest rate caps		$	19,144	$	—	$	19,144	$	—
Interest rate caps										Interest rate caps	$	20,939	$	—	$	20,939	$	—
Interest rate swaps										Interest rate swaps	4,777		—		4,777		—
Derivatives not designated as hedging instruments(b)	Derivatives not designated as hedging instruments(b)									Derivatives not designated as hedging instruments(b)
Derivative assets - interest rate caps		11,100		—		11,100		—
Foreign currency forward contract assets										Foreign currency forward contract assets	24		—		24		—
Foreign currency forward contract liabilities										Foreign currency forward contract liabilities	14		—		14		—
Embedded derivative assets	Embedded derivative assets	1,389		—		1,389		—		Embedded derivative assets	1,551		—		1,551		—
Embedded derivative liabilities	Embedded derivative liabilities	2,322		—		2,322		—		Embedded derivative liabilities	1,613		—		1,613		—
Long-Term Debt(c)
Current portion of long-term debt(c)										Current portion of long-term debt(c)
Term loan B, due 2026										Term loan B, due 2026	4,776		—		4,982		—
Other long-term debt(c)										Other long-term debt(c)	449		—		449		—
Long-Term Debt(d)										Long-Term Debt(d)
Term loan, due 2026	Term loan, due 2026	1,745,102		—		1,679,353		—		Term loan, due 2026	1,749,176		—		1,710,207		—
Other long-term debt		446		—		446		—
Finance Lease Obligations (with current portion)(d)		58,755		—		58,755		—
Term loan B, due 2026										Term loan B, due 2026	472,811		—		493,169		—
Finance Lease Obligations (with current portion)(e)										Finance Lease Obligations (with current portion)(e)	69,888		—		69,888		—


As of December 31, 2021				Fair Value
As of December 31, 2022										As of December 31, 2022			Fair Value
(thousands of U.S. dollars)	(thousands of U.S. dollars)	Carrying Amount		Level 1		Level 2		Level 3		(thousands of U.S. dollars)	Carrying Amount		Level 1		Level 2		Level 3
Derivatives designated as hedging instruments(a)	Derivatives designated as hedging instruments(a)									Derivatives designated as hedging instruments(a)
Derivative assets - interest rate caps		$	2,322	$	—	$	2,322	$	—
Interest rate caps										Interest rate caps	$	34,764	$	—	$	34,764	$	—
Derivatives not designated as hedging instruments(b)	Derivatives not designated as hedging instruments(b)									Derivatives not designated as hedging instruments(b)
Derivative assets - interest rate caps		1,654		—		1,654		—
Foreign currency forward contracts										Foreign currency forward contracts	272		—		272		—
Embedded derivative assets										Embedded derivative assets	2,721		—		2,721		—
Embedded derivative liabilities	Embedded derivative liabilities	496		—		496		—		Embedded derivative liabilities	3,508		—		3,508		—
Long-Term Debt(c)
Current portion of long-term debt(c)										Current portion of long-term debt(c)
Revolving credit facility										Revolving credit facility	196,672		—		$	196,672	—
Other long-term debt										Other long-term debt	447		—		$	447	—
Long-Term Debt(d)										Long-Term Debt(d)
Term loan, due 2026	Term loan, due 2026	1,743,090		—		1,754,285		—		Term loan, due 2026	1,747,115		—		1,626,460		—
Other long-term debt		444		—		444		—
Finance Lease Obligations (with current portion)(d)		42,037		—		42,037		—
Finance Lease Obligations (with current portion)(e)										Finance Lease Obligations (with current portion)(e)	58,677		—		58,677		—

(a)Derivatives designated as hedging instruments are measured at fair value with changes in fair value recorded as a component of accumulated other comprehensive income (loss). Interest rate caps and swaps are valued using pricing models that incorporate observable market inputs including interest rate and yield curves.

(b)Derivatives that are not designated as hedging instruments are measured at fair value with gains or losses recognized immediately in the Consolidated Statements of Operations and Comprehensive Income (Loss). ~~Interest rate caps are valued using pricing models that incorporate observable market inputs including interest rate and yield curves.~~ Embedded derivatives are valued using internally developed models that rely on observable market inputs, including foreign currency forward curves. Foreign currency forward contracts are valued by reference to changes in the forward foreign currency exchange rate over the life of the contract.

(c)Carrying value of other long-term debt and revolving credit facility approximates fair value.

(d)Carrying amounts of long-term debt instruments are reported net of discounts and debt issuance costs. The estimated fair value of these instruments is based ~~upon~~on quoted prices for the ~~Term Loan~~term loans due in 2026 in inactive markets as provided by an independent fixed income security pricing service. Fair value approximates carrying value for “Other long-term debt.”

~~(d)~~(e)Fair value approximates carrying value.

Table of Contents

Sotera Health Company

Notes to Consolidated Financial Statements

~~18.~~17.Segment Information

We identify our operating segments based on the way we manage, evaluate and internally report our business activities for purposes of allocating resources and assessing performance. We have 3three reportable segments: Sterigenics, Nordion and Nelson Labs. We have determined our reportable segments based upon an assessment of organizational structure, service types, and internally prepared financial statements. Our chief operating decision maker evaluates performance and allocates resources

~~Table of Contents~~

~~Sotera Health Company~~

~~Notes to Consolidated Financial Statements~~

based on net revenues and segment income after the elimination of intercompany activities. The accounting policies of our reportable segments are the same as those described in Note 1, “Significant Accounting Policies” of the Company’s annual consolidated financial statements and accompanying notes in our ~~2021~~2022 Form 10-K.

Sterigenics

Sterigenics provides outsourced terminal sterilization and irradiation services for the medical device, pharmaceutical, food safety and advanced applications markets using three major technologies: gamma irradiation, EO processing and E-beam irradiation.

Nordion

Nordion is a leading global provider of Co-60 used in the sterilization and irradiation processes for the medical device, pharmaceutical, food safety, and high-performance materials industries, as well as in the treatment of cancer. In addition, Nordion is a leading global provider of gamma irradiation systems.

Nelson Labs

Nelson Labs provides outsourced microbiological and analytical chemistry testing and advisory services for the medical device and pharmaceutical industries.

For the three months ended June 30, 2023, five customers reported within the Nordion segment individually represented 10% or more of the segment’s total net revenues. These customers represented 31.3%, 13.4%, 12.5%, 10.7%, and 10.7% of the total segment’s external net revenues for the three months ended June 30, 2023. For the three months ended June 30, 2022, four customers reported within the Nordion segment individually represented 10% or more of the segment’s total net revenues. These customers represented 21.7%, 15.4%, 13.2%, and 15.9% of the total segment’s external net revenues for the three months ended June 30, 2022.

For the ~~three~~six months ended June 30, ~~2021, two~~2023, four customers reported within the Nordion segment individually represented 10% or more of the segment’s total net revenues. These customers represented ~~17.9%~~26.3%, 17.5%, 10.7%, and ~~16.1%~~10.1% of the total segment’s external net revenues for the ~~three~~six months ended June 30, ~~2021.~~

2023. For the six months ended June 30, 2022, four customers reported within the Nordion segment individually represented 10% or more of the segment’s total net revenues. These customers represented 18.8%, ~~15.5%~~12.8%, ~~12.8%~~15.5%, and 10.6% of the total segment’s external net revenues for the six months ended June 30, 2022. For the six months ended June 30, 2021, four customers reported within the Nordion segment individually represented 10% or more of the segment’s total net revenues. These customers represented 14.8%, 13.1%, 12.6%, and 10.5% of the total segment's external net revenues for the six months ended June 30, ~~2021.~~2022.

Table of Contents

Sotera Health Company

Notes to Consolidated Financial Statements

Financial information for each of our segments is presented in the following table:


		Three Months Ended June 30,				Six Months Ended June 30,					Three Months Ended June 30,				Six Months Ended June 30,
(thousands of U.S. dollars)	(thousands of U.S. dollars)	2022		2021		2022		2021		(thousands of U.S. dollars)	2023		2022		2023		2022
Segment revenues(a)	Segment revenues(a)									Segment revenues(a)
Sterigenics	Sterigenics	$	157,792	$	145,182	$	307,254	$	276,333	Sterigenics	$	166,590	$	157,792	$	326,587	$	307,254
Nordion	Nordion	50,478		49,125		84,480		75,043		Nordion	31,975		50,478		40,526		84,480
Nelson Labs	Nelson Labs	58,369		57,610		111,659		112,689		Nelson Labs	56,717		58,369		108,759		111,659
Total net revenues	Total net revenues	$	266,639	$	251,917	$	503,393	$	464,065	Total net revenues	$	255,282	$	266,639	$	475,872	$	503,393
Segment income(b)	Segment income(b)									Segment income(b)
Sterigenics	Sterigenics	$	85,098	$	79,569	$	164,501	$	148,030	Sterigenics	$	91,450	$	85,098	$	174,290	$	164,501
Nordion	Nordion	29,982		31,168		48,885		44,954		Nordion	17,784		29,982		19,310		48,885
Nelson Labs	Nelson Labs	21,055		23,826		38,098		46,896		Nelson Labs	19,251		21,055		33,353		38,098
Total segment income	Total segment income	$	136,135	$	134,563	$	251,484	$	239,880	Total segment income	$	128,485	$	136,135	$	226,953	$	251,484

(a)Revenues are reported net of intersegment sales. Our Nordion segment recognized ~~$15.8~~$14.7 million and ~~$7.0~~$15.8 million in revenues from sales to our Sterigenics segment for the three months ended June 30, 2023 and 2022, respectively, and ~~2021,~~$17.6 million and $31.3 ~~million and $17.5~~ million in revenues from sales to our Sterigenics segment for the six months ended June 30, ~~2022~~2023 and ~~2021,~~2022, respectively, that is not reflected in net revenues in the table above. Intersegment sales for Sterigenics and Nelson Labs are immaterial for these periods.

~~Table of Contents~~

~~Sotera Health Company~~

~~Notes to Consolidated Financial Statements~~

(b)Segment income is only provided on a net basis to the chief operating decision maker and is reported net of intersegment profits.

Corporate operating expenses for executive management, accounting, information technology, legal, human resources, treasury, investor relations, corporate development, tax, purchasing, and marketing not directly incurred by a segment are allocated to the segments based on total net revenue. Corporate operating expenses that are directly incurred by a segment are reflected in each segment’s income.

Capital expenditures by segment for the six months ended June 30, ~~2022~~2023 and ~~2021~~2022 were as follows:


		Six Months Ended June 30,					Six Months Ended June 30,
(thousands of U.S. dollars)	(thousands of U.S. dollars)	2022		2021		(thousands of U.S. dollars)	2023		2022
Sterigenics	Sterigenics	$	55,065	$	35,851	Sterigenics	$	73,725	$	55,065
Nordion	Nordion	10,741		6,376		Nordion	16,283		10,741
Nelson Labs	Nelson Labs	5,836		2,562		Nelson Labs	8,126		5,836
Total capital expenditures	Total capital expenditures	$	71,642	$	44,789	Total capital expenditures	$	98,134	$	71,642

Total assets and depreciation and amortization expense by segment are not readily available and are not reported separately to the chief operating decision maker.

Table of Contents

Sotera Health Company

Notes to Consolidated Financial Statements

A reconciliation of segment income to consolidated income before taxes is as follows:


(thousands of U.S. dollars)	(thousands of U.S. dollars)	Three Months Ended June 30,				Six Months Ended June 30,				(thousands of U.S. dollars)	Three Months Ended June 30,				Six Months Ended June 30,
		2022		2021		2022		2021			2023		2022		2023		2022
Segment income	Segment income	$	136,135	$	134,563	$	251,484	$	239,880	Segment income	$	128,485	$	136,135	$	226,953	$	251,484
Less adjustments:	Less adjustments:									Less adjustments:
Interest expense, net(a)	Interest expense, net(a)	17,144		19,163		33,894		40,445		Interest expense, net(a)	25,271		17,144		51,811		33,894
Depreciation and amortization(b)	Depreciation and amortization(b)	36,939		37,461		72,988		75,122		Depreciation and amortization(b)	39,490		36,939		79,028		72,988
Share-based compensation(c)	Share-based compensation(c)	5,801		3,493		10,339		6,942		Share-based compensation(c)	8,409		5,801		15,757		10,339

Gain on foreign currency and derivatives not designated as hedging instruments, net(d)	Gain on foreign currency and derivatives not designated as hedging instruments, net(d)	(1,430)		(660)		(7,982)		(996)		Gain on foreign currency and derivatives not designated as hedging instruments, net(d)	(409)		(1,430)		126		(7,982)
Acquisition and divestiture related charges, net(e)	Acquisition and divestiture related charges, net(e)	691		844		531		659		Acquisition and divestiture related charges, net(e)	153		691		745		531
Business optimization project expenses(f)	Business optimization project expenses(f)	470		275		574		536		Business optimization project expenses(f)	3,322		470		5,856		574
Plant closure expenses(g)	Plant closure expenses(g)	478		756		1,149		1,298		Plant closure expenses(g)	129		478		(766)		1,149
Impairment of investment in unconsolidated affiliate(h)	Impairment of investment in unconsolidated affiliate(h)	9,613		—		9,613		—		Impairment of investment in unconsolidated affiliate(h)	—		9,613		—		9,613
Loss on extinguishment of debt(i)		—		—		—		14,312
Professional services relating to EO sterilization facilities(j)		17,678		10,644		35,737		24,043
Accretion of asset retirement obligation(k)		598		602		1,118		1,153
COVID-19 expenses(l)		45		188		148		487
Professional services and other expenses relating to EO sterilization facilities(i)										Professional services and other expenses relating to EO sterilization facilities(i)	17,080		17,678		33,382		35,737
Accretion of asset retirement obligation(j)										Accretion of asset retirement obligation(j)	555		598		1,127		1,118
COVID-19 expenses(k)										COVID-19 expenses(k)	—		45		—		148
Consolidated income before taxes	Consolidated income before taxes	$	48,108	$	61,797	$	93,375	$	75,879	Consolidated income before taxes	$	34,485	$	48,108	$	39,887	$	93,375

(a)The three and six months ended June 30, 2023 exclude $5.5 million and $7.8 million, respectively, of interest expense, net, on Term Loan B attributable to the loan proceeds that were used to fund the $408.0 million Illinois EO litigation settlement. The three and six months ended June 30, 2022 ~~excludes~~exclude $3.1 million and $9.4 million, respectively, of unrealized gains on interest rate derivatives not designated as hedging instruments.

(b)Includes depreciation of Co-60 held at gamma irradiation sites.

(c)Represents ~~non-cash~~ share-based compensation ~~expense.~~expense to employees and non-employee directors.

(d)Represents the effects of (i) fluctuations in foreign currency exchange rates, (ii) non-cash mark-to-fair value of embedded derivatives relating to certain customer and supply contracts at Nordion, and (iii) unrealized gains on interest rate caps not designated as hedging instruments.

(e)Represents (i) certain direct and incremental costs related to the acquisitions of RCA ~~the noncontrolling interests in our China subsidiaries,~~and BioScience Labs ~~in 2021, the first quarter 2021 gain on the mandatorily redeemable noncontrolling interest in Nelson Labs Fairfield (as described in Note 4, “Acquisitions”),~~ and certain related integration efforts as a result of those acquisitions, (ii) the earnings impact of fair value adjustments (excluding those recognized within

~~Table of Contents~~

~~Sotera Health Company~~

~~Notes to Consolidated Financial Statements~~

amortization expense) resulting from the businesses acquired, and (iii) transition services income and non-cash deferred lease income associated with the terms of the divestiture of the Medical Isotopes business in 2018.

(f)Represents professional fees, ~~contract termination and~~ exit costs, severance and other payroll costs, and other costs associated with business optimization and cost savings projects relating to the integration of acquisitions, operating structure realignment and other process enhancement projects.

(g)Represents professional fees, severance and other payroll costs, and other costs including ongoing lease and utility expenses associated with the closure of the Willowbrook, Illinois facility. The six months ended June 30, 2023 also includes a $1.0 million cancellation fee received from a tenant in connection with the termination of an office space lease at the Nordion facility.

(h)Represents an impairment charge on our equity method investment in ~~Auralux.~~a joint venture. Refer to Note 1, “Basis of Presentation”.

(i)~~Represents expenses incurred in connection with the repricing of our Term Loan in January 2021, including accelerated amortization of prior debt issuance and discount costs.~~

~~(j)~~Represents litigation and other professional fees associated with our EO sterilization facilities. This includes $5.5 million and $7.8 million of interest expense, net for the three and six months ended June 30, 2023, respectively, associated with Term Loan B that was issued to finance the $408.0 million cost to settle approximately 880 pending and threatened EO claims against the Settling Defendants in Illinois under Settlement Agreements entered into on March 28, 2023. See Note ~~16,~~15, “Commitments and ~~Contingencies”~~.Contingencies.”

~~(k)~~(j)Represents non-cash accretion of asset retirement obligations related to Co-60 and gamma processing facilities, which are based on estimated site remediation costs for any future decommissioning of these facilities (without regard for whether the decommissioning services would be performed by employees of Nordion, instead of by a third party) and are accreted over the life of the asset.

~~(l)~~(k)Represents non-recurring costs associated with the COVID-19 pandemic, including incremental costs to implement workplace health and safety measures.

3032

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations

You should read the following discussion and analysis in conjunction with our consolidated financial statements and related notes included in Part I, Item 1 of this Quarterly Report on Form 10-Q, as well as the audited consolidated financial statements and notes and Management’s Discussion and Analysis of Financial Condition and Results of Operations contained in our ~~2021~~2022 Form 10-K. This discussion and analysis contains forward-looking statements that are based on management’s current expectations, estimates and projections about our business and operations. Our actual results may differ materially from those currently anticipated and expressed in such forward-looking statements as a result of various factors, including the factors we describe in the section entitled Part II, Item 1A, “Risk Factors” in this Quarterly Report on Form 10-Q, as well as Part I, Item 1A, “Risk Factors” in our ~~2021~~2022 Form 10-K.

OVERVIEW

We are a leading global provider of mission-critical end-to-end sterilization solutions, lab testing and advisory services for the healthcare industry. We are driven by our mission: Safeguarding Global Health®. We provide end-to-end sterilization as well as microbiological and analytical lab testing and advisory services to help ensure that medical, pharmaceutical and food products are safe for healthcare practitioners, patients and consumers in the United States and around the world. Our services are an essential aspect of our customers’ manufacturing process and supply chains, helping to ensure sterilized medical products reach healthcare practitioners and patients. Most of these services are necessary for our customers to satisfy applicable government requirements.

We serve our customers throughout their product lifecycles, from product design to manufacturing and delivery, helping to ensure the sterility, effectiveness and safety of their products for the end user. We operate across two core businesses: sterilization services and lab services. The combination of Sterigenics, our terminal sterilization business, and Nordion, our Co-60 supply business, makes us the only vertically integrated global gamma sterilization provider in the sterilization industry. For financial reporting purposes, our sterilization services business consists of two reportable segments, Sterigenics and Nordion, and our lab services business consists of one reportable segment, Nelson Labs.

For the three and six months ended June 30, ~~2022,~~2023, respectively, we recorded net revenues of ~~$266.6~~$255.3 million and ~~$503.4~~$475.9 million, net income of ~~$30.4~~$23.5 million and ~~$61.1~~$26.4 million, Adjusted Net Income of ~~$75.8~~$59.3 million and ~~$136.1~~$97.3 million, and Adjusted EBITDA of ~~$136.1~~$128.5 million and ~~$251.5~~$227.0 million. For the definition of Adjusted Net Income and Adjusted EBITDA and the reconciliation of these non-GAAP measures from net income, please see “Non-GAAP Financial Measures.”

STRATEGIC DEVELOPMENTS AND KEY FACTORS AFFECTING OUR RESULTS OF OPERATIONS

The following summarizes strategic developments and key factors that impacted our operating results for the three and six months ended June 30, ~~2022~~2023 and may continue to affect our performance and financial condition in future periods.

•Business and market conditions. ~~During~~Consolidated revenue and net income for the three and six months ended June 30, ~~2022,~~2023 declined from the same periods of the prior year, mainly driven by expected Nordion Co-60 harvest schedule timing combined with unfavorable volume and change in mix at Nelson Labs and Sterigenics. Notwithstanding these headwinds, Sterigenics sustained favorable revenue growth for the three and six months ended June 30, 2023 compared to the same periods in the prior year, fueled mainly by the benefits of favorable pricing. As previously disclosed, we continue to expect Nordion ~~continued~~Co-60 harvest schedules to ~~benefit from a sustained demand for sterilization services. Although the decline in pandemic-related testing stabilized~~improve in the second ~~quarter,~~half of the ~~competitive labor market, broad inflationary impacts, supply chain constraints and regulatory update delays remained an ongoing challenge for Nelson Labs.~~ year.

As discussed in more detail in our ~~most recent~~2022 Form 10-K, a portion of our supply of Co-60 is generated by Russian nuclear

reactors. We continue to monitor the potential for disruption in the supply of Co-60 from Russian nuclear ~~reactors; to date there has been no~~reactors but

we do not expect a material impact for the remainder of 2023 on our supply or revenue.

•Investment initiatives. We remain focused on our investments in capacity expansions and facility improvements as well as in our efforts to strengthen our Co-60 supply chain. For the six months ended June 30, ~~2022,~~2023, we increased capital expenditures by ~~$26.9~~$26.5 million compared to the six months ended June 30, ~~2021.~~2022.

•Disciplined and strategic M&A activity. We remain committed to our highly disciplined acquisition strategy and continue to seek suitable acquisition targets in 2022. On November 4, 2021, we acquired Regulatory Compliance Associates Inc. (“RCA”) headquartered in Pleasant Prairie, Wisconsin. RCA is an industry leader in providing life sciences consulting focused on quality, regulatory, and technical consulting for the pharmaceutical, medical device and combination device industries. RCA expands and strengthens the technical consulting and expert advisory capabilities of Nelson Labs. On March 8, 2021, we acquired BioScience Laboratories, LLC (“BioScience Labs”) based in Bozeman, Montana, bringing expertise in antimicrobial and virology testing to our Nelson Labs segment.targets.

3133

•Litigation costs. We are currently the subject of tort lawsuits alleging personal injury by purported exposure to EO emitted by our former facility in Willowbrook, Illinois and our current facilities in Atlanta, Georgia and Santa Teresa, New Mexico. In addition, we are defendants in a lawsuit brought by the State of New Mexico Attorney General alleging that emissions of EO from our Santa Teresa facility constitute a public nuisance and materially contributed to increased health risks suffered by residents in the area. We maintain that these facilities did not pose and do not pose any safety risk to their surrounding communities. We deny the allegations in these lawsuits and are vigorously defending against these claims.

In connection with the ongoing litigation related to our Willowbrook, Illinois, Atlanta, Georgia and Santa Teresa, New Mexico facilities, as described in Note ~~16,~~15, “Commitments and Contingencies”, we recorded costs of ~~$17.7~~$17.1 million and ~~$35.7~~$33.4 million for the three and six months ended June 30, ~~2022,~~2023, respectively. Insurance coverage has been available for some of our costs in this ethylene oxide (“EO”) tort litigation in the past and as of June 30, 2022 we have approximately $4.0 million of such coverage remaining. Our insurance for future alleged environmental liabilities excludes coverage for EO claims. See Note 16, “Commitments and Contingencies”. In addition, we are pursuing other insurance coverage for EO tort litigation. In 2021,On January 9, 2023, Sterigenics U.S., LLC ~~filed an insurance coverage lawsuit~~and Sotera Health LLC (the “Settling Defendants”) entered into binding term sheets and on March 28, 2023 the Settling Defendants entered into full agreements to settle 879 pending and threatened EO claims against the Defendant Subsidiaries in the Circuit Court of Cook County, Illinois, and U.S. District Court for the Northern District of Illinois ~~relating~~(the “Settlement Agreements”). On May 1, 2023, pursuant to ~~two commercial general liability policies issued~~the Settlement Agreements, the Company paid $408.0 million into a settlement escrow fund to settle the claims, subject to the satisfaction or waiver of certain conditions, including but not limited to substantially all of the plaintiffs providing opt-in consents to their individual settlement allocations and dismissing their claims with prejudice.

On June 22, 2023, the opt-in process was completed for the January 2023 settlements of the EO claims against the Settling Defendants in the ~~1980s.~~Circuit Court of Cook County, Illinois and the Settling Defendants elected to proceed with settlements with the 879 eligible claimants who opted in. On ~~August 3, 2022,~~June 30, 2023, all but an immaterial fraction of the ~~Court issued a Memorandum Opinion and Order concluding that~~settlement funds were released from escrow. The claims of the ~~insurance company owes~~Settling Claimants against the Settling Defendants were dismissed with prejudice. An immaterial fraction of the settlement funds remains in escrow with respect to three claimants who did not opt in; these funds will revert to Sterigenics U.S., LLC if these claimants do not opt in before December 31, 2023.

The Settlement Agreements provided a pathway to comprehensively resolve the claims pending and ~~another party a duty~~threatened against the Company in Illinois and thereby enable the Company to ~~defend~~focus its attention on operating the business. The Company denies any liability and maintains that its Willowbrook, Illinois operations did not pose a safety risk to the community in which it operated and believes the evidence ultimately would have compelled the rejection of the plaintiffs’ claims. See Note 15, “Commitments and Contingencies” to our consolidated financial statements.

•Borrowings, financing costs and financial leverage. On February 23, 2023 the Company successfully closed on a new senior secured Term Loan B facility in an aggregate principal amount of $500.0 million. The Company used the proceeds of this debt to pay down existing borrowings under the Company’s revolving credit facility and fund the $408.0 million EO litigation ~~which may allow us~~settlement in Cook County, Illinois. In addition, the Company plans to ~~recover defense costs related~~use the remaining proceeds to ~~that litigation.~~further enhance liquidity and for other general corporate purposes.

On March 21, 2023, the Company also entered into an Incremental Facility Amendment to the First Lien Credit Agreement (“Revolving Credit Facility Amendment”), which provides for an increase in the commitments under the existing revolving credit facility in an aggregate principal amount of $76.3 million. The Revolving Credit Facility Amendment also provides additional commitments for the issuance of letters of credit under the Revolving Credit Facility in an aggregate principal amount of $165.1 million. After giving effect to the Revolving Credit Facility Amendment, the aggregate amount of the revolving commitments under the Revolving Credit Facility is $423.8 million.

CONSOLIDATED RESULTS OF OPERATIONS

Three Months Ended June 30, ~~2022~~2023 as compared to Three Months Ended June 30, ~~2021~~2022

The following table sets forth the components of our results of operations for the three months ended June 30, ~~2022~~2023 and ~~2021.~~2022.


(thousands of U.S. dollars)	(thousands of U.S. dollars)	2022		2021		$ Change		% Change		(thousands of U.S. dollars)	2023		2022		$ Change		% Change

Total net revenues	Total net revenues	$	266,639	$	251,917	$	14,722	5.8	%	Total net revenues	$	255,282	$	266,639	$	(11,357)	(4.3)	%
Total cost of revenues	Total cost of revenues	116,243		108,156		8,087		7.5	%	Total cost of revenues	115,694		116,243		(549)		(0.5)	%
Total operating expenses	Total operating expenses	78,901		65,489		13,412		20.5	%	Total operating expenses	76,384		78,901		(2,517)		(3.2)	%
Operating income	Operating income	71,495		78,272		(6,777)		(8.7)	%	Operating income	63,204		71,495		(8,291)		(11.6)	%
Net income	Net income	30,418		42,615		(12,197)		(28.6)	%	Net income	23,513		30,418		(6,905)		(22.7)	%
Adjusted Net Income(a)	Adjusted Net Income(a)	75,825		71,672		4,153		5.8	%	Adjusted Net Income(a)	59,295		75,825		(16,530)		(21.8)	%
Adjusted EBITDA(a)	Adjusted EBITDA(a)	136,135		134,563		1,572		1.2	%	Adjusted EBITDA(a)	128,485		136,135		(7,650)		(5.6)	%

(a)Adjusted Net Income and Adjusted EBITDA are non-GAAP financial measures. For more information regarding our calculation of Adjusted Net Income and Adjusted EBITDA, including information about their limitations as tools for analysis and a reconciliation of net income, the most directly comparable financial measure calculated and presented in accordance with GAAP, to Adjusted Net Income and Adjusted EBITDA, please see the reconciliation included below in “Non-GAAP Financial Measures.”

Total Net Revenues

The following table compares our revenues by type for the three months ended June 30, ~~2022~~2023 to the three months ended June 30, ~~2021.~~2022.


(thousands of U.S. dollars)	(thousands of U.S. dollars)									(thousands of U.S. dollars)
Net revenues for the three months ended June 30,	Net revenues for the three months ended June 30,	2022		2021		$ Change		% Change		Net revenues for the three months ended June 30,	2023		2022		$ Change		% Change

Service	Service	$	221,529	$	208,710	$	12,819	6.1	%	Service	$	226,050	$	221,529	$	4,521	2.0	%
Product	Product	45,110		43,207		1,903		4.4	%	Product	29,232		45,110		(15,878)		(35.2)	%
Total net revenues	Total net revenues	$	266,639	$	251,917	$	14,722	5.8	%	Total net revenues	$	255,282	$	266,639	$	(11,357)	(4.3)	%

Net revenues were ~~$266.6~~$255.3 million in the three months ended June 30, ~~2022, an increase~~2023, a decrease of ~~$14.7~~$11.4 million, or ~~5.8%~~4.3%, as compared with the three months ended June 30, ~~2021.~~2022. Excluding the impact of foreign currency exchange rates, net revenues in the three months ended June 30, ~~2022 increased~~2023 decreased approximately ~~8.5%~~4.1% compared with the three months ended June 30, ~~2021.~~2022.

Service revenues

Service revenues increased ~~$12.8~~$4.5 million, or ~~6.1%~~2.0%, to $226.1 million in the three months ended June 30, 2023 as compared to $221.5 million in the three months ended June 30, ~~2022 as compared to $208.7 million in the three months ended June 30, 2021.~~2022. The ~~increase~~growth in net service revenue was driven by favorable pricing of ~~$8.9~~$10.6 million and ~~$3.1~~$2.1 million in the Sterigenics and Nelson Labs segments, respectively, ~~and sales volume growth of $7.3~~coupled with a $1.0 million in the Sterigenics segment. The RCA acquisition also contributed $3.3 million to service revenue growth. Partially offsetting these factors was an overall decline of $2.9 million in pandemic-related testing revenue in the Nelson Labs segment.

~~Service revenue growth was also offset by a $5.3 million unfavorable~~favorable impact from changes in foreign currency exchange rates across all segments. Partially offsetting these growth factors was a decline in service revenue volume and change in mix of $4.1 million, $2.7 million, and $2.4 million in the Nelson Labs, Sterigenics and Nordion segments, respectively.

Product revenues

Product revenues ~~increased $1.9~~decreased $15.9 million, or ~~4.4%~~35.2%, to $29.2 million in the three months ended June 30, 2023 as compared to $45.1 million in the three months ended June 30, ~~2022 as compared to $43.2 million in the three months ended June 30, 2021.~~2022. The ~~increase~~decrease in product revenues was ~~attributable~~mainly driven by expected volume decline and change in mix of $17.2 million due to ~~favorable pricing of $3.0 million partially offset by a $1.3 million~~Co-60 harvest schedule timing in the Nordion segment and an unfavorable impact from changes in foreign currency exchange ~~rates.~~rates of $1.6 million. Partially offsetting this decline was a favorable pricing impact of $2.9 million.

Total Cost of Revenues

The following table compares our cost of revenues by type for the three months ended June 30, ~~2022~~2023 to the three months ended June 30, ~~2021.~~2022.

(thousands of U.S. dollars)
Cost of revenues for the three months ended June 30, 2022 2021 $ Change % Change
Service $ 98,407 $ 91,391 $ 7,016 7.7 %
Product 17,836 16,765 1,071 6.4 %
Total cost of revenues $ 116,243 $ 108,156 $ 8,087 7.5 %


(thousands of U.S. dollars)
Cost of revenues for the three months ended June 30,	2023		2022		$ Change		% Change

Service	$	103,900	$	98,407	$	5,493	5.6	%
Product	11,794		17,836		(6,042)		(33.9)	%
Total cost of revenues	$	115,694	$	116,243	$	(549)	(0.5)	%

Total cost of revenues accounted for approximately ~~43.6%~~45.3% and ~~42.9%~~43.6% of our consolidated net revenues for the three months ended June 30, ~~2022~~2023 and ~~2020,~~2022, respectively.

Cost of service revenues

Cost of service revenues increased ~~$7.0~~$5.5 million, or ~~7.7%~~5.6%, for the three months ended June 30, ~~2022~~2023 as compared to the three months ended June 30, ~~2021.~~2022. The ~~increase~~growth in cost of service revenues was ~~attributable to $6.5~~partially driven by $3.6 million of ~~increased costs arising from inflationary pressures, mainly on labor~~depreciation related to capital assets recently placed in service and ~~the~~higher energy costs. In addition, cost of ~~energy. Cost~~service revenue increased by $2.1 million as a result of ~~sales was also impacted by an incremental contribution~~higher labor costs, largely stemming from both the addition of ~~$2.3 million from the RCA acquisition in the Nelson Labs segment. Partially offsetting the total increase was a $2.7 million impact from changes in foreign currency exchange rates.~~new personnel and higher compensation costs.

Cost of product revenues

Cost of product revenues ~~increased $1.1~~decreased $6.0 million, or ~~6.4%~~33.9%, for the three months ended June 30, ~~2022~~2023 as compared to the three months ended June 30, ~~2021.~~2022. The ~~increase reflects incremental~~decrease was primarily a result of lower direct material and material transportation costs of $5.5 million due to ~~product mix offset by~~expected Co-60 harvest schedule timing in the Nordion segment coupled with a $0.7 million impact due to changes in foreign currency exchange rates.

Operating Expenses

The following table compares our operating expenses for the three months ended June 30, ~~2022~~2023 to the three months ended June 30, ~~2021:~~2022:


(thousands of U.S. dollars)	(thousands of U.S. dollars)									(thousands of U.S. dollars)
Operating expenses for the three months ended June 30,	Operating expenses for the three months ended June 30,	2022		2021		$ Change		% Change		Operating expenses for the three months ended June 30,	2023		2022		$ Change		% Change

Selling, general and administrative expenses	Selling, general and administrative expenses	$	63,132	$	49,828	$	13,304	26.7	%	Selling, general and administrative expenses	$	60,287	$	63,132	$	(2,845)	(4.5)	%
Amortization of intangible assets	Amortization of intangible assets	15,769		15,661		108		0.7	%	Amortization of intangible assets	16,097		15,769		328		2.1	%

Total operating expenses	Total operating expenses	$	78,901	$	65,489	$	13,412	20.5	%	Total operating expenses	$	76,384	$	78,901	$	(2,517)	(3.2)	%

Operating expenses accounted for approximately ~~29.6%~~29.9% and ~~26.0%~~29.6% of our consolidated net revenues for the three months ended June 30, ~~2022~~2023 and ~~2021,~~2022, respectively.

Selling, general and administrative expenses (“SG&A&A”)

SG&A ~~increased $13.3~~decreased $2.8 million, or ~~26.7%~~4.5%, for the three months ended June 30, ~~2022~~2023 as compared to the three months ended June 30, ~~2021.~~2022. The ~~increase~~decrease was driven primarily by ~~the following factors:~~

•~~$7.0~~a $6.0 million ~~increase~~decrease in litigation and other professional services expense associated with EO sterilization ~~facilities;~~

•~~$2.3~~facilities. Partially offsetting this decrease was a $2.6 million increase in share-based compensation expense ~~related~~attributable to ~~our~~awards granted under the 2020 Omnibus Incentive ~~Plan;~~Plan and

•~~$2.6~~ $1.0 million ~~increase~~ in ~~selling and administrative~~incremental SG&A personnel ~~and post-COVID-19 travel costs~~ in support of ~~our general~~various business ~~growth.~~enhancement and compliance efforts.

Amortization of intangible assets

Amortization of intangible assets ~~was $15.8~~increased $0.3 million to $16.1 million, or 2.1%, for the three months ended June 30, ~~2022, or 0.7% above~~2023 as compared to the three months ended June 30, ~~2021. The increase was~~2022 due mainly to changes in foreign currency exchange rates.

Interest Expense, Net

Interest expense, net ~~decreased $5.1~~increased $16.7 million, or ~~26.7%~~118.8%, for the three months ended June 30, ~~2022~~2023 as compared to the three months ended June 30, ~~2021.~~2022. The ~~decrease~~variance was ~~primarily~~ driven by an increase in the variable interest rate driving increased interest expense of $16.7 million on borrowings previously outstanding in the same period of the prior year coupled with interest expense of $11.1 million on incremental borrowings. Partially offsetting the increase was a ~~$4.4~~$6.8 million ~~reduction~~increase in interest income on cash and cash equivalents on deposit at financial institutions and a $5.0 million net favorable change due to interest ~~expense attributable to the favorable change in fair value and quarterly settlement of interest~~ rate derivatives not designated as hedging instruments. The decrease was also driven by a decline in interest expense on outstanding borrowings of $0.9 million, due largely to a lower average outstanding debt balance for the three months ended June 30, 2022 compared to the three months ended June 30, 2021.derivative activity. The weighted average interest rate on our outstanding debt was ~~3.81%~~8.20% and ~~3.45%~~3.81% at June 30, ~~2022~~2023 and ~~2021,~~2022, respectively.

Impairment of Investment in Unconsolidated Affiliate

During the three months ended June 30, 2022, we recorded an impairment charge of $9.6 million related to a joint venture investment in Auralux Enterprises Ltd. (“Auralux”) which was acquired as part of the 2020 Iotron acquisition. Due to a shift in business strategy, the joint venture will not proceed, and our joint venture partner will continue to rely on our other existing operating facilities. Based on these facts and circumstances, we concluded that the investment was impaired as of June 30, 2022.

Foreign Exchange Loss (Gain)

Foreign exchange ~~gain~~loss was ~~$0.8~~$0.5 million for the three months ended June 30, ~~2022~~2023 as compared to a ~~loss~~gain of ~~$0.1~~$0.8 million in the three months ended June 30, ~~2021.~~2022. The change in foreign exchange loss (gain) in our Consolidated Statements of Operations and Comprehensive Income (Loss) mainly relates to short-term losses (offset by short-term gains) on sales denominated in currencies other than the functional currency of our operating entities. As described in Note ~~17,~~16, “Financial Instruments and Financial Risk”, we enter into monthly U.S. dollar-denominated foreign currency forward contracts to manage foreign currency exchange rate risk ~~of our intercompany loans in certain of~~related to our international subsidiaries.

Other Expense (Income), Net

Other ~~expense (income),~~income, net was $2.5 million for the three months ended June 30, 2023 compared to other expense of $0.5 million for the three months ended June 30, ~~2022 compared to $(2.8) million for~~2022. The majority of the ~~three months ended June 30, 2021. The fluctuation was mainly driven by unfavorable changes~~variance stemmed from an increase in the fair value of Nordion’s embedded ~~derivatives~~derivative assets in the three months ended June 30, ~~2022.~~2023, resulting in an increase in other income of $3.4 million from the three months ended June 30, 2023.

Provision for Income Taxes

Provision for income tax decreased ~~$1.5~~$6.7 million to a net provision of ~~$17.7~~$11.0 million for the three months ended June 30, ~~2022~~2023 as compared to ~~$19.2~~$17.7 million in the three months ended June 30, ~~2021.~~2022. The change was primarily attributable to lower pre-tax income for the three months ended June 30, ~~2022~~2023 compared to the three months ended June 30, ~~2021.~~2022, partially offset by an increase in the valuation allowance, which was a direct result of the $408.0 million Illinois EO litigation settlement as described in Note 15, “Commitments and Contingencies”. This expense will eliminate a current deduction of 2023 U.S. interest and increase the valuation allowance against our excess interest expense carryforward balance.

Provision for income taxes for the three months ended June 30, 2023 differed from the statutory rate primarily to the impact of the foreign rate differential, the valuation allowance attributable to the limitation on the deductibility of interest expense, and global intangible low-tax income (“GILTI”). Provision for income taxes for the three months ended June 30, 2022 ~~and the three months ended June 30, 2022~~ differed from the statutory rate primarily due to ana net increase in the valuation allowance ~~the impact of the foreign rate differential, and tax on Global Intangible Low Taxed Income (“GILTI”). The increase in the valuation allowance was~~ attributable to the limitation on the deductibility of interest expense, ~~and~~ the ~~impairment~~impact of the investment in Auralux. Provision for income taxes for the three months ended June 30, 2021 was partially offset by a discrete item, which reversed the valuation allowance on deferred tax assets related to certain asset retirement obligations.foreign rate differential, and GILTI.

Net Income, Adjusted Net Income and Adjusted EBITDA

Net income for the three months ended June 30, ~~2022~~2023 was ~~$30.4~~$23.5 million, as compared to net income of ~~$42.6~~$30.4 million for the three months ended June 30, ~~2021.~~2022 due to the factors described above. Adjusted Net Income was $59.3 million for the three months ended June 30, 2023, as compared to $75.8 million for the three months ended June 30, 2022, ~~as compared to $71.7~~and Adjusted EBITDA was $128.5 million for the three months ended June 30, ~~2021, due~~2023, as compared to ~~the factors described above. Adjusted EBITDA was~~ $136.1 million for the three months ended June 30, ~~2022, as compared to $134.6 million for the three months ended June 30, 2021, due to the factors described above.~~2022. Please see “Non-GAAP Financial Measures” below for a reconciliation of

Adjusted Net Income and Adjusted EBITDA to their most directly comparable financial measure calculated and presented in accordance with GAAP.

Six Months Ended June 30, ~~2022~~2023 as compared to Six Months Ended June 30, ~~2021~~2022

The following table sets forth the components of our results of operations for the six months ended June 30, ~~2022~~2023 and ~~2021.~~2022.


(thousands of U.S. dollars)	(thousands of U.S. dollars)	2022		2021		$ Change		% Change		(thousands of U.S. dollars)	2023		2022		$ Change		% Change

Total net revenues	Total net revenues	$	503,393	$	464,065	$	39,328	8.5	%	Total net revenues	$	475,872	$	503,393	$	(27,521)	(5.5)	%
Total cost of revenues	Total cost of revenues	224,122		204,932		19,190		9.4	%	Total cost of revenues	224,781		224,122		659		0.3	%
Total operating expenses	Total operating expenses	154,284		134,497		19,787		14.7	%	Total operating expenses	154,521		154,284		237		0.2	%
Operating income	Operating income	124,987		124,636		351		0.3	%	Operating income	96,570		124,987		(28,417)		(22.7)	%
Net income	Net income	61,059		53,680		7,379		13.7	%	Net income	26,355		61,059		(34,704)		(56.8)	%
Adjusted Net Income(a)	Adjusted Net Income(a)	136,079		123,178		12,901		10.5	%	Adjusted Net Income(a)	97,340		136,079		(38,739)		(28.5)	%
Adjusted EBITDA(a)	Adjusted EBITDA(a)	251,484		239,880		11,604		4.8	%	Adjusted EBITDA(a)	226,953		251,484		(24,531)		(9.8)	%

Total Net Revenues

The following table compares our revenues by type for the six months ended June 30, ~~2022~~2023 to the six months ended June 30, ~~2021.~~2022.


(thousands of U.S. dollars)	(thousands of U.S. dollars)									(thousands of U.S. dollars)
Net revenues for the six months ended June 30,	Net revenues for the six months ended June 30,	2022		2021		$ Change		% Change		Net revenues for the six months ended June 30,	2023		2022		$ Change		% Change

Service	Service	$	427,747	$	397,408	$	30,339	7.6	%	Service	$	440,560	$	427,747	$	12,813	3.0	%
Product	Product	75,646		66,657		8,989		13.5	%	Product	35,312		75,646		(40,334)		(53.3)	%
Total net revenues	Total net revenues	$	503,393	$	464,065	$	39,328	8.5	%	Total net revenues	$	475,872	$	503,393	$	(27,521)	(5.5)	%

Net revenues were ~~$503.4~~$475.9 million in the six months ended June 30, ~~2022, an increase~~2023, a decrease of ~~$39.3~~$27.5 million, or ~~8.5%~~5.5%, as compared with the six months ended June 30, ~~2021.~~2022. Excluding the impact of foreign currency exchange rates, net revenues in the six months ended June 30, ~~2022 increased~~2023 decreased approximately ~~10.4%~~4.6% compared with the six months ended June 30, ~~2021.~~2022.

Service revenues

Service revenues increased ~~$30.3~~$12.8 million, or ~~7.6%~~3.0%, to $440.6 million in the six months ended June 30, 2023 as compared to $427.7 million in the six months ended June 30, ~~2022 as compared to $397.4 million in the six months ended June 30, 2021.~~2022. The ~~increase~~growth in net service ~~revenue~~revenues was driven by ~~sales volume growth~~favorable pricing of ~~$20.2 million in the Sterigenics segment and $15.9~~$19.8 million and ~~$5.4~~$4.2 million ~~from favorable pricing~~ in the Sterigenics and Nelson Labs segments, respectively. ~~The BioScience Labs and RCA acquisitions also contributed $8.0 million to~~Partially offsetting the favorable price increases was a decline in service revenue ~~growth. Partially offsetting these factors was an overall decline~~volume and change in mix of ~~$8.8~~$6.9 million ~~in pandemic-related testing revenue as well as a decrease in volumes in other testing categories~~and $3.3 million in the Nelson Labs ~~segment. Service revenue growth was offset by~~and Nordion segments, respectively, coupled with a ~~$7.7~~$1.2 million unfavorable impact from changes in foreign currency exchange rates across all segments.

Product revenues

Product revenues ~~increased $9.0~~decreased $40.3 million, or ~~13.5%~~53.3%, to $35.3 million in the six months ended June 30, 2023 as compared to $75.6 million in the six months ended June 30, ~~2022 as compared to $66.7 million in the six months ended June 30, 2021.~~2022. The ~~expansion~~decrease in product revenues was ~~attributable~~mainly driven by expected volume decline and change in mix of $40.3 million due to ~~$5.6 million of growth~~Co-60 harvest schedule timing in ~~sales volume coupled with $4.8 million from favorable pricing in our~~the Nordion ~~segment. Partially offsetting this increase was a $1.3 million~~segment and an unfavorable impact from changes in foreign currency exchange ~~rates.~~

rates of $2.9 million. Partially offsetting this decline was a favorable pricing impact of $2.9 million.

Total Cost of Revenues

The following table compares our cost of revenues by type for the six months ended June 30, ~~2022~~2023 to the six months ended June 30, ~~2021.~~2022.

(thousands of U.S. dollars)
Cost of revenues for the six months ended June 30, 2022 2021 $ Change % Change
Service $ 192,983 $ 176,427 $ 16,556 9.4 %
Product 31,139 28,505 2,634 9.2 %
Total cost of revenues $ 224,122 $ 204,932 $ 19,190 9.4 %


(thousands of U.S. dollars)
Cost of revenues for the six months ended June 30,	2023		2022		$ Change		% Change

Service	$	208,110	$	192,983	$	15,127	7.8	%
Product	16,671		31,139		(14,468)		(46.5)	%
Total cost of revenues	$	224,781	$	224,122	$	659	0.3	%

Total cost of revenues accounted for approximately ~~44.5%~~47.2% and ~~44.2%~~44.5% of our consolidated net revenues for the six months ended June 30, ~~2022~~2023 and ~~2021,~~2022, respectively.

Cost of service revenues

Cost of service revenues increased ~~$16.6~~$15.1 million, or ~~9.4%~~7.8%, for the six months ended June 30, ~~2022~~2023 as compared to the six months ended June 30, ~~2021.~~2022. The ~~increase~~growth in cost of service revenues was ~~attributable to approximately $14.0~~partially driven by $8.7 million of ~~increased~~higher energy costs ~~arising from inflationary pressures, mainly on labor~~ and ~~the~~depreciation related to capital assets recently placed in service. In addition, cost of ~~energy. Cost~~service revenue increased by $6.2 million and $1.0 million, respectively, as a result of ~~sales was also impacted by an incremental contribution of $5.9 million from the RCA~~higher employee compensation and ~~BioScience Labs acquisitions in the Nelson Labs segment.~~professional service costs. Partially offsetting this increase was a ~~$3.9~~$1.0 million impact from changes in foreign currency exchange rates.

Cost of product revenues

Cost of product revenues ~~increased $2.6~~decreased $14.5 million, or ~~9.2%~~46.5%, for the six months ended June 30, ~~2022~~2023 as compared to the six months ended June 30, ~~2021.~~2022. The ~~increase reflects incremental~~decrease was primarily a result of lower direct material and material transportation costs of $12.5 million due to ~~product mix, offset by impacts from~~expected Co-60 harvest schedule timing in the Nordion segment coupled with a $1.6 million impact due to changes in foreign currency exchanges rates.

Operating Expenses

The following table compares our operating expenses for the six months ended June 30, ~~2022~~2023 to the six months ended June 30, ~~2021:~~2022:


(thousands of U.S. dollars)	(thousands of U.S. dollars)									(thousands of U.S. dollars)
Operating expenses for the six months ended June 30,	Operating expenses for the six months ended June 30,	2022		2021		$ Change		% Change		Operating expenses for the six months ended June 30,	2023		2022		$ Change		% Change

Selling, general and administrative expenses	Selling, general and administrative expenses	$	122,674	$	102,293	$	20,381	19.9	%	Selling, general and administrative expenses	$	122,197	$	122,674	$	(477)	(0.4)	%
Amortization of intangible assets	Amortization of intangible assets	31,610		32,204		(594)		(1.8)	%	Amortization of intangible assets	32,324		31,610		714		2.3	%

Total operating expenses	Total operating expenses	$	154,284	$	134,497	$	19,787	14.7	%	Total operating expenses	$	154,521	$	154,284	$	237	0.2	%

Operating expenses accounted for approximately ~~30.6%~~32.5% and ~~29.0%~~30.6% of our consolidated net revenues for the six months ended June 30, ~~2022~~2023 and ~~2021,~~2022, respectively.

SG&A

SG&A ~~increased $20.4~~decreased $0.5 million, or ~~19.9%~~0.4%, for the six months ended June 30, ~~2022~~2023 as compared to the six months ended June 30, ~~2021.~~2022. The ~~increase~~decrease was driven primarily by ~~the following factors:~~

•~~$11.7~~a $10.0 million ~~increase~~decrease in litigation and other professional services expense associated with EO sterilization ~~facilities;~~facilities. This decrease was partially offset by the following factors:

•$~~5.2 million increase in selling and administrative personnel and post-COVID-19 travel costs in support of our general business growth; and~~

•~~$3.4~~5.4 million increase in share-based compensation expense ~~related~~attributable to ~~our~~awards granted under the 2020 Omnibus Incentive ~~Plan.~~Plan;

•$2.5 million in professional fees and other costs associated with business optimization and cost savings projects relating to the integration of recent acquisitions; and

•$1.7 million of incremental SG&A personnel costs in support of various business enhancement and compliance efforts.

Amortization of intangible assets

Amortization of intangible assets ~~was $31.6~~increased $0.7 million to $32.3 million, or 2.3%, for the six months ended June 30, ~~2022, or 1.8% below~~2023 as compared to the ~~six~~three months ended June 30, ~~2021. The change was~~2022 due mainly to ~~a reduction in amortization expense related to certain intangible assets that were fully amortized by December 31, 2021, offset by~~ changes in foreign currency exchange rates.

3639

Interest Expense, Net

Interest expense, net ~~decreased $16.0~~increased $35.2 million, or ~~39.6%~~143.8%, for the six months ended June 30, ~~2022~~2023 as compared to the six months ended June 30, ~~2021.~~2022. The ~~decrease~~variance was driven by an increase in the variable interest rate driving increased interest expense of $33.5 million on borrowings previously outstanding in the same period of the prior year coupled with interest expense of $17.7 million on incremental borrowings. Partially offsetting the increase was a ~~$10.7~~$9.4 million ~~reduction~~increase in interest income on cash and cash equivalents on deposit at financial institutions and a $7.9 million net favorable change due to interest ~~expense attributable to the favorable change in fair value and quarterly settlement of interest~~ rate caps not designated as hedging instruments. The decrease was also driven by a decline in interest expense on outstanding borrowings of $5.3 million, due largely to a lower average outstanding debt balance for the six months ended June 30, 2022 compared to the six months ended June 30, 2021 and a lower interest rate on our Term Loan following the January 20, 2021 repricing amendment.derivative activity. The weighted average interest rate on our outstanding debt was ~~3.81%~~8.20% and ~~3.45%~~3.81% at June 30, ~~2022~~2023 and ~~2021,~~2022, respectively.

Impairment of Investment in Unconsolidated Affiliate

During the six months ended June 30, 2022, we recorded an impairment charge of $9.6 million related to a joint venture investment in Auralux, which was acquired as part of the 2020 Iotron acquisition. Due to a shift in business strategy, the joint venture will not proceed, and our joint venture partner will continue to rely on our other existing operating facilities. Based on these facts and circumstances, we concluded that the investment was impaired as of June 30, 2022.

Foreign Exchange Loss ~~(Gain)~~

Foreign exchange loss was ~~$0.03~~$0.8 million for the six months ended June 30, ~~2022~~2023 as compared to aan immaterial loss ~~of $0.7 million~~ in the six months ended June 30, ~~2021.~~2022. The change in foreign exchange loss in our Consolidated Statements of Operations and Comprehensive Income (Loss) mainly relates to short-term losses (offset by short-term gains) on sales denominated in currencies other than the functional currency of our operating entities. As described in Note ~~17,~~16, “Financial Instruments and Financial Risk”, we enter into monthly U.S. dollar-denominated foreign currency forward contracts to manage foreign currency exchange rate risk ~~of our intercompany loans in certain of~~related to our international subsidiaries.

Other Expense (Income), Net

Other ~~expense (income),~~income, net was ~~$(2.5)~~$3.7 million for the six months ended June 30, ~~2022~~2023 compared to ~~$(6.7)~~$2.5 million for the six months ended June 30, ~~2021.~~2022. The ~~fluctuation was mainly driven by changes~~majority of the variance stemmed from an increase in the fair value of ~~the~~Nordion’s embedded derivatives in ~~Nordion’s sales and purchase contracts. In addition, for~~ the six months ended June 30, ~~2021, we recorded $1.2 million of~~2023, resulting in an increase in other income ~~related to the gain on our purchase~~ of ~~the 15% mandatorily redeemable noncontrolling interest of Nelson Labs Fairfield as~~$2.2 million compared to the ~~amount previously accrued.~~same the period in the prior year.

Provision for Income Taxes

Provision for income ~~tax increased $10.1~~taxes decreased $18.8 million to a net provision of ~~$32.3~~$13.5 million for the six months ended June 30, ~~2022~~2023 as compared to ~~a $22.2~~$32.3 million in the six months ended June 30, ~~2021.~~2022. The change was ~~principally~~primarily attributable to lower pre-tax income ~~of $93.4 million in~~for the six months ended June 30, 2023 compared to the six months ended June 30, 2022, ~~compared to pretax~~partially offset by an increase in the the foreign rate differential and valuation allowance against our excess interest expense carryforward balance. The increase in the valuation allowance was a direct result of the $408.0 million Illinois EO litigation settlement, as described in Note 15, “Commitments and Contingencies”. This expense will eliminate a current deduction of 2023 U.S. interest and increases the valuation allowance against our excess interest expense carryforward balance.

Provision for income ~~of $75.9 million~~taxes for the six months ended June 30, ~~2021. In addition, income tax expense for~~2023 differed from the ~~six months ended June 30, 2021 was lower~~statutory rate due to ~~a discrete item that reversed~~the impact of the foreign rate differential, the valuation allowance attributable to the limitation on ~~deferred tax assets related to certain asset retirement obligations.~~

the deductibility of interest expense and global GILTI, partially offset by a benefit for state income taxes. Provision for income taxes for the six months ended June 30, 2022 ~~and for the six months ended June 30, 2021~~ differed from the statutory rate primarily due to ana net increase in the ~~valuation allowance, the impact of the~~ foreign ~~rate~~ differential, and tax on GILTI. The increase in the valuation allowance was attributable to the limitation on the deductibility of interest expense and the impairment of the investment in Auralux. Provision for income taxes for the six months ended June 30, 2021 was partially offset by a discrete item, which reversed the valuation allowance on deferred tax assets related to certain asset retirement obligations.GILTI.

Net Income, Adjusted Net Income and Adjusted EBITDA

Net income for the six months ended June 30, ~~2022~~2023 was ~~$61.1~~$26.4 million, as compared to net income of ~~$53.7~~$61.1 million for the six months ended June 30, ~~2021.~~2022 due to the factors described above. Adjusted Net Income was $97.3 million for the six months ended June 30, 2023, as compared to $136.1 million for the six months ended June 30, 2022, ~~as compared to $123.2~~and Adjusted EBITDA was $227.0 million for the six months ended June 30, ~~2021, due~~2023, as compared to ~~the factors described above. Adjusted EBITDA was~~ $251.5 million for the six months ended June 30, ~~2022, as compared to $239.9 million for the six months ended June 30, 2021, due to the factors described above.~~2022. Please see “Non-GAAP Financial Measures” below for a reconciliation of Adjusted Net Income and Adjusted EBITDA to their most directly comparable financial measure calculated and presented in accordance with GAAP.

3740

SEGMENT RESULTS OF OPERATIONS

We have three reportable segments: Sterigenics, Nordion and Nelson Labs. Our chief operating decision maker evaluates performance and allocates resources within our business based on Segment Income, which excludes certain items which are included in income before tax as determined in our Consolidated Statements of Operations and Comprehensive Income (Loss). The accounting policies for our reportable segments are the same as those for the consolidated Company.

Our Segments

Sterigenics

Our Sterigenics business provides outsourced terminal sterilization and irradiation services for the medical device, pharmaceutical, food safety and advanced applications markets using three major technologies: gamma irradiation, EO processing and E-beam irradiation.

Nordion

As a result of the time required to meet regulatory and logistics requirements for delivery of radioactive products, combined with accommodations made to our customers to minimize disruptions to their operations during the installation of Co-60, Nordion sales patterns can often vary significantly from one quarter to the next. However, timing-related impacts on our sales performance tend to be resolved within several quarters, resulting in more consistent performance over longer periods of time. In addition, sales of gamma irradiation systems occur infrequently and tend to be for larger amounts.

Results for our Nordion segment are also impacted by Co-60 mix, harvest schedules, as well as customer, product and service mix.

Nelson Labs

Our Nelson Labs business provides outsourced microbiological and analytical chemistry testing and advisory services for the medical device and pharmaceutical industries.

For more information regarding our reportable segments please refer to Note 17, “Segment Information” to our consolidated financial statements.

Segment Results for the Three Months Ended June 30, 2023 and 2022

The following tables compare segment net revenue and segment income for the three months ended June 30, 2023 to the three months ended June 30, 2022:


	Three Months Ended June 30,
(thousands of U.S. dollars)	2023			2022			$ Change		% Change

Net Revenues
Sterigenics	$	166,590		$	157,792		$	8,798	5.6	%
Nordion	31,975			50,478			(18,503)		(36.7	%)
Nelson Labs	56,717			58,369			(1,652)		(2.8)	%
Segment Income
Sterigenics	$	91,450		$	85,098		$	6,352	7.5	%
Nordion	17,784			29,982			(12,198)		(40.7)	%
Nelson Labs	19,251			21,055			(1,804)		(8.6)	%
Segment Income margin
Sterigenics	54.9		%	53.9		%
Nordion	55.6		%	59.4		%
Nelson Labs	33.9		%	36.1		%

Net Revenues by Segment

Sterigenics net revenues were $166.6 million for the three months ended June 30, 2023, an increase of $8.8 million, or 5.6%, as compared to the three months ended June 30, 2022. The increase reflects favorable impacts from pricing of 6.7% as well as favorable changes in foreign currency exchange rates. The increase in segment revenue was partially offset by an unfavorable impact from volume and change in mix compared to the same period in the prior year.

Nordion net revenues were $32.0 million for the three months ended June 30, 2023, a decrease of $18.5 million, or 36.7%, as compared to the three months ended June 30, 2022. The decrease was driven by an expected volume decline and change in mix of 38.8%, due mainly to Co-60 harvest schedule timing, and an unfavorable impact of 3.6% from changes in foreign currency exchange rates. Partially offsetting this decrease was a favorable impact from pricing of 5.7%.

Nelson Labs net revenues were $56.7 million for the three months ended June 30, 2023, a decrease of $1.7 million, or 2.8%, as compared to the three months ended June 30, 2022. The decrease was attributable to volume decline and change in mix of 6.9%. Partially offsetting this decline was a favorable impact from pricing and foreign currency exchange rates of 3.6% and 0.5%, respectively.

Segment Income

Sterigenics segment income was $91.5 million for the three months ended June 30, 2023, an increase of $6.4 million, or 7.5%, as compared to the three months ended June 30, 2022. The increase in segment income and segment income margin was primarily a result of favorable customer pricing, partially offset by unfavorable volume and change in mix, as well as inflation.

Nordion segment income was $17.8 million for the three months ended June 30, 2023, a decrease of $12.2 million, or 40.7%, as compared to the three months ended June 30, 2022. The decrease in segment income and segment income margin was driven by expected volume decline and change in mix stemming from Co-60 harvest schedule timing, partially offset by favorable pricing.

Nelson Labs segment income was $19.3 million for the three months ended June 30, 2023, a decrease of $1.8 million, or 8.6%, as compared to the three months ended June 30, 2022. The decrease in segment income and segment income margin was primarily a result of volume decline and change in mix as well as inflation, partially offset by favorable pricing, as referenced above.

Segment Results for the Six Months Ended June 30, 2023 and 2022

The following tables compare segment net revenue and segment income for the six months ended June 30, 2023 to the six months ended June 30, 2022:


	Six Months Ended June 30,
(thousands of U.S. dollars)	2023			2022			$ Change		% Change

Net Revenues
Sterigenics	$	326,587		$	307,254		$	19,333	6.3	%
Nordion	40,526			84,480			(43,954)		(52.0	%)
Nelson Labs	108,759			111,659			(2,900)		(2.6)	%
Segment Income
Sterigenics	$	174,290		$	164,501		$	9,789	6.0	%
Nordion	19,310			48,885			(29,575)		(60.5)	%
Nelson Labs	33,353			38,098			(4,745)		(12.5)	%
Segment Income margin
Sterigenics	53.4		%	53.5		%
Nordion	47.6		%	57.9		%
Nelson Labs	30.7		%	34.1		%

Net Revenues by Segment

Sterigenics net revenues were $326.6 million for the six months ended June 30, 2023, an increase of $19.3 million, or 6.3%, as compared to the six months ended June 30, 2022. The increase was primarily attributable to the favorable impacts from pricing of 6.4%, partially offset by unfavorable impacts from changes in foreign currency exchange rates of 0.2%.

Nordion net revenues were $40.5 million for the six months ended June 30, 2023, a decrease of $44.0 million, or 52.0%, as compared to the six months ended June 30, 2022. The decrease was driven by an expected volume decline and change in mix of 51.6% due to Co-60 harvest schedule timing, and an unfavorable impact of 3.8% from changes in foreign exchange rates. Partially offsetting this decrease was a favorable impact from pricing of 3.4%.

Nelson Labs net revenues were $108.8 million for the six months ended June 30, 2023, a decrease of $2.9 million, or 2.6%, as compared to the six months ended June 30, 2022. The decrease was attributable to volume decline and change in mix of 6.2% coupled with a 0.2% impact from changes in foreign currency exchanges rates. Partially offsetting this decline was a favorable impact from pricing of 3.8%.

Segment Income

Sterigenics segment income was $174.3 million for the six months ended June 30, 2023, an increase of $9.8 million, or 6.0%, as compared to the six months ended June 30, 2022. The increase in segment income was fueled mainly by favorable customer pricing, as referenced above, partially offset by unfavorable volume and change in mix, as well as inflation.

Nordion segment income was $19.3 million for the six months ended June 30, 2023, a decrease of $29.6 million, or 60.5%, as compared to the six months ended June 30, 2022. The decrease in segment income and segment income margin was driven by expected volume decline and change in mix stemming from Co-60 harvest schedule timing, as referenced above.

Nelson Labs segment income was $33.4 million for the six months ended June 30, 2023, a decrease of $4.7 million, or 12.5%, as compared to the six months ended June 30, 2022. The decrease in segment income and segment income margin was primarily a result of volume decline and change in mix as well as inflation, partially offset by favorable pricing, as referenced above.

NON-GAAP FINANCIAL MEASURES

To supplement our consolidated financial statements presented in accordance with ~~U.S. Generally Accepted Accounting Principles (“GAAP”),~~GAAP, we consider Adjusted Net Income and Adjusted EBITDA, financial measures that are not based on any standardized methodology prescribed by GAAP.

We define Adjusted Net Income as net income before amortization and certain other adjustments that we do not consider in our evaluation of our ongoing operating performance from period to period as discussed further below. We define Adjusted EBITDA as Adjusted Net Income before interest expense, depreciation (including depreciation of Co-60 used in our operations) and income tax provision applicable to Adjusted Net Income.

We use Adjusted Net Income and Adjusted EBITDA, non-GAAP financial measures, as the principal measures of our operating performance. Management believes Adjusted Net Income and Adjusted EBITDA are useful because they allow management to more effectively evaluate our operating performance and compare the results of our operations from period to period without the impact of certain non-cash items and non-routine items that we do not expect to continue at the same level in the future and other items that are not core to our operations. We believe that these measures are useful to our investors because they provide a more complete understanding of the factors and trends affecting our business than could be obtained absent this disclosure. In addition, we believe Adjusted Net Income and Adjusted EBITDA will assist investors in making comparisons to our historical operating results and analyzing the underlying performance of our operations for the periods presented. Our management also uses Adjusted Net Income and Adjusted EBITDA in their financial analysis and operational decision-making, and Adjusted EBITDA serves as the basis for the metric we utilize to determine attainment of our primary annual incentive program. Adjusted Net Income and Adjusted EBITDA may be calculated differently from, and therefore may not be comparable to, a similarly titled measure used by other companies.

Adjusted Net Income and Adjusted EBITDA should not be considered in isolation from, or as a substitute for, financial information prepared in accordance with GAAP. There are a number of limitations related to the use of Adjusted Net Income

and Adjusted EBITDA rather than net income, the nearest GAAP equivalent. For example, Adjusted Net Income and Adjusted EBITDA primarily exclude:

•certain recurring non-cash charges such as depreciation of fixed assets, although these assets may have to be replaced in the future, as well as amortization of acquired intangible assets and asset retirement obligations;

•costs of acquiring and integrating businesses, which will continue to be a part of our growth strategy;

•non-cash gains or losses from fluctuations in foreign currency exchange rates and the mark-to-fair value of derivatives not designated as hedging instruments, which includes the embedded derivatives relating to certain customer and supply contracts at Nordion;

•impairment charges on long-lived assets, intangible assets and investments accounted for under the equity method;

•loss on extinguishment of debt incurred in connection with refinancing or early extinguishment of long-term debt;

•expenses and charges related to the litigation, settlement agreements, and other activities associated with our EO sterilization facilities, including those ~~related to~~in Willowbrook, Illinois, Atlanta, Georgia and Santa Teresa, New Mexico, even though that litigation remains ongoing;

•in the case of Adjusted EBITDA, interest expense or the cash requirements necessary to service interest or principal payments on our indebtedness; and

•share-based compensation expense, which has been, and will continue to be for the foreseeable future, a significant recurring expense and an important part of our compensation strategy.

In evaluating Adjusted Net Income and Adjusted EBITDA, you should be aware that in the future, we will incur expenses similar to the adjustments in the table below. Our presentations of Adjusted Net Income and Adjusted EBITDA should not be construed as suggesting that our future results will be unaffected by these expenses or any unusual or non-recurring items. When evaluating our performance, you should consider Adjusted Net Income and Adjusted EBITDA alongside other financial performance measures, including our net income and other GAAP measures.

The following table presents a reconciliation of net income, the most directly comparable financial measure calculated and presented in accordance with GAAP to Adjusted Net Income and Adjusted EBITDA, for each of the periods indicated:

Three Months Ended June 30, Six Months Ended June 30,
(thousands of U.S. dollars) 2022 2021 2022 2021
Net income $ 30,418 $ 42,615 $ 61,059 $ 53,680
Amortization of intangibles 21,195 21,778 41,377 44,060
Share-based compensation(a)
5,801 3,493 10,339 6,942
Gain on foreign currency and derivatives not designated as hedging instruments(b)
(1,430) (660) (7,982) (996)
Acquisition and divestiture related charges, net(c)
691 844 531 659
Business optimization project expenses(d)
470 275 574 536
Plant closure expenses(e)
478 756 1,149 1,298
Impairment of investment in unconsolidated affiliate(f)
9,613 — 9,613 —
Loss on extinguishment of debt(g)
— — — 14,312
Professional services relating to EO sterilization facilities(h)
17,678 10,644 35,737 24,043
Accretion of asset retirement obligations(i)
598 602 1,118 1,153
COVID-19 expenses(j)
45 188 148 487
Income tax benefit associated with pre-tax adjustments(k)
(9,732) (8,863) (17,584) (22,996)
Adjusted Net Income 75,825 71,672 136,079 123,178
Interest expense, net(l)
17,144 19,163 33,894 40,445
Depreciation(m)
15,744 15,683 31,611 31,062
Income tax provision applicable to Adjusted Net Income(n)
27,422 28,045 49,900 45,195
Adjusted EBITDA(o)
$ 136,135 $ 134,563 $ 251,484 $ 239,880


	Three Months Ended June 30,				Six Months Ended June 30,
(thousands of U.S. dollars)	2023		2022		2023		2022
Net income	$	23,513	$	30,418	$	26,355	$	61,059
Amortization of intangibles	20,502		21,195		41,109		41,377
Share-based compensation(a)	8,409		5,801		15,757		10,339

Loss (gain) on foreign currency and derivatives not designated as hedging instruments, net(b)	(409)		(1,430)		126		(7,982)
Acquisition and divestiture related charges, net(c)	153		691		745		531
Business optimization project expenses(d)	3,322		470		5,856		574
Plant closure expenses(e)	129		478		(766)		1,149
Impairment of investment in unconsolidated affiliate(f)	—		9,613		—		9,613
Professional services and other expenses relating to EO sterilization facilities(g)	17,080		17,678		33,382		35,737
Accretion of asset retirement obligations(h)	555		598		1,127		1,118
COVID-19 expenses(i)	—		45		—		148
Income tax benefit associated with pre-tax adjustments(j)	(13,959)		(9,732)		(26,351)		(17,584)
Adjusted Net Income	59,295		75,825		97,340		136,079
Interest expense, net(k)	25,271		17,144		51,811		33,894
Depreciation(l)	18,988		15,744		37,919		31,611
Income tax provision applicable to Adjusted Net Income(m)	24,931		27,422		39,883		49,900
Adjusted EBITDA(n)	$	128,485	$	136,135	$	226,953	$	251,484

(a) Represents ~~non-cash~~ share-based compensation ~~expense.~~expense to employees and non-employee directors.

(b) Represents the effects of (i) fluctuations in foreign currency exchange rates, (ii) non-cash mark-to-fair value of embedded derivatives relating to certain customer and supply contracts at Nordion, and (iii) unrealized gains on interest rate caps not designated as hedging instruments.

(c) Represents (i) certain direct and incremental costs related to the acquisitions of RCA ~~the noncontrolling interests in our China subsidiaries,~~and BioScience Labs ~~in 2021, the first quarter 2021 gain on the mandatorily redeemable noncontrolling interest in Nelson Labs Fairfield (as described in Note 4, “Acquisitions”),~~ and certain related integration efforts as a result of those acquisitions, (ii) the earnings impact of fair value adjustments (excluding those recognized within amortization expense) resulting from the businesses acquired, and (iii) transition services income and non-cash deferred lease income associated with the terms of the divestiture of the Medical Isotopes business in 2018.

(d) Represents professional fees, ~~contract termination and~~ exit costs, severance and other payroll costs, and other costs associated with business optimization and cost savings projects relating to the integration of acquisitions, operating structure realignment and other process enhancement projects.

(e) Represents professional fees, severance and other payroll costs, and other costs including ongoing lease and utility expenses associated with the closure of the Willowbrook, Illinois facility. The six months ended June 30, 2023 also includes a $1.0 million cancellation fee received from a tenant in connection with the termination of an office space lease at the Nordion facility.

(f) Represents an impairment charge on our equity method investment in ~~Auralux.~~a joint venture. Refer to Note 1, “Basis of Presentation”.

(g) ~~Represents expenses incurred in connection with the repricing of our Term Loan in January 2021, including accelerated amortization of prior debt issuance and discount costs.~~

~~(h)~~ Represents litigation and other professional fees associated with our EO sterilization facilities. This includes $5.5 million and $7.8 million of interest expense, net for the three and six months ended June 30, 2023, respectively, associated with Term Loan B that was issued to finance the $408.0 million cost to settle approximately 880 pending and threatened EO claims against the Settling Defendants in Illinois under Settlement Agreements entered into on March 28, 2023. See Note ~~16,~~15, “Commitments and ~~Contingencies”~~.Contingencies.”

~~(i)~~(h) Represents non-cash accretion of asset retirement obligations related to Co-60 and gamma processing facilities, which are based on estimated site remediation costs for any future decommissioning of these facilities (without regard for whether the decommissioning services would be performed by employees of Nordion, instead of by a third party) and are accreted over the life of the asset.

~~(j)~~(i) Represents non-recurring costs associated with the COVID-19 pandemic, including incremental costs to implement workplace health and safety measures.

~~(k)~~(j) Represents the income tax impact of adjustments calculated based on the tax rate applicable to each item. We eliminate the effect of tax rate changes as applied to tax assets and liabilities and unusual items from our presentation of adjusted net income.

~~(l)~~(k) The three and six months ended June 30, 2023 exclude $5.5 million and $7.8 million, respectively, of interest expense, net, on Term Loan B attributable to the loan proceeds that were used to fund the $408.0 million Illinois EO litigation settlement. The three and six months ended June 30, 2022 ~~excludes~~exclude $3.1 million and $9.4 million, respectively, of unrealized gains on interest rate derivatives not designated as hedging instruments.

~~(m)~~(l) Includes depreciation of Co-60 held at gamma irradiation sites.

~~(n)~~(m) Represents the difference between the income tax provision as determined under U.S. GAAP and the income tax provision or benefit associated with pre-tax adjustments described in footnote ~~(k)~~(j).

~~(o) $20.9~~(n) $24.4 million and ~~$21.8~~$20.9 million of the adjustments for the three months ended June 30, ~~2022~~2023 and ~~2021,~~2022, respectively, and ~~$40.7~~$47.2 million and ~~$42.5~~$40.7 million of the adjustments for the six months ended June 30, ~~2022~~2023 and ~~2021,~~2022, respectively, are included in cost of revenues, primarily consisting of amortization of ~~intangibles,~~intangible assets, depreciation, and accretion of asset retirement obligations.

~~SEGMENT RESULTS OF OPERATIONS~~

~~Our Segments~~

~~Sterigenics~~

~~Nordion~~

~~Results for our Nordion segment are also impacted by Co-60 supplier mix, harvest schedules and product and service mix.~~

~~Nelson Labs~~

~~Nelson Labs provides outsourced microbiological and analytical chemistry testing and advisory services for the medical device and pharmaceutical industries.~~

~~For more information regarding our reportable segments please refer to Note 18, “Segment Information” to our consolidated financial statements.~~

~~Segment Results for the Three Months Ended June 30, 2022 and 2021~~

~~The following tables compare segment net revenue and segment income for the three months ended June 30, 2022 to the three months ended June 30, 2021:~~

Three Months Ended June 30,
(thousands of U.S. dollars) 2022 2021 $ Change % Change
Net Revenues
Sterigenics $ 157,792 $ 145,182 $ 12,610 8.7 %
Nordion 50,478 49,125 1,353 2.8 %
Nelson Labs 58,369 57,610 759 1.3 %
Segment Income
Sterigenics $ 85,098 $ 79,569 $ 5,529 6.9 %
Nordion 29,982 31,168 (1,186) (3.8) %
Nelson Labs 21,055 23,826 (2,771) (11.6) %
Segment Income margin
Sterigenics 53.9 % 54.8 %
Nordion 59.4 % 63.4 %
Nelson Labs 36.1 % 41.4 %

~~Net Revenues by Segment~~

Sterigenics net revenues were $157.8 million for the three months ended June 30, 2022, an increase of $12.6 million, or 8.7%, as compared to the three months ended June 30, 2021. The increase reflects a 6.1% favorable impact from pricing, and volume growth of 5.1%, partially offset by unfavorable impacts from changes in foreign currency exchange rates of 2.5%.

Nordion net revenues were $50.5 million for the three months ended June 30, 2022, an increase of $1.4 million, or 2.8%, as compared to the three months ended June 30, 2021. The increase was primarily attributable to favorable pricing of 6.1% partially offset by a 3.1% unfavorable impact from changes in foreign currency exchange rates.

Nelson Labs net revenues were $58.4 million for the three months ended June 30, 2022, an increase of $0.8 million, or 1.3%, as compared to the three months ended June 30, 2021. Revenue from the RCA acquisition contributed 5.7% and favorable pricing represented 5.4%. Partially offsetting these increases was a 5.0% decline in revenue from reduced demand for pandemic-related testing. In addition, revenue growth was negatively impacted by 2.6% due to changes in foreign currency exchanges rates.

~~Segment Income~~

Sterigenics segment income was $85.1 million for the three months ended June 30, 2022, an increase of $5.5 million, or 6.9%, as compared to the three months ended June 30, 2021. The increase in segment income was primarily a result of favorable customer pricing and sales volume growth, as referenced above.

Nordion segment income was $30.0 million for the three months ended June 30, 2022, a decrease of $1.2 million, or 3.8%, as compared to the three months ended June 30, 2021. The decrease in segment income and segment income margin was driven by an unfavorable product mix and changes in foreign currency exchanges rates.

Nelson Labs segment income was $21.1 million for the three months ended June 30, 2022, a decrease of $2.8 million, or 11.6%, as compared to the three months ended June 30, 2021, primarily attributable to the decline in higher margin pandemic-related testing. This decrease was partially offset by the incremental contribution of the RCA acquisition and favorable customer pricing. The 5.3% decrease in segment income margin was driven by recent acquisitions and an unfavorable mix associated with reduced demand for pandemic-related testing.

~~Segment Results for the Six Months Ended June 30, 2022 and 2021~~

~~The following tables compare segment net revenue and segment income for the six months ended June 30, 2022 to the six months ended June 30, 2021:~~

Six Months Ended June 30,
(thousands of U.S. dollars) 2022 2021 $ Change % Change
Net Revenues
Sterigenics $ 307,254 $ 276,333 $ 30,921 11.2 %
Nordion 84,480 75,043 9,437 12.6 %
Nelson Labs 111,659 112,689 (1,030) (0.9) %
Segment Income
Sterigenics $ 164,501 $ 148,030 $ 16,471 11.1 %
Nordion 48,885 44,954 3,931 8.7 %
Nelson Labs 38,098 46,896 (8,798) (18.8) %
Segment Income margin
Sterigenics 53.5 % 53.6 %
Nordion 57.9 % 59.9 %
Nelson Labs 34.1 % 41.6 %

~~Net Revenues by Segment~~

Sterigenics net revenues were $307.3 million for the six months ended June 30, 2022, an increase of $30.9 million, or 11.2%, as compared to the six months ended June 30, 2021. The increase reflects volume growth of 7.3% and a 5.8% favorable impact from pricing, offset by unfavorable impacts from changes in foreign currency exchange rates of 1.9%.

Nordion net revenues were $84.5 million for the six months ended June 30, 2022, an increase of $9.4 million, or 12.6%, as compared to the six months ended June 30, 2021. The increase was driven by volume growth of 8.4% and a favorable impact from pricing of 6.4%, partially offset by foreign currency impacts of 2.2%.

Nelson Labs net revenues were $111.7 million for the six months ended June 30, 2022, a decrease of $1.0 million, or 0.9%, as compared to the six months ended June 30, 2021. The decrease was mainly attributable to a 7.8% decline in revenue from reduced demand for pandemic-related testing coupled with a decrease in volumes across other testing categories. In addition, revenue was unfavorably impacted by 2.0% due to changes in foreign currency exchanges rates. Partially offsetting this decline was revenue growth from the 2021 acquisitions of RCA and BioScience Labs of 7.0% and a favorable impact from pricing of 4.8%.

~~Segment Income~~

Sterigenics segment income was $164.5 million for the six months ended June 30, 2022, an increase of $16.5 million, or 11.1%, as compared to the six months ended June 30, 2021. The increase in segment income was primarily a result of sales volume growth and favorable customer pricing, as referenced above.

Nordion segment income was $48.9 million for the six months ended June 30, 2022, an increase of $3.9 million, or 8.7%, as compared to the six months ended June 30, 2021. The increase in segment income was due to the favorable impacts of volume growth and customer pricing, as referenced above. The decrease in segment income margin was due to an unfavorable product mix.

Nelson Labs segment income was $38.1 million for the six months ended June 30, 2022, a decrease of $8.8 million, or 18.8%, as compared to the six months ended June 30, 2021, primarily attributable to the decline in pandemic-related testing. This decrease was partially offset by the incremental contribution of the BioScience Labs and RCA acquisitions and favorable customer pricing. The 7.5% decrease in segment income margin was driven by unfavorable mix associated with reduced demand for pandemic-related testing, supply chain pressures, labor market constraints, which were compounded by the surge of the Omicron variant in the first quarter of 2022, and dilution resulting from the 2021 Nelson Labs acquisitions.

LIQUIDITY AND CAPITAL RESOURCES

Sources of Cash

The primary sources of liquidity for our business are cash flows from operations and borrowings under our credit facilities. We expect that our primary liquidity requirements will be to make capital expenditures, including investments in fixed assets to build and/or expand existing facilities, to fund suitable business acquisitions, service our debt, and make expenditures for other general corporate purposes.

As of June 30, ~~2022,~~2023, we had ~~$140.6~~$270.5 million of cash and cash equivalents. This is ~~an increase~~a decrease of ~~$33.7~~$125.8 million from the balance at December 31, ~~2021.~~2022. The decrease in cash and cash equivalents was mainly attributable to the release of approximately $408.0 million to settle the EO claims against the Settling Defendants in Cook County, Illinois and a $200.0 million paydown of the outstanding balance on the Revolving Credit Facility. Partially offsetting this decrease was $500.0 million in proceeds from the issuance of Term Loan B on February 23, 2023. Our foreign subsidiaries held cash of approximately ~~$114.7~~$152.8 million at June 30, ~~2022~~

2023 and ~~$87.9~~$158.3 million at December 31, ~~2021.~~2022, to meet their liquidity needs. No material restrictions exist to accessing cash held by our foreign subsidiaries notwithstanding any potential tax consequences.

~~Our capital expenditure program is a component of our long-term strategy. This program includes,~~On February 23, 2023, we entered into the First Lien Credit Agreement (the “2023 Credit Agreement”), which provides for, among other things, ~~investments~~a new Term Loan B facility in ~~new~~an aggregate principal amount of $500.0 million and ~~existing facilities, business expansion projects, Co-60 used~~bears interest, at the Company’s option, at a variable rate per annum equal to either (x) the Term SOFR Rate (as defined in the 2023 Credit Agreement) plus an applicable margin of 3.75% or (y) an alternative base rate (“ABR”) plus an applicable margin of 2.75%. The 2023 Credit Agreement is secured on a first priority basis on substantially all of our assets and is guaranteed by ~~Sterigenics~~certain of our subsidiaries. It is prepayable without premium or penalty at ~~its gamma irradiation facilities, Co-60 development projects and information technology enhancements. During the~~any time six months ~~ended June 30, 2022, our capital expenditures amounted~~after the closing date. The principal balance shall be paid at 1% of the aggregate principal amount ($5.0 million) per year, with the balance due at the end of 2026. The Company used the proceeds of this debt to ~~$71.6~~fund a previously announced $408.0 million ~~compared~~EO litigation settlement in Cook County, Illinois on May 1, 2023 and pay down existing borrowings under the Company’s revolving credit facility. In addition, the Company plans to ~~$44.8 million~~use the remaining proceeds to further enhance liquidity and for ~~the six months ended June 30, 2021.~~general corporate purposes.

Uses of Cash

We expect that cash on hand, operating cash flows and amounts available under our credit facilities will provide sufficient working capital to operate our business, meet foreseeable liquidity requirements, including debt service on our long-term debt, make expected capital expenditures including investments in fixed assets to build and/or expand existing facilities, and meet litigation costs that we expect to continue to incur for at least the next twelve months. Our primary long-term liquidity requirements beyond the next ~~twelve~~12 months will be to service our debt, make capital expenditures, and fund suitable business acquisitions. As of June 30, ~~2022,~~2023, there were no outstanding borrowings on the Revolving Credit Facility. We expect any excess cash provided by operations will be allocated to fund capital expenditures, potential acquisitions, or for other general corporate purposes. Our ability to meet future working capital, capital expenditures and debt service requirements will depend on our future financial performance, which will be affected by a range of macroeconomic, competitive and business factors, including interest rate changes and changes in our industry, many of which are outside of our control. As of June 30, ~~2022,~~2023, our interest rate caps and swap limit our cash flow exposure ~~related to LIBOR for the majority~~ of ~~the principal amount outstanding on~~ our variable rate borrowings under the Term ~~Loan.~~Loans. Refer to Note ~~17,~~16, “Financial Instruments and Financial Risk” ~~under the heading “Derivative Instruments”~~, “Derivative Instruments” for additional information regarding the interest rate caps used to manage economic risks associated with our variable rate borrowings.

Capital Expenditures

Our capital expenditure program is a component of our long-term strategy. This program includes, among other things, investments in new and existing facilities, business expansion projects, Co-60 used by Sterigenics at its gamma irradiation facilities, cobalt development projects and information technology enhancements. During the six months ended June 30, 2023, our capital expenditures amounted to $98.1 million, compared to $71.6 million for the six months ended June 30, 2022.

Cash Flow Information


(thousands of U.S. dollars)	(thousands of U.S. dollars)	Six Months Ended June 30,				(thousands of U.S. dollars)	Six Months Ended June 30,
		2022		2021			2023		2022
Net Cash Provided by (Used in):	Net Cash Provided by (Used in):					Net Cash Provided by (Used in):
Operating activities	Operating activities	$	108,256	$	134,256	Operating activities	$	(302,704)	$	108,256
Investing activities	Investing activities	(71,192)		(70,974)		Investing activities	(98,102)		(71,192)
Financing activities	Financing activities	(1,083)		(12,090)		Financing activities	273,206		(1,083)
Effect of foreign currency exchange rate changes on cash and cash equivalents	Effect of foreign currency exchange rate changes on cash and cash equivalents	(2,287)		2,578		Effect of foreign currency exchange rate changes on cash and cash equivalents	1,796		(2,287)
Net increase in cash and cash equivalents, including restricted cash, during the period		$	33,694	$	53,770
Net increase (decrease) in cash and cash equivalents, including restricted cash						Net increase (decrease) in cash and cash equivalents, including restricted cash	$	(125,804)	$	33,694

Operating activities

Cash flows ~~provided by~~from operating activities decreased ~~$26.0~~$411.0 million to net cash ~~provided~~used of ~~$108.3~~$302.7 million in the six months ended June 30, ~~2022~~2023 compared to ~~$134.3~~$108.3 million provided by operating activities for the six months ended June 30, ~~2021.~~2022. The decrease in cash flows from operating activities in the six months ended June 30, ~~2022~~2023 compared to the six months ended June 30, ~~2021~~2022 was ~~driven~~ primarily ~~by an increase~~due to the release of the settlement funds of approximately $408.0 million on June 30, 2023 in ~~cash paid for taxes~~connection with the settlements of ~~$14.6 million and a $5.4 million increase~~the EO claims in ~~cash paid for interest.~~Cook County, Illinois.

Investing activities

Cash used by investing activities increased ~~$0.2~~$26.9 million to net cash used of ~~$71.2~~$98.1 million in the six months ended June 30, ~~2022~~2023 compared to ~~$71.0~~$71.2 million for the six months ended June 30, ~~2022. Capital~~2023. The variance was primarily driven by an increase in capital expenditures ~~increased $26.9~~of $26.5 million in the six months ended June 30, ~~2022~~2023 compared to the six months ended June 30, ~~2021. 2021 included cash paid for acquisitions of $26.2 million which did not recur in~~ 2022. ~~In 2021, we acquired BioScience Labs for a net purchase price of approximately $13.8 million and we completed the acquisition of the remaining 15% ownership of Nelson Labs Fairfield for $12.4 million.~~

Financing activities

Cash ~~used for~~provided by financing activities ~~decreased $11.0~~increased $274.3 million to net cash ~~used~~provided of ~~$1.1~~$273.2 million for the six months ended June 30, ~~2022~~2023 compared to ~~$12.1~~$1.1 million of cash used for financing activities for the six months ended June 30, ~~2021.~~2022. The difference was mainly attributable to $500.0 million in proceeds from the issuance of Term Loan B on February 23, 2023, partially offset by the $200.0 million paydown of the outstanding balance on the revolving credit facility and the payment of ~~$3.7~~$24.7 million of debt issuance costs incurred in connection with the issuance of Term Loan B and the revolving credit facility amendment during the six months ended June 30, ~~2021 in connection with our January 2021 refinancing of the Senior Secured Credit Facilities (as~~2023, as described in “Debt Facilities” ~~below) and a $7.7 million payment~~below. Financing activities for the ~~acquisition of our Chinese subsidiaries noncontrolling interests.~~three months ended June 30, 2022 were insignificant.

Debt Facilities

Senior Secured Credit Facilities

On December 13, 2019, Sotera Health Holdings, LLC (“SHH”), our wholly owned subsidiary, entered into senior secured first lien credit facilities (the “Senior Secured Credit Facilities”), consisting of both a prepayable senior secured first lien term loan (the “Term Loan”) and a senior secured first lien revolving credit facility (the “Revolving Credit Facility”) pursuant to a first lien credit agreement (the “Credit Agreement”). The Revolving Credit Facility and Term Loan mature on June 13, 2026 and December 13, 2026, respectively. ~~The~~After giving effect to the Revolving Credit Facility Amendment (defined below), the total borrowing capacity under the Revolving Credit Facility is ~~$347.5~~$423.8 million. The Senior Secured Credit Facilities also provide SHH the right at any time and under certain conditions to request incremental term loans or incremental revolving credit commitments based on a formula defined in the Senior Secured Credit Facilities. As of June 30, ~~2022~~2023 and December 31, ~~2021,~~2022, total borrowings under the Term Loan were $1,763.1 ~~million, respectively, and there were no borrowings outstanding on the Revolving Credit Facility.~~million. The weighted average interest rate on borrowings under the Term Loan for the three months ended June 30, ~~2022~~2023 and June 30, ~~2021~~2022 was ~~3.53%~~7.89% and ~~3.25%~~3.53%, respectively, and ~~3.39%~~7.66% and ~~3.64%~~3.39% for the six months ended June 30, ~~2022~~2023 and June 30, ~~2021,~~2022, respectively.

On ~~January 20, 2021,~~February 23, 2023, we ~~closed on an amendment repricing our~~entered into the First Lien Credit Agreement (the “2023 Credit Agreement”), which provides for, among other things, a new Term ~~Loan. The interest rate spread over the London Interbank Offered Rate (“LIBOR”) on the~~Loan B facility ~~was reduced from 450 basis points to 275 basis points, and the facility’s LIBOR floor was reduced from 100 basis points to 50 basis points. The changes resulted~~ in an ~~effective reduction in current~~aggregate principal amount of $500.0 million and bears interest, ~~rates of 225 basis points. In connection with this amendment, we wrote off $11.3 million of unamortized debt issuance and discount costs and incurred an additional $2.9 million of expense related~~at the Company’s option, at a variable rate per annum equal to ~~debt issuance costs attributable to~~either (x) the ~~refinancing. These costs were recorded to “Loss on extinguishment of debt” in our Consolidated Statements of Operations and Comprehensive Income (Loss).~~

~~On March 26, 2021, we amended the Revolving Credit Facility, to (i) decrease the Applicable~~Term SOFR Rate (as defined in the 2023 Credit Agreement) ~~related to any Revolving Loans (as defined in the Credit Agreement) from a rate per annum that ranged from~~plus an applicable margin of 3.75% or (y) an alternative base rate (“ABR”) plus ~~2.50%~~an applicable margin of 2.75%. The 2023 Credit Agreement is secured on a first priority basis on substantially all of our assets and is guaranteed by certain of our subsidiaries. It is prepayable without premium or penalty at any time six months after the closing date. The principal balance shall be paid at 1% of the aggregate principal amount ($5.0 million) per year, with the balance due at the end of 2026. The Company used the proceeds of this debt to ~~ABR plus 3.00% depending~~fund a previously announced $408.0 million EO litigation settlement in Cook County, Illinois and pay down the $200.0 million of existing borrowings under the Revolving Credit Facility concurrent with the funding of this loan on ~~SHH’s Senior Secured First Lien Net Leverage Ratio~~February 23, 2023. In addition, the Company plans to ~~ABR plus 1.75%;~~use the remaining proceeds to further enhance liquidity and for general corporate purposes. The weighted average interest rate on borrowings under Term Loan B for the three months ended June 30, 2023 was 8.82%.

On March 21, 2023, the Company entered into the Revolving Credit Facility Amendment, which provides for an increase in the ~~case~~commitments under the existing Revolving Credit Facility in an aggregate principal amount of ~~Eurodollar Loans (as defined~~$76.3 million. In addition, certain of the lenders providing revolving credit commitments have provided additional commitments for the issuance of the letters of credit under the Revolving Credit Facility in an aggregate principal amount of $165.1 million. The Revolving Credit Facility Amendment also provides for the ~~Credit Agreement) from~~replacement of the LIBOR-based reference interest rate option for revolving loans with a reference rate ~~per annum which ranged from~~option based upon the ~~Adjusted LIBOR~~Term Secured Overnight Financing Rate (“Term SOFR”) or Daily Simple SOFR (“Daily SOFR”) plus ~~3.50%~~an applicable credit spread adjustment of 0.1% (subject to a minimum floor of 0.0%). After giving effect to the ~~Adjusted LIBOR plus 4.00% depending on SHH’s Senior Secured First Lien Net Leverage Ratio (as defined~~Revolving Credit Facility Amendment, the aggregate amount of the Lenders' revolving commitments is $423.8 million and the aggregate amount of letter of credit commitments is $361.3 million. Letter of credit commitments are part of and not in ~~the Credit Agreement),~~addition to the ~~Adjusted LIBOR (as defined in the Credit Agreement) plus 2.75% and (ii) extend the~~aggregate revolving commitments. The maturity date of the Revolving Credit Facility ~~from December 13, 2024 to~~remains June 13, 2026. ~~The other material terms~~As of June 30, 2023 there were no borrowings outstanding on the ~~Credit Agreement remain unchanged and the amendment does not change the capacity of our~~ Revolving Credit Facility. ~~No unamortized debt issuance costs associated with~~The Company borrowed $200.0 million on the Revolving Credit Facility ~~were written off and direct fees and costs incurred~~during the fourth quarter of 2022, which was repaid in ~~connection with~~ the ~~amendment were immaterial.~~first quarter of 2023, as noted above.

As of June 30, 2022 and December 31, 2021, capitalized debt issuance costs totaled $2.4 million and $2.7 million, respectively, and debt discounts totaled $15.6 million and $17.3 million, respectively, related to the Senior Secured Credit Facilities. Such costs are recorded as a reduction of debt on our Consolidated Balance Sheets and amortized as a component of interest expense over the term of the debt agreement.

The Senior Secured Credit Facilities and 2023 Credit Agreement contain additional covenants that, among other things, restrict, subject to certain exceptions, our ability and the ability of our restricted subsidiaries to engage in certain activities, such as incur indebtedness or permit to exist any lien on any property or asset now owned or hereafter acquired, as specified in the Senior Secured Credit ~~Facilities.~~Facilities and 2023 Credit Agreement. The Senior Secured Credit Facilities and 2023 Credit Agreement also contain certain customary affirmative covenants and events of default, including upon a change of control. An event of default under the Senior Secured Credit Facilities and 2023 Credit Agreement would occur if the Company or certain of its subsidiaries received one or more enforceable judgments for payment in an aggregate amount in excess of $100.0 million, which judgment or judgments are not stayed or remain undischarged for a period of 60 consecutive days or if, in order to enforce such a judgment, a judgment creditor attached or levied upon assets that are material to the business and operations, taken as a whole, of the Company and certain of its subsidiaries. As of June 30, ~~2022,~~2023, we were in compliance with all the Senior Secured Credit Facilities and 2023 Credit Agreement covenants.

Term Loan Interest Rate Risk Management

The Company utilizes interest rate derivatives to reduce the variability of cash flows in the interest payments associated with ~~the Term Loan~~our variable rate debt due to changes in LIBOR ~~(or its successor).~~(up to June 22, 2023) and SOFR. For additional information on the derivative instruments described above, refer to Note ~~17,~~16, “Financial Instruments and Financial Risk”, “Derivatives Instruments.”

~~First Lien Notes~~LIBOR Transition

~~Prior~~LIBOR, SHH entered into an amendment to the ~~redemption,~~Senior Secured Credit Facilities to replaces the ~~First Lien Notes bore~~LIBOR-based reference interest atrate option under the Term Loan with a reference interest rate ~~equal to LIBOR~~option based on Term SOFR plus an applicable credit spread adjustment of 0.11448% (for one-month interest periods), 0.26161% (for three-month interest periods) and 0.42826% (for six-month interest periods) (in all cases, subject to a ~~1.00%~~minimum floor ~~plus 6.00% per annum. Interest was payable on a quarterly basis~~of 0.50%).

CRITICAL ACCOUNTING POLICIES AND ESTIMATES

The preparation of consolidated financial statements and related disclosures in conformity with ~~accounting principles generally accepted in the United States of America~~GAAP requires management to make judgments, estimates and assumptions at a specific point in time and in certain circumstances that affect amounts reported in the accompanying consolidated financial statements. In preparing these consolidated financial statements, management has made its best estimates and judgments of certain amounts, giving due consideration to materiality. The application of accounting policies involves the exercise of judgment and use of assumptions as to future uncertainties and, as a result, actual results could differ from these estimates.

A comprehensive discussion of the Company’s critical accounting policies and management estimates made in connection with the preparation of the financial statements is included in Item 7 of ~~our Annual Report on~~2022 Form ~~10-K for the year ended December 31, 2021.~~10-K. There have been no significant changes in critical accounting policies, management estimates or accounting policies since the year ended December 31, ~~2021.~~2022.

NEW ACCOUNTING PRONOUNCEMENTS

For a description of recent accounting pronouncements applicable to our business, see Note 2, “Recent Accounting Standards”. to our consolidated financial statements.

Item 3. Quantitative and Qualitative Disclosures About Market Risk

Market risks are described within “Quantitative and Qualitative Disclosures About Market Risk” in Part II, Item 7A of our ~~Annual Report on~~2022 Form ~~10-K for the year ended December 31, 2021.~~10-K. These market risks have not materially changed for the three and six months ended June 30, ~~2022.~~

2023.

Item 4. Controls and Procedures

Evaluation of Disclosure Controls and Procedures

Our management, with the participation of our Chief Executive Officer (“CEO”) and Chief Financial Officer (“CFO”), has evaluated the effectiveness of the Company’s “disclosure controls and procedures,” (as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended (“Exchange Act”)). Based upon their evaluation, the ~~Chief Executive Officer~~CEO and ~~Chief Financial Officer~~CFO concluded that, as of the end of the period covered by this Quarterly Report on Form 10-Q, our disclosure controls and procedures are effective to provide reasonable assurance that information we are required to disclose in reports that we file or submit under the Exchange Act is recorded, processed, summarized, and reported within the time periods specified in the rules and forms of the Securities and Exchange Commission (“SEC”), and that such information is accumulated and communicated to our management, including our CEO and CFO, as appropriate, to allow timely decisions regarding required disclosure.

Changes in Internal Control

During the three and six months ended June 30, ~~2022,~~2023, there were no changes in our internal control over financial reporting that materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

4649

Part II—OTHER INFORMATION

Item 1. Legal Proceedings.

From time to time, we may be subject to various legal proceedings arising in the ordinary course of our business, including claims relating to personal injury, property damage, workers’ compensation, employee safety and ~~employee safety.~~our disclosures as a Nasdaq-listed, publicly-traded company. In addition, from time to time, we receive communications from government or regulatory agencies concerning investigations or allegations of noncompliance with laws or regulations in jurisdictions in which we operate. At this time, and except as is noted herein, we are unable to predict the outcome of, and cannot reasonably estimate the impact of, any pending litigation matters, matters concerning allegations of non-compliance with laws or regulations and matters concerning other allegations of other improprieties, or the incidence of any such matters in the future. Information regarding our material legal proceedings is included below.

Legal Proceedings Described in Note 1615 “Commitments and Contingencies” of Our Consolidated Financial Statements

Note ~~16,~~15, “Commitments and Contingencies” to our consolidated financial statements for the three and six months ended June 30, ~~2022~~2023 contained in this Quarterly Report on Form 10-Q includes information on legal proceedings that constitute material contingencies for financial reporting purposes that could have a material effect on our financial condition or results of operations. This item should be read in conjunction with Note 1615 “Commitments and Contingencies” for information regarding the following legal proceedings, which information is incorporated into this item by reference:

•Ethylene Oxide Tort Litigation – Illinois, Georgia and ~~Georgia~~New Mexico;

•~~Georgia Facility Operations Litigation;~~Insurance Coverage for Environmental Liabilities; and

•~~New Mexico Attorney General~~Sotera Health Company Securities Litigation and Related Matters.

Legal Proceedings That Are Not Described in Note 1615 “Commitments and Contingencies” to Our Consolidated Financial Statements

In addition to the matters that are identified in Note 1615 “Commitments and Contingencies” to our consolidated financial statements for the three and six months ended June 30, ~~2022~~2023 contained in this Quarterly Report on Form 10-Q, and incorporated into this item by reference, the following matter also constitutes a ~~material~~ pending legal proceeding, other than ordinary course litigation incidental to our business, to which we are or any of our subsidiaries is a party.

Zoetermeer, Holland Criminal Proceedings and Criminal Financial Investigation

In 2010, the Dutch Public Prosecution Service started criminal proceedings against our subsidiary DEROSS Holding B.V. (“DEROSS”), in relation to alleged environmental permit violations for EO emissions in the period from 2004 to 2009 at its Zoetermeer processing facility. On the basis of the final indictment issued in April 2017, assuming a rarely applied increasing mechanism is not applied in this case, fines in the amount of €0.8 million (US$0.8 million) may be imposed. We ~~have also~~ agreed to defend and indemnify the two individuals overseeing environmental compliance during the time period of the alleged claims by the Public Prosecutor. Assuming a rarely applied increasing mechanism is not applied in this case, the possible monetary penalties relating to the individuals currently are estimated at a maximum of €0.2 million (US$0.2 million).

In November 2010, the Public Prosecution Service also started a criminal financial investigation against DEROSS to determine whether it obtained illegal advantages by committing the alleged criminal offenses noted above. Any illegally obtained advantage could then be recovered from DEROSS in subsequent confiscation proceedings. The Public Prosecution Service estimates the illegally obtained advantage by DEROSS to be €0.6 million (US$0.6 million).

In February 2018, DEROSS and the two individuals received favorable judgments from the trial court, which did not hold any of them responsible for the alleged criminal offenses. In March 2018, the Public Prosecutor filed an appeal against the favorable judgments. In May 2023, the Public Prosecutor agreed to a resolution of the proceedings against DEROSS and the two individuals. Pursuant to this agreed resolution, the Public Prosecutor has withdrawn the appeals against the 2018 judgments in the cases of the two individuals. In addition, the Public Prosecutor has agreed to terminate the proceedings against DEROSS on the condition that DEROSS fulfills its obligations under the agreed resolution, including a contribution of €990,000 to a charity. The ~~appeal procedure~~resolution of proceedings against DEROSS is ~~still pending.~~further conditioned on approval by the Dutch courts.

An escrow ~~account~~ was established in 2011 to satisfy indemnity claims for losses related to this matter. The balance of ~~the~~ special escrow atfunds as of June 30, ~~2022,~~2023, was approximately US$1.8 million and the cash collateral held by ABN Amro to provide security for the claims against us was approximately €2.4 million (US$~~2.5~~2.6 million) as of June 30, ~~2022. These amounts are available to satisfy claims relating to the ongoing matter through its anticipated resolution.~~2023. At this time, there can be no assurance that the agreed resolution of this matter will be completed. If resolution is unsuccessful, we expect that the appeal of this matter ~~will likely~~could take several years to resolve; however, we believe the indemnification receivable continues to be recoverable and plan to ensure escrow funds remain in place to cover the agreed resolution described above or outcomes of an appeal.

~~It is possible that individuals living in the vicinity of our former Zoetermeer facility may file civil claims at some time in the future.~~ While we have received letters in past years from a small number of individuals claiming to live or work in the vicinity of the Zoetermeer facility, no civil claims have been filed against DEROSS or us. It is possible that these or other individuals living in

the vicinity of the Zoetermeer facility may file civil claims at some time in the future. We have not provided for a contingency reserve in connection with any civil claims as we are unable to determine the ~~likelihood~~probability of an unfavorable outcome and no reasonable estimate of a loss or range of losses, if any, can be made.

Notice of Violation for Ethylene Oxide Emissions from Our Facility in Queensbury, New York

In late May 2023, Sterigenics’ Queensbury, NY facility experienced a power outage that resulted in a failure to restart the facility’s scrubber system, which is part of the facility’s emission control systems. The disruption of the facility’s scrubber lasted for approximately 48 hours. Upon discovering the disruption, the facility restarted the scrubber to control emissions within the system and then ceased operations. Operating without the scrubber resulted in nine intermittent releases of ethylene oxide over a period of 48 hours from the 78-foot stack at the facility.

Sterigenics promptly notified the New York State Department of Environmental Conservation (“DEC”) and the US Environmental Protection Agency (“US EPA”) about the failure of the scrubber system and resulting releases of ethylene oxide. Sterigenics implemented remedial measures to prevent a recurrence in the event of future power outages and, with the DEC’s approval, resumed operations at the Queensbury facility 12 days after ceasing operations. Sterigenics received a Notice of Violation from the DEC on May 30, 2023 and expects to be fined in an amount to be determined by the DEC.

Item 1A. Risk Factors.

~~There have been no material changes~~The risk factor titled “We are subject to ~~the risk factors previously disclosed~~extensive regulatory requirements and routine regulatory audits in our ~~2021 Form 10-K. Refer to~~operations. …” included in Part I, Item 1A, “Risk Factors” of our ~~2021~~2022 Form 10-K for the year ended December 31, 2022, as amended by our Quarterly Report on Form 10-Q for the quarter ended March 31, 2023, is hereby updated by deleting the final paragraph thereof and substituting the paragraph immediately below in its place. Other than such substitution, the text of the risk factor is unchanged.

In April 2023, the US EPA proposed stricter EO regulations based on the 2016 IRIS Assessment, including (1) a ~~detailed discussion~~proposed interim decision under FIFRA that sets forth measures designed to mitigate EO exposure, in particular for workers exposed to EO in occupational settings, and (2) proposed amendments to the NESHAP governing commercial EO sterilization facilities like ours that would require these facilities to implement additional air pollution control technologies, practices and procedures designed to further reduce EO emissions from EO facilities. These April 2023 proposals contain a number of ~~risk factors affecting us.~~proposed requirements that are inconsistent with existing industry practices and set forth proposed implementation timelines that would be difficult to meet at existing facilities for some of the proposed requirements. The public comment period on these proposals closed in late June 2023, with thousands of comments received by the US EPA, which may lead to clarifications and revisions in the final US EPA regulations. Although we have been implementing enhancements at our EO sterilization facilities in the United States that we expect will facilitate our ability to meet many of the proposed requirements, certain facets of the proposed requirements are untested or not widely adopted at existing EO sterilization facilities. Compliance with the proposals in the form proposed in April 2023 will require additional facility modifications as well as added capital and operational costs, and some requirements (if adopted as proposed) could be unachievable at our EO facilities and at existing EO facilities throughout the industry. The US EPA has stated it plans to adopt final requirements by the first half of 2024 and its April 2023 proposals contemplate that existing facilities will be required to comply with many of the requirements as soon as 18 months following adoption.

Item 5. Other Information.

Rule 10b5-1 Trading Plans

During the three months ended June 30, 2023, none of the Company’s directors or executive officers adopted or terminated any contract, instruction or written plan for the purchase or sale of Company securities that was intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) or any “non-Rule 10b5-1 trading arrangement” (as those terms are defined in Regulation S-K, Item 408).

4851

Item 6. Exhibits.

The exhibits listed in the following Exhibit Index are filed, furnished, or incorporated by reference as part of this Quarterly Report on Form 10-Q.

~~Incorporated by Reference~~

~~Exhibit No~~

~~Description of Exhibits~~

~~Form~~

~~File No.~~

~~Exhibit~~

~~Filing Date~~

Furnished/Filed
Herewith

~~31.1~~

~~Certification of Principal Executive Officer pursuant to Exchange Act Rules 13a-14(a) and 15d-14(a), as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002~~

~~31.2~~

~~Certification of Principal Financial Officer pursuant to Exchange Act Rules 13a-14(a) and 15d-14(a), as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002~~

~~32.1~~

~~Certifications of Principal Executive Officer and Principal Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002~~

~~101.INS~~

~~Inline XBRL Instance Document - The XBRL Instance Document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document~~

~~101.SCH~~

~~Inline XBRL Taxonomy Extension Schema Document~~

~~101.CAL~~

~~Inline XBRL Taxonomy Extension Calculation Linkbase Document~~

~~101.DEF~~

~~Inline XBRL Taxonomy Extension Definition Linkbase Document~~

~~101.LAB~~

~~Inline XBRL Taxonomy Label Linkbase Document~~

~~101.PRE~~

~~Inline XBRL Taxonomy Extension Presentation Linkbase Document~~

~~104~~

~~Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101)~~

Incorporated by Reference

Exhibit No

Description of Exhibits

Form

File No.

Exhibit

Filing Date

Furnished/Filed
Herewith

31.1

Certification of Principal Executive Officer pursuant to Exchange Act Rules 13a-14(a) and 15d-14(a), as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002

31.2

Certification of Principal Financial Officer pursuant to Exchange Act Rules 13a-14(a) and 15d-14(a), as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002

32.1

Certifications of Principal Executive Officer and Principal Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002

10.1

Amendment, dated as of June 22, 2023, to the First Lien Credit Agreement dated as of December 13, 2019 by and among Sotera Health Company, Sotera Health Holdings, LLC, certain subsidiaries of Sotera Health Company, JPMorgan Chase Bank, N.A., as First Lien Administrative Agent and the lenders and issuing banks party thereto.

8-K

001-39729

10.1

2023-06-22

10.2

Executed Employment Offer by Sotera Health Company and Jonathan M. Lyons dated as of May 31, 2023

10.3

Executed Restrictive Covenants Agreement by and between Sotera Health Company and Jonathan M. Lyons dated as of June 26, 2023

101.INS

Inline XBRL Instance Document - The XBRL Instance Document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document

101.SCH

Inline XBRL Taxonomy Extension Schema Document

101.CAL

Inline XBRL Taxonomy Extension Calculation Linkbase Document

101.DEF

Inline XBRL Taxonomy Extension Definition Linkbase Document

101.LAB

Inline XBRL Taxonomy Label Linkbase Document

101.PRE

Inline XBRL Taxonomy Extension Presentation Linkbase Document

104

Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101)

* Filed Herewith

** Furnished Herewith

4952

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.


			SOTERA HEALTH COMPANY

			By:			/s/ ~~Michael F. Biehl~~Jonathan M. Lyons
			Name:			~~Michael F. Biehl~~Jonathan M. Lyons
			Title:			~~Interim~~Senior Vice President and Chief Financial Officer
						(Principal Financial Officer)

Date: August ~~4, 2022~~3, 2023

5053